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ABSTRACT 
Atherosclerosis, a chronic inflammatory disease of arteries, occurs 
predominantly at regions of the arterial system that are exposed to disturbed 
patterns of blood flow. Blood flow influences the atherosclerosis by exerting 
shear stress on endothelial cells (ECs). 
 
Although the signalling pathways that activate pro-inflammatory NF-κB 
transcription factors are well defined, the regulation and physiological 
significance of differential NF-κB subunit expression is poorly understood. In 
this thesis, we demonstrate that RelA NF-κB sub-unit expression is positively 
regulated in ECs via c-Jun N-terminal kinase (JNK) and the transcription 
factor ATF2. This pathway promoted focal arterial inflammation as genetic 
deletion of JNK1 reduced RelA expression and macrophage accumulation at 
an athero-susceptible site. Furthermore, JNK signalling to RelA is controlled 
by mechanical forces as en face immunostaining revealed that disturbed flow 
patterns (generated by a constrictive cuff) elevated RelA expression in 
murine carotid arteries via JNK1. Positron emission tomography and en face 
staining revealed that disturbed flow enhanced 18F-fluorodeoxyglucose 
uptake (a marker of inflammation) and accumulation of CD68-positive 
inflammatory cells in arteries via JNK1. We conclude that disturbed flow 
promotes arterial inflammation via a novel JNK-NF-κB cross-talk. 
 
The duration of RelA nuclear localisation is an important determinant of the 
magnitude and specificity of target gene expression. En face staining 
revealed that RelA rapidly accumulated in the nucleus upon LPS stimulation 
in ECs at both athero-protected and athero-susceptible sites. RelA was 
exported from the nucleus to the cytoplasm in response to prolonged 
stimulation in the athero-protected region but not in the athero-susceptible 
region. The duration of RelA nuclear localisation was suppressed by histone 
deacetylases which displayed higher activity at the protected site compared 
to the susceptible site. 
 
Overall, our findings reveal that ECs at athero-susceptible sites are primed 
for inflammatory activation via complementary mechanisms that enhance 
both the expression and the activity of NF-κB transcription factors. 
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1.1 Inflammation 
Inflammation is a biological process which plays a pivotal role in the 
response of organisms to infection or injury. The Roman doctor Cornelius 
Celsus was the first to describe the four cardinal signs of inflammation: rubor 
et tumor cum calore et dolore (redness and swelling with heat and pain) in 
the 1st century AD. This was complimented by the description of a fifth 
cardinal sign: functio laesa (disturbance of function) by Rudolph Virchow in 
1858.1 In general, an inflammatory response requires four different 
components: the inducers, the sensors for detection of the inducer, the 
inflammatory mediator which is induced by the sensors, and the target 
tissues which are affected by the mediator.2 Under normal conditions, the 
acute inflammatory reaction is terminated subsequent to the elimination of 
the triggering insult and the infection is cleared and damaged tissue repaired. 
This termination, described as the resolution of inflammation, results in a 
return to basal homeostatic conditions. However, if the cause of inflammation 
is persistent or the resolution of inflammation fails, a state of chronic 
inflammation can occur.1,3 This chronic inflammation can result in a 
disturbance of normal physiological functions. Thus, the mechanisms that 
regulate chronic inflammation are of great interest and importance since they 
are involved in a variety of diseases such as cancer, neurodegenerative 
diseases, obesity, type 2 diabetes and atherosclerosis.1,3 
 
1.2 Atherosclerosis and the role of vascular inflammation 
Atherosclerosis was once believed to be exclusively a lipid-storage disease. 
However, this view has now changed and atherosclerosis is recognised as a 
chronic inflammatory disease characterised by accumulation of lipids in 
arterial walls, a process that can subsequently lead to a heart attack or 
stroke.4,5 
 
After invading the arterial wall, cholesterol-rich, very low-density and low-
density lipoproteins (LDL) and other apoB-containing lipoproteins are 
retained in the extracellular matrix of the subendothelium where they are 
subjected to chemical modification, such as oxidation.6 Oxidised LDL (ox-
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LDL) activates smooth muscle cells (SMCs) and ECs which in turn leads to 
the secretion of inflammatory mediators (e.g. Tumor necrosis factor-
α (TNFα), interleukin (IL)-1).7 Unactivated ECs do not express selectins and 
integrin ligands such as VCAM-1 (vascular cell adhesion molecule-1) on the 
luminal EC surface and thereby resist the adhesion of circulating leukocytes 
from the arterial lumen. This physiological state has been termed 
quiescence. However, it is now emerging that the maintenance of an 
uninflamed state may be an active process that requires expression of anti-
inflammatory genes such as IκBα 8,9 and Erg.10 Subsequent to their 
activation, ECs express adhesion molecules which in turn facilitate leukocyte 
adhesion (Figure 1.1).4,11 In addition to ox-LDL, various pro-inflammatory 
molecules can activate ECs, such as microbial products (e.g. 
lipopolysaccharide (LPS), endotoxin) and cytokines (e.g. TNFα, IL-1). The 
latter two can be secreted by a variety of cells including, monocytes, 
macrophages, SMCs and ECs.12-14 Activation leads to expression of pro-
inflammatory molecules on ECs including ICAM-1 (intracellular adhesion 
molecule-1), VCAM-1, the P- and E-selectins, cytokines, and chemotactic 
factors, including monocyte chemotactic protein-1 (MCP-1) and macrophage 
colony stimulation factor (M-CSF).15 Upon the activation of ECs, leukocytes 
can bind to the endothelium and transmigrate to the underlying intima in 
response to chemokines such as MCP-1, RANTES, and fractalkine.16 
Collectively, these molecules orchestrate the migration of leukocytes from the 
bloodstream to the vessel wall via the so-called leukocyte adhesion cascade. 
Leukocytes are initially captured and subsequently roll across the EC layer 
via interactions between glycoproteins and EC selectins. Chemokines then 
activate integrins on the surface of leukocytes which enables them to engage 
in firm interactions with ECs via adhesion molecules such as VCAM-1. 
Subsequently, adhesion strengthening and spreading, intravascular crawling 
and paracellular/transcellular transmigration can occur.17 After 
transmigration, M-CSF induces the differentiation of monocytes into 
macrophages.18 A key process of atherosclerotic plaque development is the 
differentiation of macrophages into foam cells (lipid-laden macrophages). 
Intimal macrophages express scavenger receptors,19 and these endocytic 
 16 
receptors are involved in the clearance of oxLDL. Thereby they promote the 
internalisation of the modified LDL particles which leads to the enrichment of 
cholesteryl esters in the cytoplasm and the formation of foam cells.20 It has 
been suggested that the receptors SR-A and CD36 play central roles in this 
process. Nevertheless the definite contribution to atherosclerosis remains 
unclear, because several reports suggest that these receptors can both 
protect and aggravate atherogenesis.21-26 The scavenger receptor CD68 is 
predominantely expressed in late endosomes and lysosomes of 
macrophages. Due to its expression pattern, CD68 has been proposed not to 
play a major role in oxLDL internalisation but contribute to oxLDL 
endolysomal processing and subsequent foam cell formation. So far, the role 
of CD68 in atherosclerosis has not been studied using knockout mouse 
models.27-31 Subsequent to their formation, foam cells proliferate within the 
intima, maintain and amplify the inflammatory process by different pathways. 
This includes the secretion of metalloproteinases (MMPs) cytokines, reactive 
oxygen species (ROS) and thereby promoting vascular damage. 
Furthermore, cell death of both macrophages and smooth muscle cells 
leading to an antigenic and thrombogenic environment that contribute to 
atherogenesis (Figure 1.1).32-35 
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Figure 1.1: Monocyte recruitment and foam cell formation in 
atherosclerosis 
Circulating monocytes do not adhere to unactivated ECs. Circulating LDL particles can enter 
the arterial intima where they are subjected to chemical modifications such as oxidation. 
Antioxidants in the plasma protect against oxidation and thus only a very small portion of 
oxidized LDL (oxLDL) can be detected in the blood.
36
 Therefore, it has been suggested that 
LDL oxidation occurs within the intima.
37
 OxLDL subsequently activates ECs, which leads to 
the expression of adhesion molecules. Monocytes can then bind to the activated 
endothelium and transmigrate to the underlying intima. After transmigration, M-CSF induces 
the differentiation of monocytes into macrophages. Intimal macrophages express scavenger 
receptors which promote internalisation of LDL particles. This leads to the enrichment of 
cholesteryl esters in the cytoplasm causing foam cell formation (lipid-laden macrophages). 
Foam cells influence atherosclerosis through a variety of mechanisms including the secretion 
of cytokines, ROS, and growth factors (Adapted from 
32,38
; List of abbreviations can be found 
in Chapter 8) 
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The importance of inflammation in atherosclerosis is evident because 
pharmacological inhibition or genetic deletion of pro-inflammatory proteins 
ICAM-1, VCAM-1, selectins, MCP-1, TNFα, IL-1β and/or their receptors 
leads to a reduction in lesion size, macrophage infiltration and disease 
progression in experimental models of atherosclerosis.15,39-49 For example, 
the adhesion molecule VCAM-1 is expressed on ECs, macrophages, and 
SMCs,4,50,51 and contributes to both the inflammatory initiation and 
progression of atherosclerotic lesions,4,41,51-53 and it has been shown that 
mice with an impaired VCAM-1 function have a reduction in lesion 
formation.42 
 
Fatty streaks (early lesions) are characterised by the subendothelial 
accumulation of lipids, foam cells and T-lymphocytes. More advanced 
plaques can be characterised into various types including so-called stable 
and vulnerable plaques. Stable plaques are defined by the deposition of 
fibrous tissue. This stage of lesion development is driven by SMCs which 
migrate from the media into the intima where they proliferate and synthesize 
extracellular matrix.54 Thus, SMCs control the progression of a lipid-rich 
atherosclerotic lesion into a fibrotic plaque.20 By contrast, vulnerable plaques 
are particularly prone to rupture which leads to a high risk of proximate 
thrombus-mediated myocardial infarction and stroke.55 In humans, the 
histopathological feature of vulnerable plaques are well defined. They contain 
a large necrotic core, a thin fibrous cap which weakens the mechanical 
resistance of the lesion, relatively low levels of extracellular matrix (collagen 
and proteoglycans) and SMCs, infiltration by macrophages and T-cells and 
display outward positive remodelling and increased plaque vascularity.56-59 
Vulnerable plaques contain a variety of inflammatory cells such as 
neutrophils, mast cells, monocytes, T-lymophocytes and dendritic cells. By 
experimental cell transfer, depletion and inactivation of these cell types in 
atherosclerotic mouse models the role of inflammation in the progression of 
atherosclerosis has been characterized.60-65 
 
 19 
Plaque rupture results in luminal thrombosis due to contact of flowing blood 
with a thrombogenic necrotic core.56,66 Despite the great interest in plaque 
vulnerability, an ideal animal model for plaque rupture is still missing.59 In 
general, mice are highly resistant to the development of atherosclerosis. 
However, wild-type C57BL/6 mice developed lesions after feeding a very 
high cholesterol diet, but the lesions developed were small and usually did 
not develop beyond the early foam cell, fatty streak stage. The location 
differed from the human situation as they were mainly confined to the aortic 
root. Furthermore, this model was criticised because the diet used was very 
toxic resulting in weight loss as well as an increased occurrence of 
respiratory infection and a higher mortality of the animals.67 The development 
of genetically modified mice lacking genes in lipid metabolism greatly 
facilitated the study of atherosclerosis. ApoE (apolipoprotein E) deficient mice 
68-70 have increased total plasma cholesterol levels and some of the features 
involved in lesion formation are similar to larger animal models of 
atherosclerosis and humans.71 Another mouse model of atherogenesis is the 
LDL receptor knockout mouse.72 These animals have a more modest 
lipoprotein abnormality and on a high cholesterol diet they develop large 
atherosclerotic lesions.73,74 Despite the development of lesions, an ideal 
murine model for plaque rupture is still lacking because most of the plaques 
formed are stable  and the occurrence of spontaneous plaque rupture is 
under debate.59 Cheng et al. applied a flow-altering device around the carotid 
arteries of hypercholesteremic ApoE deficient mice and showed that 
hemodynamics affected lesion development and vulnerability.75 They 
observed that plaques in a low flow region had characteristics of a vulnerable 
plaque such as a large lipid core, a thin fibrous cap, a paucity of SMCs in the 
cap and an accumulation of inflammatory cells in the fibrous cap and 
spontaneous intra-plaque hemorrhages (14%). In contrast, lesions obtained 
in a region exposed to a low/oscillatory flow were described as stable 
plaques and displayed a higher content of SMCs and collagen and a lower 
content of macrophages and lipids.75,76 
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1.2.1 LPS signalling 
Cells use extracellular and intracellular receptors to sense inducers of 
inflammation. Toll-like receptors (TLRs) belong to the class of pattern-
recognition receptors (PRRs) which can sense, in combination with their 
accessory proteins, exogenous and endogenous inflammatory inducers.3 
Elevated expression and activation of PRRs has been correlated with the 
pathology of obesity, diabetes, coronary artery diseases and atherosclerosis 
in humans.77-81 In addition, animal work revealed that the deletion of some 
PRRs protects against the development of atherosclerosis e.g. TLR4 82 and 
TLR2.83-85 
 
TLRs are transmembrane receptors with an intracellular Toll-IL-1 (TIR) 
domain which is critical for signal transduction and interacts with adaptor 
molecules.86 Five TIR domain-containing adaptor proteins have been 
described: MyD88 (myeloid differentiation primary response gene 88), Mal 
(MyD88-adapter-like; also known as TIRAP), TRIF (TIR domain-containing 
adaptor inducing IFN-β), TRAM (TRIF related adaptor molecule) and SARM 
(sterile α and HEAT-Armadillo motifs-containing protein).87 Different TLRs 
require different combinations of adaptor proteins to activate signalling 
cascades. LPS, a major component of the outer membrane of Gram-negative 
bacteria, is a so-called pathogen-associated molecular pattern (PAMP) that 
signals through TLR4. LPS is sensed by the TLR4 receptor, the only 
described receptor which makes use of all five TLR adaptors. TLR4 signalling 
can be MyD88-dependent or MyD88-independent (TRIF-dependent). 
Thereby, TLR4 uses the adaptors Mal and MyD88 for activation of the NF-κB 
signalling pathway, while using TRIF and TRAM to activate the type 1 
interferon (IFN) pathway.88 Recent work has shown that the localisation and 
trafficking of TLRs between the Golgi apparatus optimises their ability to 
sense ligands and, in addition, to decrease the possibility of overactivation of 
the signalling pathway.89 In resting cells, TLR4 is located in the Golgi 
apparatus and at the membrane of human monocytes.90,91 TLR4 shuttles 
between Golgi and membrane until it interacts with LPS at the surface 
through a mechanism that involves the protein MD-2, LPS binding protein 
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(LBP), and CD14 (Figure 1.2).92,93 Binding of LPS leads to oligomerisation of 
TLR4 and interaction with the adaptor proteins Mal and MyD88.94 A 
dissociation of the complex occurs after MyD88 interacts with the IL-1 
receptor-associated-kinase (IRAK) 1 and 4, and TNF receptor-associated 
factor 6 (TRAF6) resulting in activation of transforming growth factor-β-
activated kinase 1 (TAK1), which can activate the NF-κB (Nuclear factor 
kappa B) and MAPKs (Mitogen activated protein kinase) pathways (Figure 
1.2).95 LPS-TLR4 engagement also leads to the internalisation of TLR4 in 
endosomes and consequently to the activation of the MyD88-independent 
TRAM-TRIF pathway leading to the induction of type 1 IFN (Figure 
1.2).89,96,97 
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Figure 1.2: TLR4 signalling  
Localisation and trafficking of TLR4 between the Golgi apparatus optimises ligand sensing 
and decreases the possibility of overactivation of the signalling pathway. LPS recognition is 
facilitated by LBP and CD14 and is subsequently mediated by the TLR4/MD-2 receptor 
complex. TLR4 signalling can be MyD88-dependent or MyD88-independent (TRIF-
dependent). MyD88-dependent signalling: LPS binding leads to TLR4 oligomerisation and 
interaction with the adaptor proteins Mal and MyD88. A dissociation of the complex occurs 
after MyD88 interacts with IRAK 1 and 4, and TRAF6 resulting in activation of TAK1 which 
can activate the NF-κB and MAPKs pathways. MyD88-independent signalling: LPS-TLR4 
engagement leads to the internalisation of TLR4 in endosomes (expressing EEA1) and 
consequently to the activation of the TRAM-TRIF pathway leading to the induction of type 1 
interferons. (Adapted from 
89,94
; List of abbreviations can be found in Chapter 8) 
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1.2.2 TNFα signalling 
TNFα was first described as an endotoxin-induced serum factor with the 
capacity of inducing cytotoxicity in a tumor cell line 98 and later the human 
gene was cloned.99 Newly synthesized TNFα is transported to the cell 
membrane where it functions as a transmembrane protein. The soluble 
cytokine is formed via proteolytic cleaveage by the TNFα converting enzyme 
(TACE).100 TNFα  is a homotrimeric cytokine which binds to two distinct 
surface receptors: TNFR1 and TNFR2. TNFR1 is expressed in most tissues, 
whereas TNFR2 is mainly expressed on haematopoietic cells. The function of 
TNFR2 is not well described but it has been suggested to modulate the 
action of TNFR1 on immune and endothelial cells.101 TNFR1 is involved in 
most of the described functions of TNFα including the regulation of cell 
survival, apoptosis, differentiation, proliferation and the activation of immune 
functions. The binding of TNF to the TNFR1 receptor results in the activation 
of the NF-κB and the activation of MAPKs including, JNK, p38 and ERK. 
Importantly, it also results in the induction of cell death by caspase activation, 
however the described signalling pathways are not entirely independent and 
there are several known interactions between them. For example, it is well 
established that the activation of NF-κB is essential to protect cells from 
TNFR1 mediated apoptosis.101-104 
 
TNFR1 signalling involves two distinct protein complexes. After the binding of 
TNF to its receptor TNFR1, TRADD (TNFR1-associated death domain), RIP1 
(receptor interacting protein kinase 1), and TRAF2 (TNFR-associated factor 
2) are recruited to the intracellular domain of TNFR1 and form a receptor-
proximal signalling complex also known as complex I (Figure 1.3). This 
complex activates NF-κB and MAPK signalling pathways.105 Overall 
signalling via complex I increases cell survival. Subsequently a dissociation 
of the complex I occurs, whereby TRADD, RIP1, and TRAF2 form a soluble 
intracellular signalling complex (complex II) which then attracts FADD (Fas-
associated death domain) and caspase-8 for the initation of apoptosis (Figure 
1.3).105 The successful engagement of the required components of complex I 
lead to the TNF-induced activation of NF-κB and subsequently to the 
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expression of pro-inflammatory cytokines and anti-apoptotic factors such as 
XIAP (x-linked inhibitor of apoptosis protein), cIAP (cellular inhibitor of 
apoptosis protein) 1, and cIAP2, the caspase-9 decoy c-FLIP, and the BCL-2 
homologue BCL-XL which efficiently blocks initiation of apoptosis from 
complex II.101,105,106 In this regard, it has been described that caspase-8 is 
quickly recruited and activated on a FADD-RIP1 complex to induce 
apoptosis. But this pro-apoptotic pathway can be inhibited by the 
ubiquitination of RIP1 which leads to signaling to NF-κB and expression of 
NF-κB-dependent anti-apoptotic molecules. Therefore, cells expressing a 
form of RIP1 that cannot be ubiquitinated are sensitive to TNFα induced 
apoptosis.107,108 
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Figure 1.3: TNF signalling 
TNFR1 signalling: This signalling pathway involves two distinct protein complexes. Complex 
I: After the binding of TNF to its receptor TNFR1, TRADD, RIP1 and TRAF2 are recruited to 
the intracellular domain of TNFR1 and form a receptor-proximal signalling complex. This 
leads to the formation of ubiquitin chains (UB) which acts as a scaffold for TAK1 – IKK 
complex activation. IKK phosphorylates IκBα which is then ubiquitinated and degraded. This 
pathway activates NF-κB signalling pathways leading to the expression of pro-inflammatory 
and anti-apoptotic genes. Therefore, signalling via complex I increases cell survival. 
Complex II: Dissociation of the complex I components can occur, whereby TRADD, RIP1, 
and TRAF2 form a soluble intracellular signalling complex (complex II). Complex II attracts 
FADD and this association leads to activation of caspase-8 and the initation of apoptosis. 
(Adapted from 
101,109
; List of abbreviations can be found in Chapter 8) 
 26 
1.3 NF-κB 
1.3.1 The NF-κB (nuclear factor κB) family 
The NF-κB family consists of five members: p65 (RelA), RelB (RelB), c-Rel 
(Rel), p105/p50 (NFKB1) and p100/p52 (NFKB2). All members share an N-
terminal RHD (Rel-homology domain), which is required for homo- and 
hetero-dimerization, nuclear translocation, association with inhibitory 
proteins, such as IκB (inhibitory κB), and DNA binding (Figure 1.4).110 NF-κB 
subunits can bind DNA sequences that contain the consensus motif 5`-
GGGRNWYYCC-3` (where R is any purine, N is any nucleotide, W is 
adenine or thymidine and Y is any pyrimidine).111-113 In addition, p65, RelB 
and c-Rel contain a C-terminal TAD (transcription activation domain), which 
is necessary for transcriptional activation of target genes. p105 and p100 lack 
this domain and are synthesized as inactive precursors consisting of the 
RHD and C-terminal ankyrin repeats. The production of p50 and p52 requires 
removal of the ankyrin repeats, which relies on their modification at lysine 
residues with a small protein called ubiquitin. Modified versions of p100 or 
p105 are recognized by the proteasome, which leads to partial proteolytic 
processing and results in the release of the N-terminal portion of these 
molecules: p50 and p52 respectively (Figure 1.4). These mature forms can 
bind DNA. However, given they lack the TAD, they are incapable of 
transactivation. In fact, the p50–p50 homodimer can act as a repressor by 
competing for binding sites.114 Nevertheless, p50 and p52 can positively 
regulate transcription by forming heterodimers with other molecules such as 
p65, RelB or c-Rel, or as homo or hetero-dimers complexed with Bcl-3. In 
unstimulated cells, NF-κB dimers are inactivated by binding to IκBs, which 
sequester NF-κB in the cytoplasm by masking the nuclear localisation 
sequence. There are eight known IκBs: IκBα, IκBβ, IκBγ, IκBε, IκBζ, Bcl-3, 
p100 and p105, which bind to NF-κB via ankyrin repeats.115 
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Figure 1.4: The NF-κB family 
All five mammalian Rel-related proteins [p65 (RelA), c-Rel, RelB, p100 (p52), p105 (p50)], 
contain a Rel-homology domain (RHD), which mediates their dimerization and binding to 
DNA. Only RelA, c-Rel and RelB contain a carboxy-terminal transactivation domain (TAD). 
p100 and p105 contain ankyrin repeats (yellow circles), which mediate their binding to NF-κB 
dimers in order to sequester them in the cytoplasm. p100 and p105 require ubiquitin-
dependent proteolytic processing of the C-terminal portion to generate p52 and p50 NF-κB 
subunits, respectively (the cleavage point is indicated with an arrow). GRR; glycine-rich 
region, LZ; leucine zipper. (Adapted from 
116
; List of abbreviations can be found in Chapter 8) 
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1.3.2 NF-κB regulation 
Studies of NF-κB regulation have mainly focused on signalling pathways that 
activate NF-κB and these processes are relatively well defined. However, the 
regulation of expression of NF-κB sub-units and the physiological 
significance of differential NF-κB expression has received little attention. So 
far, it is established that c-Rel NF-κB sub-units are regulated at the 
expression level.117,118 Furthermore, it has been suggested that RelA 
expression may be altered during cellular senescence which is a state of 
stable proliferative arrest.119-121 However, signalling pathways that influence 
RelA expression have not been described. 
 
NF-κB is activated by several signalling pathways that cause it to be released 
from IκB (usually by ubiquitination and degradation of IκB), allowing NF-κB to 
translocate to the nucleus (Figure 1.3 and 1.5). These pathways are 
classified as canonical (classical) and non-canonical (alternative) (Figure 
1.5). In the non-canonical pathway, the IKK (IκB kinase) complex (a 
homodimer of IKKα) 122 is phosphorylated by NIK (NF-κB-inducing kinase) 
which is activated upon the degradation of its negative regulators TRAF2, 
TRAF3, c-IAP1 and c-IAP2 123 in response to LT-β (lymphotoxin-β), BAFF (B-
cell activation factor), CD40 or RANKL (receptor activator of activation of NF-
κB ligand). Activation of the IKK complex leads to proteasomal processing of 
the RelB–p100 heterodimer to RelB–p52, which then translocates to the 
nucleus and regulates a specific subset of target genes.115 In the canonical 
pathway, the IKK complex (an IKKα–IKKβ heterodimer) is activated by 
signalling through receptors, such as TNFR1, IL-1R (IL-1 receptor), TLRs 
and other pro-inflammatory receptors, in response to their cognate ligands, 
including cytokines, viral, yeast and microbial products.110 Engagement of IL-
1R and TLRs leads to the recruitment of signal adaptors, resulting in the 
activation of TRAF6. TRAF6 contains a RING finger that functions as an E3 
ligase that can catalyse auto-ubiquitination. Engagement of TNFR1 leads to 
the recruitment of other signalling intermediaries, including TRADD, TRAF2 
and RIP. TRAF2, like TRAF6, contains a RING finger E3 ligase which drives 
polyubiquitination of RIP.124 The ubiquitin chains on RIP and TRAF6 may act 
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as a scaffold for binding of the pro-inflammatory kinases TAK1, complexed 
with the adaptor protein TAB2 (TAK1-binding protein 2), and IKK.125 This 
allows TAK1 to interact with the polyubiquitin chain and IKK to complex with 
NEMO (NF-κB essential modulator). TAK1 is a MAPKKK [MAPK (mitogen-
activated protein kinase) kinase kinase] that can activate IKK through 
phosphorylation. This process may position TAK1 in an optimal configuration 
for phosphorylation of IKK. The canonical NF-κB pathway can be activated 
by other stimuli, including hypoxia 126-128, ROS 129, for instance induced by G-
protein-coupled receptor agonists 130, and mechanical forces 131; however, 
the signalling pathways that underlie these responses are relatively poorly 
characterized. 
 
Another level of NF-κB regulation involves post-translational modifications 
(PTM). In general, there are hundreds of different PTMs. For NF-κB, these 
modifications within the RHD, TAD or linker domains influence various 
physiological functions. In particular, phosphorylation and acetylation control 
binding activity of NF-κB to DNA or IκBs. RelA can be acetylated by a 
histone acetyltransferases (HATs) at five different lysine residues (Lys-122, 
Lys-123, Lys-218, Lys-221, Lys-310).132 These modifications lead to different 
binding properties. For instance, p300/CBP HAT acetylates RelA at Lys-218, 
Lys-221 and Lys-310. The modification at Lys-221 attenuates the binding of 
RelA to IκBα and increases the binding affinity of RelA to DNA.133 For full 
transcriptional activity, acetylation of Lys-310 is required.134 On the other 
hand, acetylation of RelA at Lys-122 and Lys-123 decreases RelA activation 
by accelerating its disscociation from DNA, resulting in the binding of IκBα 
and subsequent nuclear export.135 Removal of the acetyl group is catalysed 
by histone deactylases (HDACs). By now, 18 HDACs have been described 
and divided into four classes. Class I contains HDAC1, 2, 3 and 8.136 HDAC3 
deacetylates the lysine residue 221 of RelA in the nucleus and thereby 
promotes the binding of RelA to IκBα. This leads to its nuclear export and 
terminates RelA activity.133 HDAC3 can be activated by LPS treatment which 
enhances HDAC3 nuclear localisation and activity in cardiomyocytes.137 
HDACs play a role in various diseases including cancer 138,139, autoimmune 
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diseases 140, and inflammatory regulation.141 Therefore, the inhibition of 
HDACs gained great interest for therapeutic approaches. HDACs can be 
targeted by several structurally diverse compounds, the so called HDAC 
inhibitors (HDIs). The inhibitory effect is probably due to their interaction with 
a specific site in the catalytic pocket of HDACs.142,143 Some HDIs have a 
significant anti-tumor activity 138,139 and have shown to be a potential 
therapeutic tool for the treatment of autoimmune diseases,140,144 and other 
processes.142 MS-275 is a benzamide HDI specific for class I HDACS with a 
high affinity for HDAC1 and HDAC3 but relatively weak inhibition of 
HDAC8.145,146 
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Figure 1.5: Signalling to NF-κB 
On the left, the canonical signalling pathways are shown. IL-1R and TLR recruit signal 
adaptors (including MyD88, TOLLIP, IRAK’s) leading to the modification of TRAF6 with 
Lys63 polyubiquitin chains (Ub, red circles). Signal transduction through TNFRs relies on the 
recruitment of signalling intermediaries (including TRAF2) which leads to Lys63 
ubiquitination (Ub, red circles) of RIP. The ubiquitin chains act as a scaffold for 
oligomerisation of TAB-TAK1 and IKK-NEMO complexes. This may create an optimal 
configuration for TAK1-mediated phosphorylation of IKK or neighbouring TAK1 molecules. 
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Finally, the activated IKK complex phosphorylates IκBα which is subsequently modified with 
Lys48 polyubiquitin chains (Ub, blue circles) and then transported to the proteasome where it 
is degraded, thus liberating NF-κB for nuclear entry. NF-κB activation is regulated by 
multiple negative feedback mechanisms, including NF-κB-dependent IκBα expression. 
Newly synthesized IκBα removes NF-κB from the nucleus, thereby terminating NF-κB 
activation. The deubiquitinating enzymes A20, CYLD, and Cezanne block IKK activation by 
removing poyubiquitin chains from upstream intermediaries and are, therefore, negative 
regulators of NF-κB. (Adapted from 
116
; List of abbreviations can be found in Chapter 8) 
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1.3.3 Negative regulation of NF-κB 
The activity of NF-κB is tightly regulated by several negative feedback 
mechanisms such as the NF-κB dependent induction of IκBα, A20 147-149 and 
Cezanne.150,151 IκBα, which is induced at a transcriptional level by NF-κB, 
has a nuclear export sequence enabling it to remove NF-κB from the 
nucleus, thereby terminating NF-κB activation.152 This generates a feedback 
loop which results in oscillations of NF-κB between the nucleus and the 
cytoplasm. Studies have revealed that the deubiquitinating enzymes CYLD 
(cylindromatosis gene), A20 and Cezanne 153,154 are critical negative 
regulators of NF-κB. They are induced by pro-inflammatory signalling and 
can block IKK activation by removing polyubiquitin chains from upstream 
intermediaries.150,155-157 This process dampens NF-κB oscillations by 
stabilizing re-synthesized IκBα for NF-κB inactivation. 
 
1.3.4 NF-κB dynamics 
The duration of NF-κB nuclear localisation in response to a stimulus is tightly 
regulated. NF-κB dynamics are important because they regulate the 
magnitude and specificity of target gene expression.158,159 
 
A short pulse of TNFα stimulation does not result in oscillatory activation of 
NF-κB but only in a single wave of activity. Sustained activation of cells with 
a range of TNFα concentrations on the other hand can result in the 
translocation of NF-κB into and out of the nucleus with a period of roughly 
100 minutes, a process that depends on the continuous degradation and re-
synthesis of IκB proteins.147,160-162 It was important to analyse NF-κB 
dynamics in single cells since oscillations are asynchronous in the whole 
population, with different phases occurring in different cells.147 There is a 
continuous discussion regarding the extent of NF-κB oscillations in 
physiological systems. It has been suggested that IκBβ and IκBε are 
responsible for dampening of oscillations following delayed transcription after 
TNFα stimulation.163,164 Hoffman et al. described that the oscillatory 
activation gradually dampens in wild-type cells with one or two cycles and 
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that in cells lacking both IκBβ and IκBε the oscillation is maintained.159 
However, a study by Nelson et al. showed sustained NF-κB oscillations in 
wild-type cells transfected with fluorescent fusion proteins of RelA.147 This 
approach has been criticised for not being directly applicable to the dynamic 
behaviour of endogenous NF-κB.165 However, the observations by Nelson et 
al were supported by Sung et al. who used GFP-p65 knock in mouse 
embryonic fibroblasts and showed that NF-κB oscillations were sustained in 
the majority of cells, with several cycles of transient nuclear localisation 
subsequent to TNFα stimulation.166 Despite disagreement on the factors that 
regulate oscillations, there is a consensus view that the oscillation of NF-κB 
is an important factor in temporal regulation of gene transcription. Ashall et 
al. showed that varying the frequency of NF-κB translocation can influence 
gene expression. It was observed that 200 min pulses with TNFα resulted in 
synchronous NF-κB oscillations with full amplitude and to the induction of 
early NF-κB response genes (IκBα, IκBε, MCP-1).161 For shorter pulses of 
TNFα stimulation (60 or 100 min) the amplitude of the oscillation was 
gradually decreased by each pulse and this dampened oscillation was 
associated with the expression of the early (IκBα, IκBε, MCP-1) but also late 
NF-κB response genes (RANTES).161 
 
By contrast to TNFα, LPS does not induce oscillations in NF-κB 
activation.167,168 A recent study revealed that cellular responses to LPS are 
very heterogenous due to the secretion of TNFα and the subsequent overlap 
of the TNF and LPS signalling cascades. Specifically, LPS-stimulated cells 
can be clustered into a transient response group where NF-κB was exported 
from the nucleus quickly after stimulation and a persistent response group 
where NF-κB remained in the nucleus for hours. The latter response could be 
linked to a secondary paracrine TNFα signal that led to a late phase of LPS-
dependent NF-κB activation.169 Interestingly, Bartfeld et al. demonstrated that 
bacterial infection also induces oscillations of RelA. They observed a 
dampened oscillation subsequent to the exposure of cells to the bacterium 
Helicobacter pylori.170 In conclusion, the stimulation frequency coordinates 
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the specificity of gene expression by influencing the dynamics of NF-κB 
activation. 
 
1.3.5 NF-κB in atherosclerosis 
The NF-κB pathway is activated in most cell types involved in the different 
stages of lesion development, indicating that NF-κB might be involved in 
vascular inflammation and the initiation and progression of atherosclerotic 
lesion formation.110,171,172 
 
An important event in the initiation of atherosclerosis is the recruitment of 
leukocytes from the circulation to the vessel wall for subsequent migration 
into the subendothelial layer. Quiescent inactive ECs resist leukocyte 
adhesion; however, ECs can become activated in response to various stimuli 
and express adhesion proteins, chemokines and other pro-inflammatory 
proteins to facilitate leukocyte adhesion (see section 1.2).173,174 This process 
involves activation of NF-κB in ECs in response to pro-atherogenic 
molecules, including TNFα, IL-1, CD40, cytokines, bacterial and viral 
infections,175 oxLDLs,176 ROS 151,177 and advanced glycation endproducts.178 
These molecules activate NF-κB via distinct signalling pathways that 
converge to activate IKK.  
 
EC dysfunction is defined as an impaired balance between vasodilating and 
vasconstrictive molecules, which are either produced by or act on ECs, and 
is an early manifestation of several cardiovascular diseases.179-181 One 
consequence of endothelial dysfunction is impaired production of nitric oxide 
(NO), which is a potent vasodilator, antioxidant and anti-inflammatory 
molecule. Essential for the synthesis and release NO is the enzyme eNOS 
(endothelial NO synthase). This function of eNOS requires dimerisation of the 
enzyme, the presence of the substrate L-arginine and the cofactor 
tetrahydrobiopterin. In some circumstances (e.g. during exposure to oxidative 
stress) eNOS can be uncoupled from tetrahydrobiopterin, an event that 
switches eNOS function from NO production to superoxide formation or 
generation of hydrogen peroxide if the substrate L-arginine is reduced. This 
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process, termed eNOS uncoupling, has been associated with endothelial 
dysfunction. Overall this leads to the transformation of eNOS from a 
protective enzyme to a contributor of oxidative stress.182 Therefore oxLDL, 
ROS and other pro-atherogenic agents can activate NF-κB indirectly through 
uncoupling of eNOS with NO production, thus reducing production of NO 
which is a negative regulator of NF-κB.183-187 In addition, NF-κB activation in 
ECs has been associated with hypertension, which is one of the major risk 
factors for atherosclerosis.188 Indeed, angiotensin II, an important mediator of 
the renin–angiotensin–aldosterone system, which is elevated in 
hypertension, can activate NF-κB by inducing intracellular ROS.189-191 
 
The central role of NF-κB in atherosclerosis has been studied recently using 
transgenic mice with endothelium specific inhibition of RelA due to ablation of 
NEMO or overexpression of dominant-negative IκBα. This intervention led to 
the suppression of adhesion molecule expression on ECs, impaired 
macrophage recruitment to atherosclerotic plaques, and decreased 
expression of cytokines and chemokines in the aorta of ApoE-null mice.172 
These results indicate that NF-κB activation in ECs plays an essential role in 
vascular inflammation and atherosclerosis by regulating the expression of 
pro-inflammatory molecules. In addition to the regulation of inflammatory 
activation, NF-κB activation may also enhance EC viability by inducing anti-
apoptotic genes.192 
 
NF-κB is also involved in the progression of atherosclerosis. In human aortic 
atherosclerotic lesions, activated NF-κB (RelA) was first detected by Brand et 
al.193 They demonstrated nuclear NF-κB in ECs overlying early lesions, and 
in SMCs, macrophages and T-cells in more advanced lesions. Bourcier et al. 
detected active nuclear p65 and p50 in SMCs in human lesions, whereas NF-
κB was inactive in SMCs in healthy tissues.176 In cells isolated from human 
atherosclerotic tissue, active NF-κB p65, p50 and c-Rel were detected, but 
not p52 and RelB.194 The consequences of NF-κB activation in plaques are 
likely to be complex. Activity of the canonical pathway results in up-regulation 
of pro-inflammatory (TNFα, IL-6 and IL-8) and pro-thrombotic MMPs (matrix 
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metalloproteinases) and TF (tissue factor) mediators, which are pro-
atherogenic.194 NFκB signalling in ECs may promote recruitment and 
activation of inflammatory cells, whereas NF-κB activity in SMCs led to their 
proliferation.195 Interestingly, inhibition of NF-κB activity in macrophages, by 
IKK2 deletion, in mice with an LDLR-null background increased 
atherosclerosis, suggesting NF-κB activation in macrophages is beneficial.196 
They observed that IKK2 deletion leads to decreased secretion of the anti-
inflammatory cytokine IL-10 but did not affect the secretion of the pro-
inflammatory cytokines IL-6 and IL-12. Therefore they suggested that IKK2 
deletion in macrophages influences the pro- and anti-inflammatory balance 
that controls the development of atherosclerosis.196 In contrast, genetic 
deletion of NF-κB1 in macrophages in the LDLR-null background resulted in 
a decrease in atherosclerosis. The NF-κB1- deficient macrophages show a 
reduced uptake of oxLDL but a prolonged production of TNFα in response to 
a pro-inflammatory LPS stimulus.197 
 
Rupture of an atherosclerotic lesion can lead to infarction/ischaemia of the 
area downstream of the lesion site. Patients with unstable angina, who are at 
risk of plaque rupture, have high levels of activated NF-κB in their white 
blood cells.198 Plaque rupture has been associated with high MMP activity in 
macrophages. Excessive MMP production leads to the destruction of the 
extracellular matrix, which plays an important role in plaque rupture. Several 
MMPs (MMP1, 3 and 9) proposed to be instrumental in this process are 
transcriptionally regulated by NF-κB, suggesting that NF-κB activation may 
influence rupture via MMP induction.199 
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1.4 Mitogen-activated protein kinases 
Mitogen-activated protein kinases (MAPKs) are serine-threonine kinases that 
play an important role in cell physiology. MAPKs can be separated into three 
major families; extracellular signal-regulated kinase (ERK), p38, and c-jun 
NH2-terminal kinase (JNK) which is also known as stress-activated protein 
kinase (SAPK). These families contain different isoforms, ERK1 to ERK8; 
p38 (α, β, γ, δ) and JNK1 to JNK3.200 MAPKs are regulated by various 
intracellular or extracellular stimuli that trigger a cascade of kinase activation 
(Figure 1.6). Thus MAPK kinase kinase kinase (MAP4Ks) and GTPases 
activate MAP3Ks, which in turn activate MAP2Ks which activate MAPKs by 
dual phosphorylation of threonine tyrosine residues in the kinase domain 
(Figure 1.6).201 MAPKs themselves phosphorylate numerous target 
substrates, including transcription factors, leading to the regulation of cellular 
responses such as proliferation, migration, differentiation, apoptosis and 
inflammatory responses. This described activation occurs through the 
formation of a signalling complex with the multiple kinases which is guided by 
a scaffolding protein.200 
 
1.4.1 JNK signalling pathway 
The MAPK JNK was first described as a stress-activated protein kinase due 
to its activation in response to the inhibition of protein synthesis.202 Three 
genes encode the JNK family members JNK1, JNK2 and JNK3. JNK1 and 
JNK2 are ubiquitously expressed while JNK3 is mainly expressed in the brain 
and to a lesser degree in the heart and testis.203 It has been shown that four 
splice variants of JNK1, four splice variants of JNK2, and two splice variants 
of JNK3 exist. Thus 10 JNK isoforms can be generated as either 46 or 54kDa 
proteins.204 However, despite the variety of alternatively spliced variants their 
specific functions in vivo have not largely been addressed.205  
 
Activation of JNK by pro-inflammatory cytokines occurs via upstream 
MAP3Ks such as MEKK1-4, apoptosis signal-regulating kinase 1 (ASK1), 
TAK1 and mixed lineage kinase 3 (MLK3).206-212 However, the specific 
MAP3K involved in the activation of JNK (or p38 MAPK) is not known in 
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many physiological conditions.213 In addition, an overlap regarding the 
upstream activators in particular on the level of the MAP3Ks of the p38 and 
JNK MAPK pathway occurs. It has been suggested that signalling pathway 
specificity is achieved by the usage of scaffolding proteins which allow 
binding to unique combinations of MAP2Ks and substrates in different 
subcellular localisations. For example, JNK-interacting protein (JIP) and β-
Arrestin 2 act as scaffold proteins for the JNK pathway (Figure 1.6).214,215 
MAP3Ks activate MKK4 and MKK7 which are the MAP2Ks involved in JNK 
activation (Figure 1.6).  
 
Upon activation, JNK phosphorylates transcription factors belonging to the 
AP-1 superfamily.216 This family contains proteins with a bZIP (basic region 
leucine zipper) domain which is essential for dimerisation and binding the 
DNA binding target seqeuence.217,218 It consists of the Jun (c-Jun, JunB, and 
JunD), Fos (c-fos, FosB, Fos-related antigen 1 and 2 (Fra), v-maf 
musculoaponeurotic fibrosarcoma oncogene homolog (Maf, c-Maf, MafB, 
MafA, MafG/F/K, and neurofibromatosis 1 (Nf1)), and ATF (ATF2, ATF3, 
ATF4, ATF6, ATF7, and cyclic AMP-responsive element-binding protein 5 
(CRE-BPa)) subfamilies. Jun proteins are capable of building homo- as well 
as heterodimers, while Fos protein can only heterodimerize with Jun proteins 
to bind to DNA.218 Of these transcription factors, JNK is known to activate 
transcription factors such as c-Jun, ATF and ETS domain-containing protein 
Elk-1 (Elk-1) through phosphorylation. This activity is important in EC 
activation and vascular inflammation as JNK plays a role in TNFα induced 
expression of the adhesion molecule E-selectin by phosphorylation of ATF2 
and c-Jun.219-221 There are conflicting reports on the phenotype of JNK1 -/- 
mice. The group led by Professor Flavell reported that JNK1 knockouts were 
fertile and of normal size.222 However, another study demonstrated that lean, 
male JNK1 -/- mice have decreased body weights at ages older than 12 
weeks, fasting blood glucose levels, and fasting blood insulin levels 
compared to their wild-type controls.223,224 In addition, work by Witczak et al. 
observed that JNK1 -/- mice had lower body weights at all ages.225 
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Figure 1.6: JNK signalling 
Intracellular signalling is initiated by extracellular or intracellular stimuli. MAP4Ks or GTPases 
activate MAP3Ks which in turn activate MAP2Ks which activate MAPKs by dual 
phosphorylation of threonine tyrosine residues in the kinase domain. MAPKs themselves 
phosphorylate numerous target substrates leading to a cellular response. Signalling 
specificity is achieved by the usage of scaffolding proteins which allow binding to unique 
combinations of MAP2Ks and substrates in different subcellular locations. Stimuli such as 
pro-inflammatory cytokines, growth factors, and stress lead to the activaton of MAP3Ks 
including MEKK1-4, ASK1, TAK1, and MLK3. JNK-interacting protein (JIP) and β-Arrestin 2 
act as scaffold proteins for the JNK pathway and the MAP3Ks activate the MAP2Ks MKK4 
and MKK7, which mediate the phosphorylation and activation of JNK. Subsequently, JNK 
activates transcription factors such as c-Jun, ATF and Elk-1 through phosphorylation. 
(Adapted from 
200,201,226
; List of abbreviations can be found in Chapter 8) 
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1.4.2 ATF2 
Activating transcription factor (ATF)-2 is part of the ATF/cAMP-response 
element (CRE)-binding (CREB) family.227,228 These transcription factors can 
form homodimers or heterodimers via their b-ZIP domains and bind to the 
consensus ATF/CRE site (TGACGTCA) within promoters of their target 
genes.229 The b-ZIP domain is in the C-terminal region, while the N-terminus 
contains a trans-activation domain. ATF2 is inactive in unstimulated cells due 
to an intramolecular association between the C-terminal DNA binding domain 
and the N-terminal trans-activation domain which suppresses activity.230 
Furthermore, ATF2 monomers and ATF2 homodimers are mainly located in 
the cytoplasm of unstimulated cells. Subsequent to a stress response, the 
residues T69 and T71 in the N-terminus are phosphorylated, leading to the 
relief of intramolecular inhibition 231,232 and increased transcriptional 
activation of ATF2.233,234 C-Jun is one of the major partners of ATF2 and 
phosphorylation of c-Jun-ATF2 heterodimers by JNK or p38 results in full 
transcriptional activity.232,235-241 However, it has also been shown that ATF 
has transcriptional activity in the absence of c-Jun.233 
 
1.4.3 JNK signalling and ATF2 in atherosclerosis 
Numerous studies have revealed that JNK isoforms play important roles in 
cardiovascular injury and disease. As mentioned, JNK1 and JNK2 are 
ubiquitously expressed while JNK3 is mainly expressed in the brain, heart 
and testis.203 Animal studies have revealed that JNK can be activated in 
arteries in response to injury,242-244 during the development of aneurysms,245 
in regions susceptible for atherosclerosis,246,247 and atherosclerotic 
lesions.248,249 In vitro studies have implicated a role of JNK in foam cell 
formation as mouse peritoneal macrophages showed an activation of JNK 
subsequent to oxLDL treatment and pharmacological inhibition of JNK using 
the inhibitor SP600125 blocked the oxLDL induced macrophage formation.250 
Moreover, it was concluded that JNK is involved in the pathophysiology of 
atherosclerosis because gene transfer of a dominant negative form of JNK 
reduced neointimal formation in injured arteries 242 and genetic deletion of 
JNK2 reduced foam cell formation and EC dysfunction in 
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hypercholesterolaemia.249,251 The study by Ricci et al. also assessed the role 
of JNK1 and JNK2 in atheroma formation and found a significant reduction of 
lesion development in ApoE -/- JNK2 -/- double knock out animals compared 
to ApoE -/- animals following 14 weeks on a high-cholesterol diet. 
Examination of ApoE -/- JNK1 -/- double knock out animals revealed a 
minimal reduction in plaque area, but this difference was not statistically 
significant compared to ApoE -/- animals.251 The role of JNK1 and JNK2 
together in the context of atherosclerosis has not been addressed, since 
JNK1 -/- JNK2 -/- double knock outs are embryonic lethal.252,253 Therefore, 
conditional knockout animals with tissue-specific deletion of JNK1 and JNK2 
would be required to address their combined role in atherogenesis. 
 
The involvement of ATF2 in vascular inflammation has been suggested by in 
vitro studies that demonstrated that exposure of human umbilical vein 
endothelial cells (HUVEC) to an athero-protected form of shear stress led to 
reduced DNA binding activity of ATF2, and silencing of ATF2 resulted in 
reduced expression of pro-inflammatory genes.254 In addition, it has been 
shown that ATF2 directly regulates expression of TNFα 234 and, 
antagonistically with CREB, the expression of eNOS.255 Furthermore, ATF2 
was activated by phosphorylation in human ECs overlying atherosclerotic 
lesions.254 The effect of ATF2 deletion on the development of atherosclerosis 
in mouse models has not been addressed. This approach would require the 
generation of conditional knockouts with tissue-specific deletion of ATF2, 
since ATF2 null mice die shortly after birth due to severe respiratory 
distress.256 
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1.5 NF-κB – MAP kinase crosstalk 
The NF-κB and MAP kinase signalling pathways are regulated through 
multiple mechanisms that involve crosstalk at several different levels. It is 
well established that NF-κB induces several negative regulators of MAP 
kinases. For instance, studies have shown that NF-κB induces mitogen-
activated protein kinase phosphatase 1 (MKP-1) which acts as a prosurvival 
factor by attenuating JNK- mediated pro-apoptotic responses.257 In addition, 
it has been shown that the NF-κB pathway suppresses TNFα mediated JNK 
activation by inducing other negative regulators, including A20, GADD45β 
and XIAP.258-260 Several studies have also demonstrated that the NF-κB 
signalling pathway downregulates JNK activation by the suppression of 
ROS.261-263 Overall, NF-κB plays a key role in maintaining cell viability by 
preventing prolonged activation of JNK which can lead to apoptosis.264 
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1.6 Shear stress 
Shear stress is a fluid mechanical force generated by blood flow on ECs. 
Besides shear stress, mechanical stresses on the vessel wall include the 
perpendicular forces of blood pressure and cyclic stretch generated by 
pulsatile flow.5 Shear stress is measured in dyne/cm2 or N/m2 (= Pascal 
(Pa)), and defined as the friction between two adjacent layers in a fluid and 
arises from the difference in the velocity of the two layers. Shear stress of 
laminar flow through a straight circular tube can be mathematically expressed 
by the Hagen-Poiseuille equation: 
 
τ =4µQ/πR3=4µV/R 
 
The equation shows, that shear stress (τ; N/m2, Pa or dynes/cm2) is 
proportional to the velocity (V) of the fluid, and Q which represents the 
amount of fluid which passess through a given Unit per time (volumetric flow 
rate) and µ the fluid viscosity (Pa s). However, shear stress is reciprocally 
proportional to the radius (R) of the tube.265 The vascular shear stress of 
large arteries usually varies between 5-20 dyne/cm2. Nevertheless, 
significant instantaneous values alternate from negative measures to nearly 
40 dyne/cm2 during states of increased cardiac output.266 
 
Another important parameter in fluid dynamics to describe flow conditions 
and stability is the Reynolds number (Re) which is a dimensionless ratio of 
blood inertial forces to viscous forces. It determines whether laminar or 
turbulent flow occurs. Re is calculated as following: 
 
Re = VD/µ= 4Q/πDµ 
 
V is the temporally and spatially averaged blood velocity, Q is the time-
averaged cardiac output, D the vessel diameter, µ the blood viscosity. At very 
low Re (i.e. below 1), viscous forces dominate inertial forces resulting in a 
laminar flow which follows the vessel geometry, while at higher Re, when 
viscous forces and inertial forces are similar, secondary flows such as 
vortices and other non-axial flow phenomena occur at arterial bends and 
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bifurcations. When inertial forces dominate dramatically, a turbulent flow may 
occur.265 The generation of turbulent flow where lateral motion of the blood 
becomes fully randomised occurs at Re greater than 2000. The development 
is dependent on vascular geometries, the presence or absence of lumen 
stenosis and on flow pulsatility. It has been described, that transient 
turbulence arises in the human aorta at peak systole, during heavy dynamic 
exercise in much of the central arterial system and distal to arterial lumenal 
stenosis and aneurysms.5 It is important to note the Re is smaller in arteries 
of rodents compared to larger mammals, hence secondary flows at arterial 
branches and bends occur less frequently in mice compared to humans. 
 
The persistent exposure of the vasculature to a physiological shear stress, 
especially in regions of the artery exposed to a unidirectional laminar flow, 
results in the establishment of physiological characteristics of the arterial wall 
promoting an anti-inflammatory, anti-thrombotic, anti-coagulative, pro-
fibrinolytic and anti-hypertrophic state. Furthermore shear stress is involved 
in flow-mediated vasodilation to normalize mechanical forces and thereby 
helping the maintenance of normal endothelial function.5 Besides ECs, SMCs 
may also be directly or indirectly exposed to shear stress in vivo.267,268 
 
1.6.1 Role of shear stress in atherosclerosis 
Shear stress arises at the interface between blood and the endothelial layer, 
where this mechanical stress induces a shearing deformation of the 
endothelial cells in parallel to the flow direction.269 Shear stress varies in 
time, magnitude and direction according to vascular pulsatility and 
anatomical geometry. Parts of the arterial tree with uniform geometry are 
exposed to uni-directional shear stress, whereas arches and branches are 
exposed to disturbed, oscillatory shear. Low/oscillatory comprise the 
following characteristics: low average shear stress, continously changing 
gradients of shear stress, oscillatory flow due to flow reversal, and 
multifrequency, multidirectional, secondary flows. For example, within 
pulsatile arteries the region of disturbed flow expands and contracts with the 
cardiac cycle. With regards to the aortic arch a complex series of flow 
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reversal events occur in the inner curvature. In decelerating systole, the 
forward movement of blood away from the heart reverses on the inside of the 
curvature and thereby creating a separated, oscillatory, flow pattern. In 
addition to the effects of the cardiac cycle, the geometry of the aortic arch 
(curvature) itself, leads to a lower average shear stress in the inner curvature 
compared to the outer curvature.265 A relation between local blood flow 
pattern and atherogenesis is evident as atherosclerotic plaques are not 
evenly distributed over the arterial system, but occur predominantly at branch 
points and bifurcations. The first indication in the role of shear stress in the 
focal distribution of atherosclerosis was described by Caro et al. in 1969 and 
has been validated by numerous subsequent studies.270-278 Atherosclerotic 
lesions occur at regions which are exposed to relatively low, oscillatory 
shear, whereas regions of the vasculature exposed to relatively high, 
unidirectional shear are athero-protected. Analysis of human carotid artery 
and the murine aorta using computational fluid dynamics described a 
correlation between shear stress and the development of atherosclerosis.279-
281 In this work Suo et al. described an association between relatively low and 
oscillatory shear stress and the expression of various adhesion molecules.280 
It is important to mention that despite the fact that average wall shear 
stresses are 20 times higher in mice compared to men,282-284 the focal 
distribution of atherogenic molecules in the murine aorta are similar to the 
lesion localisation in the human aorta. In this context, atherogenesis in mice 
occurs at prediliction sites which are the aortic root, the inner curvature of the 
aortic arch, the brachiocephalic trunk, and the branch points of the left carotid 
and subclavian arteries. In contrast to the distribution of atherosclerosis in 
human coronary arteries, the major lesions in mice are located in the valve 
sinus, including the origins of the coronary arteries. However, the first 
segment and first branch of all the major coronary arteries, which are the 
usual sites of atherogenesis in humans, are protected from atherosclerosis in 
mice. An additional complication in the comparison of mouse and man is the 
presence of major branches of the coronary arteries within the myocardium. 
In man, the left and right coronary arteries are extramural. Intramural 
branches arise along the course of the coronary arteries and do not display 
atherosclerosis. However, in the murine system, vessels are intramyocardial 
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and display small lesions.285,286 Regarding the differences in average wall 
shear stress between men and mice it has been suggested that relative 
differences in shear stress magnitude and direction, instead of the absolute 
magnitude, may determine flow-mediated inflammatory responses.280 A 
causal link between altered hemodynamics and atherogenesis has been 
described by Cheng et al. and others.75,287 Cheng et al. developed a cuff 
which alters the geometry of the murine carotid artery and consequently 
exposes distinct regions to low shear, high shear and low/oscillatory shear 
stress. The geometry of the cuff has been designed with computational flow 
dynamics software to produce vortices downstream of the device. It consists 
of two halves with a cone-shaped lumen that is 500 µm wide in diameter 
upstream and narrows down to a diameter of 250 µm in the downstream part. 
Once placed around the right common carotid artery, the cuff introduces a 
reduction of blood flow (low shear stress) solely due to the increase in 
resistance from the stenosis caused by the cuff. This tapering effect 
increases the shear gradually in the cuff region (high shear stress). The 
occurrence of low/oscillatory shear stress was determined by Doppler 
measurements in rabbits where reversals in velocity indicate the occurrence 
of vortices.288 Consistent with this, ECs in the low/oscillatory shear stress 
region displayed a more irregular, polygonal morphology which is a 
characteristic of oscillatory flow. Recent work from van Bochove et al. in mice 
used phase-contrast velocity imaging and observed low flow rates in the 
downstream region. Furthermore, they proposed that the observed absence 
of a laminar flow profile in this region provides a strong indicator that the flow 
pattern is highly irregular and therefore an indirect proof for the oscillatory 
nature of the flow.289 By using this cuff Cheng et al. demonstrated that 
atherosclerotic lesion size and stability are determined by defined patterns of 
shear stress.75,288 
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1.6.2 Effects of shear stress on EC activation and vascular inflammation 
Shear exerts its local effects through endothelial mechanotransduction, which 
is the transformation of mechanical stress into a biochemical response. This 
requires a variety of sequential steps starting with the physical deformation of 
the cell surface, intracellular transmission of stress, conversion of the 
mechanical force to chemical activity and downstream biochemical signalling 
with feedback. The temporal control of this sequence of events has not yet 
been firmly established.265 Interestingly, shear stress activates almost 
simultaneously a variety of membrane molecules and microdomains resulting 
in signal transduction of multiple pathways. To date, a diversity of candidates 
as shear sensors have been described including ion channels such as K+ 
channels,290-293 tyrosine kinase receptors (VEGFR2 and Tie-2),294-297 
caveolae,298-303 G-protein-coupled receptors (GPCRs),304-306 the 
cytoskeleton,307,308 the glycocalyx,309-314 and primary cilia.315-317 Recently, the 
importance of JNK in flow shear stress-induced actin remodelling has been 
described.318 Tzima et al. provided particularly convincing evidence that a tri-
molecular complex, comprising platelet endothelial cell adhesion molecule-1 
(PECAM-1, CD31), vascular endothelial cadherin (VE-cadherin), and 
vascular endothelial growth factor receptor 2 (VEGFR2) can respond to 
shear stress because they demonstrated that this complex can be directly 
activated by the application of mechanical force.319 Recently, it has been 
shown, that PECAM-1 promotes atherosclerotic plaques in regions of 
disturbed flow in ApoE-deficient mice, which is consistent with its known role 
in biomechanical signal transduction.320 
 
High shear stress can potentially suppress atherogenesis by altering EC 
physiology (Figure 1.7). For example, high shear stress induces eNOS 
expression and thus results in greater availability of NO which is a potent 
vasodilator antioxidant and anti-inflammatory mediator.182,288 In addition, the 
transcription factor KLF2 can be activated by high shear stress and can 
reduce NF-κB activity in cultured cells.321,322 Shear stress also exerts its 
protective function by modulating p38 and JNK signalling pathways via 
apoptosis signal-regulating kinase 1 (ASK1) 206-212,323,324 and the induction of 
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MKP-1 and Nrf2.246,325 In general, high shear stress reduces EC permeability 
to lipoproteins, inhibits EC proliferation, suppresses activities of pro-
thrombotic tissue factor in ECs and promotes EC viability.5 A variety of 
studies have shown that high shear stress suppresses pro-inflammatory 
activation in cultured ECs 279,326-329 and reduces leukocyte adhesion to 
cultured EC.328 High shear stress reduced the induction of VCAM-1 and E-
selectin mRNA by TNFα in cultured ECs.327 Additionally, VCAM-1 induction 
by TNFα was suppressed by high shear in rabbit aortae perfused ex vivo.326 
These observations were supported by the finding that shear stress can 
decrease the expression of VCAM-1 in cultured murine lymph node venule 
ECs, thus reducing lymphocyte adhesion.330-332 In contrast, low or oscillatory 
shear has been suggested to trigger pro-inflammatory activation of ECs and 
therefore, to drive vascular inflammation at susceptible sites (Figure 1.7). By 
using a flow altering cuff, it has been shown in vivo that low shear stress 
increases the expression of VCAM-1 and ICAM-1, whereas high shear 
decreases it.75,288 
 
1.6.3 Effects of shear stress on inflammatory signalling 
Various studies have associated the anti-inflammatory effects of high shear 
stress in cultured ECs with an inhibition of JNK and p38 MAP kinase 
signalling 221,246,326 and altered NF-κB activity and function.192,327,329 Our 
group could demonstrate that high shear stress reduces p38 and JNK 
acitivity by the induction of MKP-1.246 Consequently, it was suggested that 
arteries exposed to high shear stress are protected from atherogenesis by 
altered MAP kinase and NF-κB signalling in ECs.269 In addition, we 
demonstrated that spatial variation of JNK1 activity determines the spatial 
distribution of apoptosis and turnover of ECs in arteries.333 In contrast, 
studies using cultured ECs suggest that low or oscillatory shear can induce 
pro-inflammatory activation by activating NF-κB RelA, c-Jun and c-fos. The 
transcription factors KLF2 and Nrf2 have been shown to be activated by 
shear stress and reduce MAP kinase activation and NF-κB activity in cultured 
cells and have therefore been suggested as potential mediators of the anti-
inflammatory effects of shear stress in ECs.254,321,322,334-338 
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In vivo studies have revealed elevated NF-κB expression in ECs at athero-
susceptible sites which are exposed to low shear in the murine and pig aorta, 
suggesting that they are primed for enhanced activation in response to pro-
inflammatory stimuli.131,339 Furthermore, Tzima et al. suggested that NF-κB 
RelA is constitutively localised to endothelial nuclei in regions of the mouse 
aorta exposed to disturbed flow.319 These finding have been confirmed by 
Partridge et al. who showed that constitutive NF-κB transcriptional activity is 
elevated in low shear regions in vivo.192 Additionally, a study by Dai et al. 
characterised the blood flow patterns in human carotid artery bifurcations. 
Thereby they defined the flow pattern and shear stress in two distinct regions 
of the artery. The area of the carotid sinus is susceptible to lesion 
development whereas the distal internal carotid artery is protected against 
atherosclerosis. The distinct flow pattern and shear stresses observed in 
these two regions were applied to cultured cells ECs using a cone and plate 
dynamic flow system. They observed, that NF-κB was activated in the ECs 
exposed to the athero-susceptible flow pattern but remained inactive in ECs 
exposed to athero-protective waveforms.279 Summarised, these studies 
suggest that vascular endothelium exposed to low and/or low/oscillatory 
shear stress, may be athero-susceptible partially due to enhanced 
constitutive or inducible NF-κB activity. Nevertheless, although shear stress 
has been correlated with NF-κB expression and activity in vascular 
endothelium, a causal relationship has not yet been established in vivo. 
Furthermore the signalling pathways regulating the differential expression of 
NF-κB at low shear and high shear sites have not been identified. 
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Figure 1.7: Effects of shear stress on EC activation and atherogensis 
(A) Laminar shear stress maintains the anti-inflammatory and anti-apoptotic phenotype of 
ECs by the release of factors leading to inhibition of coagulation, leukocyte migration, 
smooth muscle proliferation, while promoting EC survival. (B) In contrast, low oscillatory 
shear stress leads to the secretion and expression of proteins promoting an environment 
allowing the development of atherosclerotic lesions, such as the expression of adhesion 
molecules allowing leukocyte adhesion and subsequent migration and a pro-apoptotic 
environment. Abbreviations: PGI2, prostacyclin; tPA, tissue plasminogen activator; TGFβ, 
transforming growth factor β, Ang II, angiotensin II; PDGF, platelet-derived growth factor; 
NO, nitric oxide. (Adapted from 
340,341
; List of abbreviations can be found in Chapter 8) 
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1.7 Vascular inflammation imaging using PET 
Molecular imaging is used to characterize and assess biological processes in 
humans and animals using relatively non-invasive techniques. This method 
needs a molecular probe that provides analytical properties and a method to 
monitor it.342 In this regard, nuclear imaging techniques such as positron 
emission tomography (PET) have been widely used in clinical practice 343 
and are used to study inflammation in multiple tissues including 
atherosclerotic lesions.344 PET provides several advantages such as very 
high sensitivity, excellent temporal resolution, the possibility to label 
molecular probes without altering their chemical properties and the short half-
life of the isotopes. However PET has a very limited spatial resolution and 
therefore may not provide precise anatomical information. To overcome this, 
PET scans are combined with computed tomography angiography (CTA) 
which provides detailed anatomical information of the vasculature. 
Traditionally, molecular imaging studies of atherosclerosis in humans using 
only one imaging technique have been performed at later stages of the 
disease. Using hybrid imaging systems such as PET/CT enables imaging of 
molecular events in atherosclerosis at far earlier stages.344 
 
Inflammation is an important contributor to the formation, progression and 
rupture of atherosclerotic plaques.342 Accordingly, various aspects of the 
inflammatory cascade are targets of molecular imaging of atherogenesis.345 
An important molecule during the leukocyte adhesion cascade is the 
adhesion molecule VCAM-1 which is expressed on the surface of activated 
ECs, allowing the recruitment of inflammatory cells from the blood. Using 
peptide-based ligands with binding specificity to VCAM-1, PET/CT was 
performed to show inflammatory activation of ECs.346 To assess monocyte 
accumulation in atheromata a radiotracer [111In] oxine was first validated 
using autoradiography and used to show that the accumulation of monocytes 
is progressive and proportional to the degree of disease.347 Using this probe, 
single photon emission CT (SPECT) revealed that monocytes were recruited 
to atherosclerotic plaques.348 In addition, Nahrendorf et al. developed a 
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trimodality nanoparticle 64Cu-TNP which could be used to detect 
macrophages in atherosclerotic lesions.349 
 
Macrophages can also be detected using ligands that recognise the 
translocator protein/peripheral benzodiazepine receptor (TSPO/PBR) which 
is highly expressed on this cell type.350 The ligand PK11195 binds to TSPO 
and has been used to image vascular inflammation and atherosclerosis in 
humans and mice.351-353 However, PK11195 displays a low signal-to-noise 
ratio and high levels of non-specific binding were detected in vivo.354,355 The 
radio tracer 18F-FEDAA (N-(5-Fluoro-2-phenoxyphenyl)-N-(2-18F-fluoroethyl-
5-methoxybenzyl)acetamide) also binds to the TSPO but has a higher 
selectivity and specificity compared to PK11195.356,357 However, FEDAA has 
not been described so far in the context of vascular inflammation or 
atherosclerosis. In summary, these examples show the potential of non-
invasive imaging techniques to assess inflammation during the early stages 
and the progression of atherosclerosis. 
 
1.7.1 Molecular imaging using 18F-Fluorodeoxyglucose 
Recent studies used 18F-fluorodeoxyglucose-PET (FDG-PET) as a potential 
tool to assess plaque metabolism.358 FDG, a glucose analogue, is taken up 
by cells through the same carrier-mediated process as glucose. Transport of 
glucose is generally mediated by two families of transporters, facilitative 
glucose transporters (GLUTs) and sodium glucose co-transporters. The 
transport via GLUTs is not ATP-dependent and uses a concentration gradient 
via stereospecific diffusion.359,360 Subsequent to the uptake, glucose is 
phosphoylated by hexokinase isoforms forming glucose-6-phosphate which 
consecutively can be consumed in glycogenesis, glycolysis and further 
metabolic pathways.358 Glucose analogues such as 2-deoxy-D-glucose 
(2DG) contain a hydrogen atom instead of a hydroxyl group at C2. Therefore 
2DG is transported into the cell in the same way as glucose and undergoes a 
phosphorylation by hexokinase to form 2DG-6-phosphate. In contrast to 
glucose-6-phosphate, it cannot be further processed and becomes trapped in 
the cytosol.358 Due to the fact that glucose and FDG feature the same 
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properties, in vivo phosphorylation by hexokinase are proportional to each 
other. Thus, the distribution of 2DG provides a good reflection of glucose 
uptake and phosphorylation by cells in the body. The labelling of 2DG at C2 
with the positron emitter 18F generates 18F-FDG. 18F is a positron emitter with 
a half life of 109 min and decay of the radiotracer leads to emission of a 
positron that travels a short distance and annihilates with an electron. 
Annihilation generates two 511-kdV photons which propagate in almost 
opposite directions allowing a detection within a short time window (~10 ns). 
Many of these events are summed to display the distribution of the 
radiotracer. Within the last decade, FDG-PET imaging has become an 
essential tool in oncology because it can identify tumours which have higher 
metabolic activity compared to surrounding, healthy tissue.343 Nevertheless, 
the utility of FDG-PET in atherosclerosis imaging has not been fully 
established,358 especially in regard to early detection of the disease and 
unstable plaque.361 However, Rudd et al. showed that human vessels 
containing atherosclerotic plaques display an increased uptake of FDG, and 
also contained a dense macrophage infiltration.362 This was supported by 
other clinical studies which have shown that vessels containing an 
atherosclerotic plaque feature an increased FDG signal compared to 
unaffected vessels.363-366 The source and mechanism of elevated FDG 
uptake in atherosclerosis has been studied in animal models. In rabbit 
studies, Vallabhajosula et al. revealed a significant accumulation of FDG in 
aortas of cholesterol-fed, but not chow-fed animals.367 Histological analysis 
demonstrated that the intensity of FDG accumulation correlated with 
macrophage density. In addition, Ogawa et al. demonstrated that vascular 
FDG uptake correlates with the number of macrophages in the vessel wall, 
but does not with the ratio between intima and media in hypercholesterolemic 
rabbits.368 A study by Davies et al. also supported the correlation between 
the infiltration of macrophages and FDG accumulation but only when the 
aortas were imaged ex vivo. Their in vivo measurements did not support the 
correlation. However, they explained the discrepancy of their findings due to 
numerous technical limitations such as the merging signals from the 
lumen/intima with signals from blood and surrounding tissue.369 Taken 
together, human and animal studies of atherosclerotic plaques have shown a 
 55 
positive correlation between uptake of FDG or 3H-2HDG and the 
accumulation of macrophages.362,368-378 In addition to these in vivo studies, in 
vitro experiments have been performed to further analyse the role of 
macrophages in the uptake of FDG. It has been shown that cultured 
monocytes and macrophages showed an increased uptake of FDG 
subsequent to their exposure to pro-inflammatory stimuli such as LPS and 
interferon-γ. 379-381 Due to the fact that atherosclerotic lesions are 
characterised by the occurrence of macrophages and high level of 
inflammatory mediators, this observation would support the hypothesis that 
macrophages are involved in the increased glucose activity and thus the 
uptake of FDG in atherosclerotic lesions. On the other hand, recent studies of 
ApoE deficient mice showed a poor correlation between 14C-2DG uptake and 
en face macrophage staining in the aorta, and demonstrated that removal of 
the interscapular brown fat can diminish FDG-PET signals in atherosclerotic 
lesions, thus questioning the validity of FDG-PET for studies of vascular 
inflammation in murine models.382,383 These and other studies 369,384-386 
underline the importance of further investigation of the role of macrophages 
in the accumulation of FDG in plaques in animal models and clinical 
studies.358  
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2.1 Materials 
2.1.1 Primary cell culture  
The required reagents to harvest and isolate primary cell cultures were 
obtained commercially: M199 (Medium 199 with Earl’s salts and NaHCO3, 
without L-glutamine; Sigma), Penicillin/streptomycin (Sigma), L-glutamine 
(Sigma), endothelial cell growth factor (ECGF; Sigma), fetal calf serum (FCS; 
Sigma), sodium pyruvate (Invitrogen), trypsin/EDTA (MP Biomedical), gelatin 
(Sigma), fibronectin (Sigma), heparin (Pharmacy) and collagenase (Roche), 
Hanks balanced salt solution without calcium and magnesium (HBSSw/o; 
Sigma), Hanks balanced salt solution with calcium and magnesium 
(HBSSwith; Sigma) and PBS pH 7.0 (Invitrogen) Gentamycin (Invitrogen), 
sodium pyruvate (Invitrogen). The composition of media is described in the 
Appendix (Chapter 7)  
 
2.1.2 Chemicals and reagents 
TNFα (human) (R&D, Minneapolis, MN, USA), DMSO (Dimethyl sulfoxide; 
D8418; Sigma), lipopolysaccharide (LPS; E.coli serotype 055:BS, Sigma), 
the anesthetic isoflurane (IsoFlo; Abott Laboratories Ltd.), the  analgesic 
Vetergesic (0.324 mg/ml buprenorphine hydrochloride; Reckitt Benckiser 
Healthcare, UK, Ltd) were purchased commercially. 
 
2.1.3 Inhibitors 
Inhibition of the MAP kinase JNK was achieved using two pharmacological 
inhibitors SP600125 (Figure 2.1 A) and CT536706 (Figure 2.1 B). SP600125 
is a commercially available JNK inhibitor (GlaxoSmithKline) whereas 
CT536706 was provided by UCB Celltech (Brussels, Belgium).387 Binding of 
ATP (adenosine tri-phosphate) is required for JNK activation. Both SP600125 
and CT536706 interact with the ATP-binding site on JNK and therefore inhibit 
JNK reversibly by competing for ATP binding. To inhibit the activity of histone 
deacytylase (HDAC), the inhibitor MS-275 (Enzo Life Sciences), a synthetic 
benzamide, was used. MS-275 directly inhibits HDAC activity by binding to its 
catalytic pocket. This leads to hyperacetylation of histones and other target 
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proteins.388 The inhibitors were provided in DMSO stock solutions. Therefore, 
cellular responses to inhibitors and appropriate amounts of DMSO were 
compared in order to separate the effects of the inhibitor from the potential 
effects of the vehicle. 
 
                         
Figure 2.1: Pharmacological JNK inhibitors  
Chemical structure of the pharmacological JNK inhibitor CT536706 (UCB Celltech (A) and 
SP600125 (GlaxoSmithKline) (B). 
 
2.1.4 PET probes 
18F-fluorodeoxyglucose (FDG) was used for non-invasive imaging of mice 
using positron emission tomography (PET). For PET scans, an activity of 
approximately 1.4 Giga Becquerel (GBq) in 1 ml was ordered (PETnet 
solutions, UK). 
 
The radiotracer 18F-N-(5-Fluoro-2-phenoxyphenyl)-N-(2-18F-fluoroethyl-5-
methoxybenzyl) acetamide (FEDAA) was synthesized and provided by Dr 
Joe Bird (Wolfson Brain Imaging Centre, University of Cambridge) 
 
2.1.5 Contrast agent 
For computed tomography angiography (CTA) a radiological contrast agent 
(Ultravist 370) was injected intravenously using a syringe pump (PHD 
22/2000, Harvard Apparatus). The volume of injection did not exceed a 
volume of 0.5 ml. 
 
 
 
 
 
A. B. 
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2.1.6 Plasmids 
To overexpress the RelA NF-κB subunit, a mammalian expression plasmid 
containing a RelA-dsRed fusion protein was used (stock concentration 1.96 
µg/µl). The corresponding control was a plasmid containing dsRed alone 
(stock concentration 2.52 µg/µl). The plasmids were provided by Prof. 
Michael White (University of Liverpool). 
 
2.1.7 Antibodies 
Antibodies have been used for protein detection via Western blotting, 
immunohistochemistry and flow cytometry. Primary antibodies are shown in 
Table 2.1. Secondary antibodies are shown in Table 2.2. 
 
For the detection of NF-κB RelA mRNA levels by in situ hybridization, a Cy3-
conjugated NF-κB RelA probe and a Cy3-conjugated non-target mRNA 
probe was used (Exiqon). 
 
For immunohistochemical detection of DNA to visualize cell nuclei, TOPRO-3 
iodide (Invitrogen) was used. 
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Table 2.2: Secondary antibodies 
 
Name 
 
Source 
 
Use 
 
Concentration 
 
Goat anti-rabbit IgG 
 
Sigma 
 
WB 
 
1:10000 
 
Goat anti-mouse IgG 
 
Sigma 
 
WB 
 
1:10000 
 
Goat Alexa 568 anti-rabbit 
 
Invitrogen 
 
IF 
 
1:500 
 
Goat Alexa 568 anti-mouse 
 
Invitrogen 
 
IF 
 
1:500 
 
Goat Alexa 568 anti-rat 
 
Invitrogen 
 
IF 
 
1:500 
 
Goat Alexa 488 anti-rabbit 
 
Invitrogen  
 
IF 
 
1:500 
 
Goat Alexa 635 anti-mouse 
 
Invitrogen 
 
FCM 
 
1:100 
WB, Western blotting; IF, immunofluorescence; FCM, flow cytometry 
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2.2 Methods 
 
In vitro procedures 
2.2.1 Isolation and culture of primary human umbilical vein endothelial 
cells (HUVEC) 
For safety reasons and to avoid microbial contamination, the isolation of 
HUVEC and their subsequent culture was performed using a flow cabinet. 
Umbilical cords were collected from the maternity ward and incubated in 
HBSSwith (with gentamycin and sodium pyruvate) for at least two hours to limit 
the possibility of bacterial infection. Using a 3-way tap, the umbilical veins 
were cannulated, fixed with surgical sutures and then perfused with HBSSw/o 
to flush out blood and locate leaks. Leaks were closed using surgical clips. 
The cords were then perfused with 20 ml warm collagenase (0.5 mg/ml) and 
incubated at 37 °C for 20 min. To increase the yield of endothelial cells, the 
cords were massaged for 1-2 min. Afterwards, the collagenase solution 
containing the endothelial cells was transferred to a 50 ml falcon tube. In 
addition, 15-20 ml of HBSSw/o was used to flush the vein and harvest the 
residual cells. This wash was added to the collagenase solution and cells 
were collected by centrifugation (1400 rpm for 5 min; Hareaus Instruments, 
275 g). The cell pellet was resuspended in 15 ml complete growth medium 
and transferred in a 75 cm2 cell culture flask (coated with 1% gelatin). The 
following day, the growth medium was changed to remove red blood cells 
and debris. 
 
HUVEC were grown until they reached 80-90% confluency. To passage the 
cells the HUVEC were washed with HBSSw/o followed by an incubation with 
trypsin-EDTA for 1-2 min at 37 °C. To dilute the trypsin HBSSw/o was added 
and cells were then collected by centrifugation (1400 rpm for 5 min; Hareaus 
Instruments, 275 g). The cell pellet was resuspended in growth medium and 
cells were transferred to culture flasks at 30–50% confluency. For 
experiments, cells were used before passage 4 and were grown in 6–well 
plates or on glass slides coated with fibronectin (25 µg/ml) until the required 
cell number was achieved. 
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2.2.2 Gene silencing (siRNA) 
To assess their function, particular genes were silenced using small 
interfering RNA (siRNA). Electroporation was used to transfect cells with 
specific siRNAs or scrambled controls. The following siRNAs were obtained 
commercially: JNK1 (s11153; Applied Biosystems), c-Jun (s7658; Applied 
Biosystems), ATF2 (sc-2905; Santa Cruz Biotechnology). Electroporation 
was performed using the manufacturers’s guidelines (MicroPorator). The 
electroporation protocol for certain siRNAs was optimised to increase the 
degree of silencing (see Table 2.3). Subsequent to electroporation the cells 
were plated on fibronectin coated 6-well plates using complete medium 
without antibiotics. Transfected cells were studied 48 h following 
electroporation. 
 
Table 2.3: Transfection paremeters for gene silencing 
 
siRNA 
(concentration) 
 
pulse voltage 
 
pulse width 
 
pulse number 
 
JNK1 (5 µM) 
 
1350 V 
 
30 mSec 
 
1 
 
c – jun (1-5 µM) 
 
1400 – 1550 V 
 
20 mSec 
 
1 
 
ATF-2 (1 µM) 
 
1350 V 
 
30 mSec 
 
1 
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2.2.3 RNA extraction 
The RNeasy mini kit (Qiagen) was used to extract total RNA from cultured 
cells. The cells were washed with PBS (cold) and then exposed to 350 µl 
RLT (RNeasy Lysis Buffer) (with 1% β–mercaptoethanol) buffer. The cultures 
were subsequently scraped and lysates were homogenized through a 19-21 
gauge needle. An equal volume of 70% ethanol was then added and the 
mixture was transferred to a spin column and centrifuged at 10000 rpm for 1 
min in a microfuge. The flow through was discarded and the spin column was 
then washed according to the manufacturers instructions. Total RNA was 
eluted using 30 µl RNAse-free water and then stored at -80 °C. 
 
2.2.4 cDNA synthesis 
cDNA was synthesised using the qScriptTM cDNA SuperMix (Quanta 
Biosciences). The proprietary master mix provides the required components 
for first strand synthesis. For the reverse transcriptase reaction, 10 µl of total 
RNA (containing approximately 1 µg) was mixed with 5 µl of the master mix 
and 5 µl RNase/DNase free water to achieve a total volume of 20 µl. This 
solution was then incubated at 25 °C for 5 min; 30 min at 42 °C; 5 min at 85 
°C using a thermal cycler (Bio-Rad). The resulting cDNA was then stored at -
20 °C. 
 
2.2.5 Quantitative reverse transcriptase PCR 
To assess transcript levels, comparative real-time PCR with gene specific 
primers was used (table 2.4). For the PCR master mix, 5 µl of cDNA (1:10 
dilution with H2O), gene specific primers (forward and reverse; 0.5 µl, 1 µM 
each), 12.5 µl SYBR green master mix (Bio-Rad) and 6.5 µl water were 
combined and transferred to an optical 96-well reaction plate (Bio-Rad). To 
control for technical differences, triplicate reactions were set up. The real-
time PCR reaction was carried out using the iCycler system (Bio-Rad, 
Hercules, CA, USA). Reactions were incubated at 94 °C for 2 min before 
thermal cycling at 94 °C for 15 s, 60 °C for 60 s and 72 °C for 60 s. Relative 
gene expression was calculated by comparing the number of thermal cycles 
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that were required to generate threshold amounts of product (CT). The CT 
was calculated for the housekeeping gene ß-actin, as a control for cDNA 
input, and for the gene of interest. For each sample, the CT for ß-actin was 
subtracted from the CT for each gene of interest to obtain the parameter 
∆CT. This allowed normalisation for the initial amount of RNA used for each 
individual sample. The relative difference in gene expression between 
different samples was calculated as 2–∆∆CT, where ∆∆CT is the difference 
between the ∆CT of the cDNA samples to be compared. 
 
2.2.6 Chromatin immunoprecipitation 
2.2.6.1 Preparation of lysates 
To determine protein-DNA interactions, ChIP was used. To minimise the 
potential effect of variations between individuals, pooled HUVEC from 3 
different cords were studied. Approximately 10.5 x 106 cells were used for 
each ChIP. Cells were fixed for 10 min with 1% formaldehyde (stock 
concentration 37.5% HCHO; 10% methanol; Sigma). To quench the 
formaldehyde, 2 ml Tris (1M) was added. The cells were than scraped off 
and collected in a 50 ml tube by centrifugation for 5 min at 1400 rpm in a 
microfuge. The supernatant was gently discarded and the pellet washed 3 
times with ice cold PBS. For the cell lysis and subsequent sonication, the cell 
pellet was resuspended in 600 µl cell lysis buffer (see Appendix, Chapter 7) 
with protease inhibitors (0.4% aprotinin, 0.4% leupeptin and 0.4% PMSF) and 
transferred to a cold 1.5 ml tube and then incubated for 10 min on ice. After 
centrifugation at 1350 rpm for 5 min at 4 °C, the supernatant was discarded 
and the pellet was resuspended in 600 µl lysis buffer with protease inhibitors 
(see Appendix, Chapter 7) for the removal of detergents. The mixture was 
incubated for 10 min at room temperature and then exposed to centrifugation 
(1350 rpm, 5 min, 4 °C). After removal of the supernatant, the pellet was 
resuspended in 600 µl nuclear lysis buffer (see Appendix, Chapter 7). The 
material was then sonicated (8 min using a 30 sec on and 30 sec off interval) 
prior to the addition of 60 µl Triton X-100. The mixture was then centrifuged 
at 13000 rpm for 10 min at 4 °C using a microfuge. A portion of the lysate 
was stored at -20 °C. Magnetic beads coated with proteinG were washed 
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twice with 0.5% BSA/PBS before incubation with antibodies (10 µg 
antibodies for 50 µl packed beads) for 16 h at 4 °C on a rotating platform. 
The beads were washed 3 times with 0.5% BSA/PBS and then resuspended 
in 100 µl 0.5% BSA/ PBS. For the chromatin immunoprecipitation, 40 µl of 
the antibody-conjugated-beads were combined with 300 µl cell lysate and 
gently mixed on a rotator overnight at 4 °C. The beads were collected by 
magnetism washed 6 times with 1 ml RIPA buffer (see Appendix, Chapter 7) 
and the supernatant collected which was used as a flow through control 
(stored at -20 °C). Subsequently, the beads were washed with 1 ml TE (10 
mM Tris-Cl, pH 7.5. 1 mM EDTA; + 50 mM NaCl). 75 µl pre-warmed (65 °C) 
elution buffer (1x TE + 2% SDS) was then added to the beads and tubes 
were rotated for 10 min. The supernatant (elute) was collected. This step was 
repeated twice to gain a total elute of 225 µl.  
 
2.2.6.2 Analysis of co-precipitated DNA 
For further analysis, the crosslinking for the elute, input and flow through was 
reversed by overnight incubation at 65 °C. The DNA was purified using a 
PCR purification kit (Qiagen; Cat: 28106). The input of DNA and the 
assessment of protein binding to a specific promoter region of the DNA was 
subsequently determined by quantitative RT-PCR. The primer sequences 
used are shown in table 2.4. 
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Table 2.4: PCR primers 
 
gene 
 
forward (5’-3’) 
 
reverse (5’-3’) 
 
Genomic DNA PCR (for ChIP) 
  
 
NF-κB 
(p65) 
ChIP 
 
CTTAAGGAAAATTGAGGGAGGGCACGC 
 
 
TGACTCAGTTTCCCTCCACACCGTCC 
 
 
CDK4 
 
AGAACACCACCAGCATCCCATCCCC 
 
 
GATCTTTGTGCGGGGCGCGATTGTC 
 
GAPDH 
 
TGATGACATCAAGAAGGTGGTGAAG 
 
 
TCCTTGGAGGCCATGTGGGCCAT 
 
Reverse transcriptase PCR 
  
 
NF-κB 
(p65) 
 
TCAAGATCTGCCGAGTGAAC 
 
TGTCCTCTTTCTGCACCTTG 
 
JNK1 
 
GAAGCTCCACCACCAAAGAT 
 
GGTTCTCTCCTCCAAGTCCA 
 
c-Jun 
 
CAGCCCACTGAGAAGTCAAA 
 
CACCAATTCCTGCTTTGAGA 
 
ATF2 
 
GTACCATTGGCACAAACTG 
 
GTGAAGGTACTGCCTGCTGA 
 
β -actin 
 
CTGGAACGGTGAAGGTGACA 
 
AAGGGACTTCCTGTAACAATGCA 
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2.2.7 Western blotting 
2.2.7.1 Preparation of total cell lysates 
Total cell lysates for protein detection were prepared by using the Extract kit 
from Active motif (40010). Cultured ECs were washed with ice-cold PBS (1x) 
and 1 ml ice-cold PBS/phosphatase Inhibitors (0.8%, Sigma). Subsequently 
cells were resuspended in 150 µl complete lysis buffer. The lysis buffer 
comprised 15 µl DTT (10 mM), 133.5 µl lysis buffer AM-1, and 1.5 µl 
protease inhibitor cocktail (all provided by the Active motif kit). The cells were 
then scraped and incubated at 4 °C for 30 min. The lysate was then 
centrifuged for 10 min at 14000 rpm in a pre-cooled microcentrifuge at 4 °C 
to remove cell debris and the supernatant stored at -20 °C. 
 
2.2.7.2 Western blotting 
The concentration of protein in cell lysates was determined by the Bradford 
assay.389 Equal total amounts of protein were mixed with the required amount 
of loading buffer (see Appendix, Chapter 7) and denatured at 95 °C for 5 min. 
Protein separation was achieved by loading the denatured samples on Bis-
Tris polyacrylamide 4-12% gradient gels (Invitrogen) and expose to a 
potential difference of 200 Volts for 60 min in a NuPAGETM Western blot tank 
(Invitrogen), containing running buffer (see Appendix, Chapter 7). To 
determine the size of the proteins a pre-stained marker (SeeBlue® Plus2 
Prestained Standard (1x), Invitrogen) was run alongside the samples as a 
size reference. After electrophoretical separation, the proteins were 
transferred to a PVDF membrane (Immobilon-P Transfer membrane, filter 
type: PVDF, pore size: 0.45 µM, Millipore) using the NuPAGETM system 
(Invitrogen) (60-90 min at 25 Volts). Membranes were blocked using 20 ml 
blocking solution (see Appendix, Chapter 7) for 1 h. After three washes in 20 
ml PBST (see Appendix, Chapter 7) the membrane was incubated with the 
primary antibody in blocking solution (see Appendix, Chapter 7) at 4 °C over 
night on a shaker. The membrane was subsequently washed in PBST (see 
Appendix, Chapter 7) three times, after which it was incubated with a 
horseradish peroxidise (HRP) -conjugated secondary antibody for 1 h at 
room temperature on a shaker. After a final wash step the proteins were 
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detected by applying enhanced chemiluminescence (ECL) Western blot 
solution (Perkin Elmer) to the membrane. The membranes were then 
exposed to an autoradiographic film (Biomax light film, Kodak) and 
developed using a Compact X4 automatic X-ray film developer (X-ograph).  
 
Relative expression levels of particular proteins were estimated by 
densitometry of autoradiograms. Optical densities of proteins of interest were 
measured and compared to values generated form Western blotting analysis 
of so-called “house keeping” proteins that displayed little or no change in 
expression between experimental conditions. The ratio of optical densities 
between proteins of interest and the housekeeping protein was calculated 
using bioimaging software from Labwork. 
 
2.2.8 Enzyme-linked immunosorbent assay 
Levels of active NF-κB RelA were assessed using a DNA-binding ELISA 
(TransAmTM, NF-κB p65 (RelA) kit, Active Motif). The 96-well plate contained 
immobilised oligonucleotides corresponding to a NF-κB consensus binding 
site. Thereby the binding of RelA to the consensus site is a measure of 
activity. Cells were lysed in situ by the addition of 30 µl complete binding 
buffer (TransAm Active Motif) and 20 µl complete lysis buffer (TransAm 
Active Motif) followed by incubation for 1 h at room temperature. The wells 
were then washed three times with 200 µl washing buffer (TransAm Active 
Motif). 100 µl NF-κB antibody (1:1000 in antibody binding buffer (1x), 
TransAm Active Motif) was added, the plate sealed, and incubated for 1 h at 
room temperature. After washing three times, the samples were incubated 
with 100 µl HRP-conjugated secondary antibody (1: 1000 in antibody binding 
buffer (1x, TransAm Active Motif) for 1 h at room temperature. Samples were 
washed four times with 200 µl washing buffer (1x, TransAm Active Motif) and 
then incubated with developing solution for 30 seconds to 5 min at room 
temperature without direct exposure to light. The wells were monitored for 
blue colour development and, when appropriate, 100 µl stop solution 
(TransAm Active Motif) was added. Within 5 minutes the absorbance was 
assessed on a spectrophotometer (at 450 nm with reference wavelength of 
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655 nm). The level of NF-κB binding was calculated by subtracting OD655 
values from OD450 values, and by normalising OD655 - OD450 values by 
subtracting values obtained from controls which did not contain total cell 
lysates. 
 
2.2.9 Flow cytometry 
Cells were washed twice with HBSSw/o and lifted by trypsinization (see 
Section 2.2.1) and resuspended in growth medium. The cell suspension was 
transferred to a flow cytometry tube and 3 ml HBSSwith was added. After 
centrifugation at 1400 rpm for 5 min, the supernatant was discarded and the 
cell pellet was washed using HBSS with 1% FCS, followed by centrifugation 
for 5 min at 1400 rpm. The supernatant was removed and the cell pellet was 
resuspend in 100 µl HBSS with 1% FCS prior to the addition of primary 
antibodies at the required concentration and incubation for 30 min on ice. 
After two washes, the cells were resuspended in HBSS with 1% FCS 
containing secondary antibodies conjugated to a fluorophore and incubated 
for 15 min on ice. Subsequently, cells were washed with HBSS with 1% FCS 
twice, followed by three washes with PBS containing Ca2+ and Mg2+ and 
analysis by flow cytometry. A CyAn ADP Flow cytometer (Beckman Coulter) 
was used to quantify fluorescence after gating for single cells using forward 
and side scatter. For the identification of HUVEC the voltages, gain, and 
threshold were adjusted to achieve the appropriate forward and side scatter 
plot. A gate was created around the endothelial cell population to avoid 
signals from debris/dead cells. To identify the background fluorescence 
staining of ECs, cells were treated with secondary antibody only. Any 
increase in fluorescence above background was considered specific staining.  
 
2.2.10 Immunohistochemistry  
Immunohistochemistry was used to assess the expression level and 
localisation of particular proteins in cultured ECs. Cells were fixed using 
100% methanol for 5 min, washed three times with PBS (1x) for 5 min, and 
then blocked and permeabilised in 20% serum and 0.5% triton X-100 in PBS 
(1x) at 4 °C overnight. Subsequently, cells were incubated with primary 
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antibodies (Table 2.1) overnight at 4 °C, washed (3 x 5 min PBS) and then 
incubated with appropriate secondary antibodies (Table 2.2) for 1 h in the 
dark at room temparature. In case of a double staining to assess the 
expression and localisation of two proteins of interest in parallel, cells were 
subsequently incubated with a second primary antibody which was directly 
conjugated to a fluorophore for 2 h room temperature or overnight at 4 °C. 
The samples were then exposed to TO-PRO3 for 30 min at room 
temperature to counterstain the nuclei. Coverslips were mounted on slides 
for imaging using Vectashield. 
 
In vivo procedures 
2.2.11 Animals and treatment 
Animal care and all experimental procedures were performed according to 
the regulations of the UK Home Office. Wild-type C57BL/6 mice (male; 8-12 
weeks) were commercially obtained from Harlan Olac Ltd. JNK1-deficient 
animals were initially provided by Professor Roger Davis from the University 
of Massachusetts and were originally generated in the group of Professor 
Flavell.222 A colony was maintained in the animal facility at Hammersmith 
Campus, Imperial College London. To perform recovery surgery, mice were 
anaesthetised using an isoflurane (1.5-3%), air and oxygen mixture and were 
injected with Vetergesic (0.324 mg/ml buprenorphine hydrochloride) (0.05 
mg/kg) subcutaneously (sc) for pain relief subsequent to the procedure. 
Depending on the experimental set up, mice were either treated with LPS by 
intraperitoneal (ip) injection (4 mg/kg) for various time points (30-240 min) or 
remained untreated (control). 
 
2.2.12 Cuff placement on murine carotid arteries 
To assess the effect of altered shear stress on endothelial cells, a flow 
altering cuff (Figures 2.2 and 2.3 A) was placed around the right common 
carotid artery in mice. The shear stress-altering cuff 288 consists of two halves 
with a cone-shaped lumen that is 500 µm wide in diameter upstream and 
narrows down to a diameter of 250 µm in the downstream part. Once placed 
around the right common carotid artery, the cuff introduces a low shear 
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stress region proximal and low/oscillatory shear stress region distal from the 
cuff. Due to its tapering effect it increases the shear gradually in the cuff 
region. This model mimics the flow pattern found at athero-susceptible sites 
(e.g. side branches, inner curvature) and athero-protected sites (outer 
curvature) of curved vessels. For some experiments a non-constrictive 
control cuff was placed around the carotid artery to control for the possible 
effects of surgical manipulation per se. The lumen of the control cuff was 600 
µm wide to avoid any constriction of the artery. 
 
C57/Bl6 mice were anaesthesized using an isoflurane (1.5-3%), air and 
oxygen mixture. Full anaesthesia was induced by exposing the animal to 3% 
isoflurane in an induction chamber. The mice were subsequently kept 
anaesthetised using a snout piece providing 1.5-3% isoflurane. After 
removing fur, the neck was opened by a midline incision. Following the 
removal of subcutaneous tissue, the salivary gland was split by gently pulling 
and the area for cuff placement was exposed by dissection. It was essential 
to remove fibrous tissue from the external surface of the artery but this was 
restricted to the region intended for the placement. The cuff was placed 
around the common carotid artery and fixed by a suture. The wound was 
sutured and the animal was allowed to recover. Mice were sacrificed by CO2 
inhalation 7–14 days after cuff placement. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  74 
 
Figure 2.2: Flow altering cuff 
Diagrammatic representation of the flow altering cuffwhich, after placement around the 
murine common carotid artery, introduces a low shear region proximal and a low/oscillatory 
shear region distal form the cuff. Due to its tapering effect, a gradual increase in shear 
occurs. (Adapted from 
75
) 
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2.2.13 En face immunofluorescent staining 
To assess the expression level and localisation of particular proteins in ECs, 
arteries were studied by en face immunofluorescence staining. After 
sacrificing the animal using CO2 inhalation, the heart and aorta were 
perfused in situ with 1x PBS (37 °C) via the left ventricle. To allow a flow-
through, the right atrium was incised. Following perfusion, the tissue was 
perfusion fixed by slowly injecting 2% formalin (in PBS). The aorta and the 
common carotid artery were then removed, and dissected and surrounding 
fat was removed. ECs were permabilized and blocked to prevent non-specific 
binding of antibodies by incubation with 20% serum (corresponding to the 
species the secondary antibody was raised in), 0,5% Triton X-100 in 1x PBS 
overnight at 4 °C. After washing thoroughly with PBS, the tissue was 
incubated with unconjugated primary antibodies overnight at 4 °C. After 
additional washes with PBS, appropriate secondary antibodies were applied 
for 2-3 h at room temperature followed by incubation with anti-CD31 antibody 
(directly conjugated to AlexaFluor 488) for 72 h at 4 °C. After another wash 
with PBS, the samples were exposed to TO-PRO3 to counterstain nuclei. 
The ascending aorta, arch and carotid artery were opened and mounted 
using Vectashield with the endothelium facing the cover slip. Samples were 
incubated with secondary antibodies alone to control for specific staining. In 
addition, potential non-specific binding of primary antibodies was assessed 
by staining using IgG isotype controls or pre-immune serum. 
 
2.2.13.1 Analysis of immunofluorescent staining of arterial EC by 
confocal microscopy 
ECs in the aorta or carotid artery were imaged using an inverted laser 
scanning confocal microscope (LSM 510 Meta inverted; Zeiss, Oberkochen, 
Germany) at a 40x magnification. Samples stained with secondary antibody 
only were utilised to optimise laser settings and microscopic set up to avoid 
detection of background staining or autofluorescence. The ascending aorta 
contains a region with a low probability (LP) (outer curvature, athero-
protected) and a region with a high probability (HP) for developing 
atherosclerosis (inner curvature, athero-susceptible) (Figure 2.3 A). For 
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identification of the protected and susceptible regions, anatomical landmarks 
described by Hajra et al. were used as reference points (Figure 2.3 A).131 
Furthermore, the morphology of ECs was used to ensure the imaging of the 
correct region as it is established that ECs at the athero-protected region are 
aligned whereas ECs at the susceptible site show a more irregular, polygonal 
morphology (Figure 2.3 B). Specialized software was used to quantify the 
fluorescent intensity and to analyse the localisation of particular proteins 
(Zeiss LSM Meta software). This software measures mean intensity in a 
given area. We measured mean fluorescence intensity (MFI) in >50 cells or 
regions of cells (e.g. nucleus, cytoplasm) by drawing around each cell or 
region and measuring the intensity of the protein of interest using the 
software. For a particular protein, to assess the proportion that was located in 
the nucleus we calculated the total fluorescence (MFI x area) in the nucleus 
and the entire cell and expressed it as the ratio nucleus : entire cell. Another 
important factor was ensuring that the images that were analysed were made 
from the same z-axis plane of the cells. In our experimental set up, it was 
important to visualise ECs and nuclei in parallel to the protein of interest. Due 
to the morphological characteristics of these stainings, it was possible to 
ensure the imaging of the correct image ECs always in the same plane and 
to ensure the imaging of the correct region. 
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Figure 2.3: The en face staining technique 
(A) Diagrammatic representation of the heart and mounting procedure for en face staining of 
the ascending aorta. The localisation of the athero-protected and athero-susceptible regions 
including the anatomical landmarks of the tissue are shown. The flow altering cuff is placed 
around the right common carotid artery (light blue). (B) Identification of EC in the murine 
aorta was achieved by staining with anti-CD31 (conjugated to Alexa Fluor 488; green). 
Nuclei were detected by TO-PRO3 staining (purple). Images were taken by using Zeiss LSM 
510 confocal microscopy (40x magnification). Representative images of the athero-protected 
and athero-susceptible region are shown. 
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2.2.14 In situ hybridization 
To assess the expression of RelA transcripts in ECs in the athero-protected 
and athero-susceptible region of the murine aorta, mRNA fluorescence in situ 
hybridization was used. LNATM mRNA in situ hybridization probes with 
sequence specificity for murine RelA (5’- 
GGTCCCGTGAAATACACCTCAATG-3’) (5 nmol) were generated by 
EXIQON. To facilitate detection by fluorescence microscopy, the probe was 
fluorescently labelled at the 5` end with Cy3. A Cy3 labelled scrambled, non-
targeting probe 5’- GTGTAACACGTCTATACGCCCA-3’ (5 nmol), was also 
synthesized and was used as a control for non-specific staining. All reagents 
were treated with DEPC to suppress any potential RNAse activity. 
 
Animals were sacrificed using CO2 inhalation, and the heart and aorta were 
perfused in situ with 1X DEPC treated PBS prewarmed to 37 °C via the left 
ventricle. To allow a flow–through, the right atrium was incised. Following 
perfusion, the tissue was perfusion fixed by slowly injecting 4% 
paraformaldehyde (PFA) (in DEPC treated PBS). The aorta was removed 
and the surrounding fat was removed and incubated in 4% PFA overnight at 
4 °C. For dehydration, the aorta was then incubated in 15% sucrose (in 
DEPC treated PBS) for 1 h at 4 °C and transferred into fresh 15% sucrose 
and incubated overnight at 4 °C. Prior to hybridization, the aorta was 
rehydrated using DEPC treated PBS and treated with 0.75% glycine in DEPC 
treated PBS for 10 min at room temperature. To permeabilize and block the 
ECs, the sample was incubated for 1 hour at room temperature with 0.5% 
Triton X-100 in 1x DEPC treated PBS. Following a wash with DEPC treated 
PBS, the tissue was treated with Proteinase K (1 µg/ml) in 10 mM Tris buffer 
for 30 min at 37 °C to provide access of the probe to RNA. After the tissue 
was post-fixed in 4% PFA for 10 min and washed twice with DEPC treated 
PBS, non-specific binding was blocked by exposing the tissue to 1.3% 
triethanolamine (100 mM), and 0.25% acetic anhydride in DEPC treated H2O 
mixture. The aorta was then pre-hybridized in 50% formamide in 2x SSC for 
15 min at room temperature. Subsequently, the aorta was dehydrated by 
incubation in a series of ethanol concentrations (70%, 90%, 100%) for 5 min 
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each and then washed twice in the hybridization buffer (10% Dextran 
sulphate, 5x Denhardt`s solution, 50% formamide, 0,5% sodium dodecyl 
sulphate (SDS), 0.5% sodium pyrophosphate, 100 mM dithiotreitol (DTT)) for 
5 min.  
 
To prepare the probe for hybridization, 200 µl hybridization buffer was 
combined with 0.015 pmol/µl of the in situ hybridization probe at 60 °C for 30 
min and directly placed on ice for 5 min. The aorta was then incubated with 
the probe/hybridization buffer mixture for 19 h at 50 °C in the dark. For post-
hybridization, the aorta was washed with 4x SSC for 20 min twice at room 
temperature. To facilitate visualization of the endothelial monolayer, samples 
where then incubated with anti CD31-antibody (directly conjugated to Alexa 
Fluor 488) (in 4x SSC) for 2 h at room temperature. After an additional wash 
with 4x SSC, the aorta was treated with RNase (20 µg/ml) in 2x SSC for 20 
min at 37 °C. After another wash with 2X SSC, the samples were exposed to 
TO-PRO3 in 2x SSC (20 min; room temperature) to counterstain the nuclei. 
Subsequently, the tissue was washed with 2x SSC (5 min) and 1x SSC (20 
min). The ascending aorta and arch were opened and mounted using 
Vectashield with the endothelium facing the cover slip. RelA transcripts of 
ECs in the aorta were imaged using an inverted laser scanning confocal 
microscope (LSM 510 Meta inverted; Zeiss, Oberkochen, Germany) and a 
40x magnification. 
 
2.2.15 PET-CT: Imaging of Inflammation 
Nuclear imaging techniques such as PET have been used to image 
inflammation in atherosclerotic lesions. PET provides a very high sensitivity 
but spatial resolution is limited to 1 mm. Thus, to map PET signals to 
anatomical information, PET scans are usually combined with computed 
tomography angiography (CTA) which can generate a detailed anatomy of 
the vasculature.344 We combined this approach with the use of a flow-altering 
cuff to asses the effect of modifying shear stress in common carotid arteries 
on vascular physiology. Specifically, we assessed uptake of FDG which is 
known to by elevated in cells with a high metabolic rate and has been used 
  80 
previously to study vascular inflammation. We placed a flow altering cuff 
around the right common carotid artery in the mouse as described in section 
2.2.12. After 14 days, the animals (C57BL/6 and JNK1 -/-) were imaged with 
a microPET–CT scanner (Siemens Inveon). Once anaesthetised using 
isoflurane, the animals were positioned on the scanning bed and a CT scan 
was first acquired to correct PET data for photon attenuation (220 steps over 
220 degrees, 80kV, 500mA, reconstruction to 384 x 384 x 256 with a final 
isotropic spatial resolution of 207 microns). Animals were injected 
intravenously with 18F-FDG (8.9 ± 3.6 MBq) and PET scanning was initiated 
immediately and carried out for 1 h. CTA was performed with gating of ECG 
and respiraton. During CT acquisition, a contrast agent, Ultravist 370 (Bayer 
Healthcare Pharmaceuticals) was infused intravenously at a speed of 6 ml/hr 
using a syringe pump (PHD 22/2000, Harvard Apparatus).  
 
To quantify the uptake of FDG, the PET acquisition data were reconstructed 
(FBP reconstruction with a matrix of 128 x 128) in 20 min frames. The last 
frame of the scan (40 min – 60 min) was used for the analysis to avoid signal 
from the circulating radiotracer. FDG uptake data were then overlayed with 
CTA images to allow measurement of FDG metabolism in distinct regions of 
cuffed arteries. This was achieved by counting photons emitted in a 3D 
region of interest (ROI) with a defined volume. The standardised uptake 
values (SUV) were calculated factoring the body weight, the decay correction 
and the radioactivity which remained in the syringe after injection (SUV = 
Value in ROI x Body weight /activity injected). To compare the uptake of FDG 
with the untreated left carotid artery, ROIs were drawn at corresponding 
positions and the proportional difference of FDG uptake on the left compared 
to the right common carotid artery was calculated.  
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2.2.16 Statistics 
All quantitative analyses display either the mean value ± standard deviation 
(SD) or ± standard error of the mean (SEM). To assess significant 
differences, unpaired and paired Student t-tests and one way ANOVA 
(Bonferroni's Multiple Comparison Test) were performed. Statistical 
significance was accepted when p<0.05 (p<0.05 *, p<0.01 **, p<0.001 ***) 
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Chapter Three: NF-κB RelA expression is 
positively regulated in endothelial cells by 
c-Jun N-terminal kinase 
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3.1 Introduction 
The RelA NF-κB subunit is differentially expressed in particular anatomical 
regions of the murine aorta as demonstrated by Hajra et al.131 Specifically an 
athero-susceptible region (inner curvature) displayed an increased 
expression of RelA compared to the athero-protected region (outer 
curvature). However, the mechanism of this differential expression has not 
been studied and, in general, very little is known about the regulation of RelA 
expression. 
 
A microarray study of the transcriptome in HUVEC treated with the 
pharmacological JNK inhibitor CT536706 387 was performed by our group.333 
Interestingly, the array data showed that RelA mRNA expression was 
reduced subsequent to the inhibition of JNK, suggesting a role for JNK in 
regulating basal RelA expression. Analysis of the RelA promoter revealed the 
existence of potential binding sites for AP-1 transcription factors which are 
known to be regulated by JNK.390 
 
Therefore, we wished to assess the potential role of JNK and AP-1 
transcription factors in the regulation of RelA expression. 
 
Studies from our group of the murine aorta revealed that activation of JNK by 
phosphorylation occurs constitutively at athero-susceptible sites but is 
suppressed in athero-protected regions.246 As the spatial distribution of JNK 
activation correlates with RelA expression, we hypothesized that activation of 
JNK may be responsible for the elevated expression of RelA at athero-
susceptible sites. 
 
Although shear stress has been correlated with RelA activity in vascular 
endothelium,131 a causal relationship in vivo had not been established. Using 
a flow altering cuff 288 we examined whether RelA expression and activity in 
vivo is directly regulated by shear stress. 
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3.2 Hypothesis and Aims 
We hypothesise that the JNK pathway positively regulates expression of 
RelA in ECs. In addition, that shear stress directly regulates the expression 
and activity of RelA via the JNK pathway. 
 
To assess this hypothesis the following aims were addressed: 
 
A. Confirm that JNK positively regulates RelA expression using cultured 
ECs. 
 
B. Assess the role of AP-1 transcription factors in the regulation of basal 
expression of RelA. 
 
C. Examine the role of JNK1 in the regulation of RelA expression and 
activity in arterial ECs in vivo. 
 
D. Establish the causal relationship between shear stress and RelA 
expression and activity in vivo. 
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3.3 Results 
3.3.1 JNK positively regulates NF-κB in vitro 
We validated the microarray data obtained by our group using quantitative 
RT-PCR which showed that the inhibition of JNK via the small molecule 
inhibitor CT536706 led to a significant reduction of RelA mRNA levels (Figure 
3.1 A). CT536706 inhibits all the family members JNK1, JNK2, and JNK3. 
Out of these, JNK1 and JNK2 are ubiquitously expressed.203 We used gene 
silencing to examine the potential role of JNK1 and observed that treatment 
of cells with a siRNA designed to target JNK1 led to a reduction of JNK1 
mRNA of 82% (Figure 3.1 B). This resulted in a significant reduction of RelA 
mRNA levels whereas a scrambled control oligonucleotide had no effect 
(Figure 3.1 B). In addition, we examined the effect of JNK inhibition on RelA 
protein levels by exposing HUVEC to CT536706 or to the commercially 
available JNK inhibitor SP600125. Western blotting revealed a reduction of 
RelA protein levels in JNK inhibitor treated cells compared to the vehicle 
treated controls (Figure 3.1 C). We analysed Western blots from several 
different independent experiments using densitometry and observed a 
significant reduction of RelA protein subsequent to the application of 
CT536706 or SP600125 (Figure 3.2 D). Taken together, these data show 
that JNK positively regulates basal RelA expression in ECs in vitro. 
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Figure 3.1: JNK positively regulates NF-κB expression 
HUVEC were treated with the pharmacological JNK inhibitor CT536706 (1 µM for 16 h) (A, 
C) or SP600125 (50 µM for 16 h) (C, D) or with JNK1 (5 µM) specific siRNA (B) or a 
corresponding control. The inhibitors and siRNAs employed in this study were used at 
concentrations that were previously optimized by our laboratory (Chaudhury, H, 
unpublished). (A, B) Expression levels of particular transcripts were assessed by quantitative 
RT-PCR and were normalised by measuring β-actin transcript levels. Mean values (± SEM) 
were determined from triplicate measurements and data were pooled from at least 3 
independent experiments. (C) The Effect of pharmacological JNK on RelA protein levels 
were assessed by Western blotting on total lysates followed by densitometry and were 
normalised by measuring tubulin protein levels (D). Mean values (± SEM) were calculated 
from data pooled from at least 3 independent experiments. [unpaired Student’s t-test; ** < 
0.01; *** < 0.001] 
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3.3.2 Expression of NF-κB is regulated by JNK via the transcription 
factor ATF2 
JNK does not activate the promoters of target genes directly. Once activated, 
JNK phosphorylates transcription factors of the AP-1 superfamily. C-Jun and 
ATF2 are key components of this family and act as homodimers or 
heterodimers and thereby bind specific DNA sequences and regulate target 
gene expression.232 We used gene silencing to examine whether c-jun and/or 
ATF2 regulate the basal expression of RelA. Although we were able to 
silence c-Jun RNA by 55% using a specific siRNA this did not influence RelA 
mRNA levels (Figure 3.2 A). However, silencing of ATF2 led to a significant 
reduction of RelA mRNA (Figure 3.2 B). These data indicate that ATF2 is a 
positive regulator of RelA expression, whereas c-Jun is not involved. 
 
To investigate whether ATF2 regulates RelA at the transcriptional level, ChIP 
experiments were performed to identify potential ATF2-RelA promoter 
interactions. Confirming previously described findings,390 our sequence 
analysis of the RelA promoter revealed potential AP-1 binding sites (Figure 
3.3 A). ChIP using anti-ATF2 antibodies revealed that ATF2 co-precipitates 
with the RelA promoter in HUVEC (Figure 3.3 B). Pre-treatment of cells with 
CT536706 reduced the levels of co-precipitated RelA promoter DNA (Figure 
3.3 C). For a technical confirmation of the ChIP technique, we analysed the 
binding of ATF2 to the cyclin-dependent kinase 4 (CDK4). CDK4 is 
necessary during the cell cycle for the G1-to-S phase transition, and its 
expression is predominantly controlled at the transcription level. It has 
previously been shown that ATF2 can bind to the CDK4 promoter 391 and we 
confirmed this binding in HUVEC (Figure 3.3 D). As a negative control we 
used the promoter of the glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) which was not co-precipitated with ATF2 (Figure 3.3 D). To 
summarise, ATF2 binds to the RelA promoter and treatment with a JNK 
inhibitor significantly reduced this binding. Furthermore, silencing ATF2 with 
siRNA led to a significant reduction of RelA expression. This suggests that 
JNK-ATF2 signalling positively regulates RelA basal expression via a 
transcriptional mechanism. 
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Figure 3.2: Effects of silencing c-jun or ATF2 on RelA mRNA expression 
HUVEC were treated with c-jun-specific siRNA (A), ATF2-specific specific siRNA (B) or with 
a scrambled, non-targeting sequence and incubated for 48 h. C-Jun (A), ATF2 (B) and RelA 
(A, B) transcript levels were assessed by quantitative RT-PCR and were normalised by 
measuring β-actin transcript levels. Mean values (± SEM) were determined from triplicate 
measurements and data were pooled from at least 5 independent experiments. [unpaired 
Student’s t-test; * < 0.05; *** < 0.001] 
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GGGAAGCTGAATCAGGGCCTGTTGTACTTTCTTAAGGAAAATTGAGGGAGGGCACGCCCC
ACCTCCCTCCAGAGAGGAAACTGAATCAGATGCGTTCTCCCCTAATAGGGAAACGAAGCCA
GAGCTGCCCCCATGGACGGTGTGGAGGGAAACTGAGTCAAGGTTCCCTCTGCTCCCCCAC
CCAGGGAGGATGCTGAGTCAAGGGCCACCCCCTCCACCCAGAGGGGAAACTGAGTCAGA
CCCCTCCCCGCCTGCCCCGCCCCGCGCCACCATCCGGCAGGCCGACCGCTCCCTGCGCA
GCGCCCGTCGGCGCAGGAAGGGGCGGAAAGCGGCGCGGGGGCTCCCGCCACAGCCGC
GGCGGCCCCGGCGATGCCACCCCGCGGGGTCAGAGGGCGACCTCACCGTCCATGGCCG
GGGTCCCGGGGGCGGGGCCGGGGTCGCAGCTGGGCCCGCGGCGTGCACTACAGACGAG
CCATTCGCCAGAGGCGGAAATGCGCCGCGCGGCCCGCCGTCGCGTCACTGCCCGGAATC
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Figure 3.3: ATF2 binds to the RelA promoter 
(A) Analysis of the human RelA promoter revealed potential AP-1 binding sites (highlighted 
in red). ChIP was used to assess the potential interaction between ATF2 and the RelA 
promoter using PCR primers that bound with close proximity to AP-1 binding sites 
(underlined is the resulting PCR product). (B) Binding of ATF2 to the 5’ untranslated region 
of the RelA gene was assessed by ChIP. Nuclear lysates prepared from HUVEC were 
incubated with anti-ATF2 or irrelevant isotype-control antibodies prior to precipitation. The 
levels of RelA promoter DNA in precipitates and in non-precipitated lysates (input) were 
assessed by quantitative RT-PCR. The proportion of RelA promoter sequence that was 
precipitated from the starting material was calculated (% input) and mean levels (± SEM) are 
shown from 4 independent experiments. (C) HUVEC were exposed to CT536706 (2 µM) for 
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16 h or were treated with vehicle alone. Nuclear lysates prepared from HUVEC were 
incubated with anti-ATF2 antibodies prior to precipitation and quantitation of RelA gene DNA 
levels in precipitates and input material was determined as above. The proportion of RelA 
promoter sequence that was precipitated from the starting material was calculated (% input) 
and mean levels (± SEM) were calculated from three independent experiments. (D) Binding 
of ATF2 to the 5’ untranslated region of the CDK4 (positive control) and GAPDH (negative 
control) gene was assessed in independent experiments. Nuclear lysates prepared from 
HUVEC were incubated with anti-ATF2 antibodies prior to precipitation and quantitation of 
CDK4 and GAPDH gene DNA levels in precipitates and input material as mentioned above. 
The proportion of CDK4 and GAPDH promoter sequence that was precipitated from the 
starting material was calculated (% input) and mean levels (± SEM) were calculated from 
three independent experiments for CDK4 and GAPDH. [Student’s t-test; * < 0.05; *** < 0.001] 
The described ChIP experiments were carried out by Dr. Kim Van der Heiden in 
collaboration with Dr. David Saliba (Genomics of Inflammation group, Kennedy Institute, 
Imperial College). 
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3.3.3 Activation of ATF2 increases RelA expression 
We demonstrated that JNK1 and ATF2 regulate basal RelA levels. We next 
examined whether the activation of ATF2 in response to H2O2 (a JNK 
activator) leads to elevated expression of RelA. In this context it is important 
to mention, that H2O2 does not exclusively activates the JNK pathway but it 
has been shown that H2O2 stimulation leads to prolonged JNK activation.
392 
We observed that unstimulated HUVEC contained relatively low levels of 
activated ATF2 by immunostaining for phosphorylated ATF2 (Figure 3.4, 
upper panels). H2O2 treatment resulted in activation of ATF2 for at least 4 
hours (Figure 3.4). To investigate the effect of H2O2 treatment on RelA 
expression we performed immunohistochemical staining (Figure 3.5). 
Treatment with H2O2 resulted in a significant increase in RelA protein levels 
compared to the untreated cells (Figure 3.5). To determine whether the 
induction of RelA by H2O2 is JNK-dependent we pre-treated HUVEC with 
CT536706 and SP600125. Pre-treatment with CT536706 significantly 
reduced RelA induction by H2O2 (Figure 3.5 A). The induction of RelA by 
H2O2 was also reduced by SP600125 pre-treatment, however this difference 
did not reach statistical significance (p = 0.0764) (Figure 3.5 B). In summary, 
treatment of HUVEC with H2O2 resulted in a prolonged activation of ATF2 
and led to an increased expression of RelA through a JNK dependent 
mechanism. Our data are consistent with the hypothesis that JNK-ATF2 
signalling regulates both basal and inducible RelA expression. 
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Figure 3.4: H2O2 treatment leads to prolonged ATF2 activation 
HUVEC were treated with H2O2 (100 µM) for 30, 120 and 240 min or remained untreated as 
control. Expression levels of phosphorylated ATF2 were assessed by immunostaining with 
anti-pATF2 antibodies and Alexa Fluor 488-conjugated secondary antibodies (green). Cell 
nuclei were identified using TOPRO-3 (pseudocoloured red). Fluorescence was assessed by 
confocal microscopy (40x magnification). Representative images for each time point are 
shown. Mean levels of phosphorylated ATF2 (Mean fluorescence intensity ± SD) were 
calculated from 20 cells for each time point from one experiment. 
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Figure 3.5: H2O2 activates ATF2 and induces RelA via JNK 
HUVEC were pre-treated with CT536706 (2 µM) (A) or SP600125 (50 µM) (B) for 1 h or 
were treated with vehicle alone and then treated with H2O2 (50 µM for CT; 200 µM for SP ± 
JNK inhibitor) for 4 h or remained untreated as a control. Fixed cells were assessed by 
immunofluorescence staining using anti-RelA antibodies (red). Cell nuclei were identified 
using TOPRO-3 (purple). Fluorescence was assessed by confocal microscopy (40x 
magnification). Images shown are representative of 4 independent experiments. RelA protein 
levels were quantified by using image analysis software and are presented as fold change of 
mean fluorescent intensities (MFI ± SEM). [one way ANOVA (Bonferroni's Multiple 
Comparison Test); ** < 0.01] 
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3.3.4 JNK primes cells for endothelial cell activation via NF-κB 
To investigate whether JNK could play a role in priming ECs for RelA 
activation, we performed a RelA DNA binding ELISA. This assay measures 
binding of RelA to immobilised oligonucleotides, which contain a NF-κB 
consensus binding site, and is therefore a measure of activity. We compared 
HUVEC treated with either of the JNK inhibitors (CT536706: Figure 3.6 A; 
SP600125: Figure 3.6 B) (or with vehicle alone as a control) in the presence 
or absence of TNFα (for 15 min) (Figure 3.6). We observed that treatment of 
cells with TNFα significantly enhanced RelA binding to DNA (Figure 3.6). 
Pre-treatment of cells with CT536706 or SP600125 did not influence basal 
RelA-DNA binding but significantly reduced RelA activation in response to 
TNFα. (Figure 3.6 A and B). These data suggest that JNK potentiates cells 
for RelA activation. Therefore, we wanted to investigate if JNK primes ECs 
for increased expression of RelA target genes such as the adhesion 
molecule VCAM-1. 
 
By flow cytometry analysis, we could show that TNFα treatment for 6 hours 
induced expression of VCAM-1 (Figure 3.7 A). This increase was not 
obtained in cells pre-treated with the CT536706 inhibitor indicating that JNK 
is required for full VCAM-1 expression, as described previously 393 (Figure 
3.7 B). We hypothesized that JNK enhances VCAM-1 induction by positively 
regulating RelA expression, or in other words, that the JNK inhibitor blocks 
VCAM-1 induction by reducing RelA levels. To test this, we restored RelA 
levels in cells pre-treated with CT536706 by transfecting them with a 
mammalian expression plasmid containing a RelA-dsRed fusion protein. As a 
control we used a plasmid expressing dsRed alone. To determine VCAM-1 
expression in transfected cells we performed immunoflurescence staining 
using anti-VCAM-1 antibodies and Alexa Fluor 635-conjugated secondary 
antibodies followed by flow cytometry. The laser and emission filter were 
configurated to measure VCAM-1 flourescence in cells that were gated for 
dsRed expression. We concluded that these signals did not overlap as 
unstained transfected cells did not emit fluorescence at the laser and filter 
configuration for VCAM-1 and likewise, stained untransfected cells did not 
  97 
emit fluorescence at the configuration of dsRed. Flow cytometry showed that 
transfection with RelA-dsRed or dsRed alone had relatively modest effects 
on VCAM-1 expression subsequent to TNFα treatment in cells that were not 
pre-treated with a JNK inhibitor (Figure 3.7, compare white histograms in 
B,C,D). Strikingly, overexpressing RelA-dsRed enhanced VCAM-1 induction 
by TNFα in the presence the JNK inhibitor but did not restore VCAM-1 
expression completely. By contrast, the dsRed control had no effect (Figure 
3.7 C and D). This experiment suggests that JNK affects VCAM-1 expression 
mainly through regulation of RelA levels, and also through an RelA-
independent pathway. 
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Figure 3.6: JNK potentiates RelA for activation 
The effects of JNK inhibition on RelA-DNA binding were assessed. HUVEC were pre-treated 
with CT536706 (1 µM) or SP600125 (50 µM) or vehicle alone for 16 h. Cells were then 
treated with TNFα (10 ng/ml) for 15 min (or remained untreated as a control) prior to the 
preparation of cell lysates. Binding of RelA to consensus oligonucleotides was assessed by 
DNA-binding ELISA. Mean values (± SEM) were calculated from data pooled from 3 
independent experiments. [unpaired Student’s t-test; * < 0.05] 
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Figure 3.7: JNK signalling primes ECs for VCAM-1 induction via and NF-
κB-dependent pathway 
VCAM-1 expression was studied in HUVEC that were transfected with expression vectors 
encoding dsRed-RelA or dsRed alone (C, D) or in cells that remained untransfected as a 
control (A, B) and secondary antibody only control (broken line). To distinguish between 
emission of the dsRed coupled to RelA and VCAM-1 expression a specific Alexa Fluor 635 
secondary antibody was used (A, B) untransfected cells were pre-treated for 4 hours with 
CT536706 (2 µM) (grey) or with vehicle alone as a control (white) and some cells were 
treated then with TNFα (10 ng/ml) for 6 h (B). (C, D) Transfected cells were pre-treated for 4 
h with CT536706 (2 µM) (grey) or with vehicle alone as a control (white) and were then 
treated with TNFα (10 ng/ml) for 6 h. VCAM-1 surface expression was quantified by 
immunostaining and flow cytometry in non-transfected cultures and in transfected cells after 
gating for dsRed-positive cells. Representative data from three independent experiments are 
shown. The described flow cytometry experiments were carried out by Dr. Kim Van der 
Heiden 
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3.3.5 Activated ATF2 is elevated at athero-susceptible region 
We observed that JNK is a positive regulator of RelA expression via ATF2 
and that it potentiates ECs for inflammatory activation in vitro. Therefore, we 
wanted to investigate whether we can confirm these findings in murine aortic 
ECs in vivo.  
 
Studies from our group of the murine aorta revealed that activation of JNK, 
which was determined by the detection of JNK phosphorylation, occurs 
constitutively at athero-susceptible sites but is suppressed in athero-
protected regions.246 We therefore predicted that ATF2 activation would 
occur constitutively in ECs at athero-susceptible sites. To test this, we 
performed en face staining to assess the spatial distribution of activated 
ATF2 (pATF2) in the murine aorta. Quantification of the amount of nuclear 
pATF2 revealed significantly higher levels in the athero-susceptible 
compared to the athero-protected region (Figure 3.8). Thus the predominant 
activation of ATF2 at the susceptible sites reflects the pattern of JNK 
activation.246 
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Figure 3.8: ATF2 phosphorylation is elevated at an athero-susceptible 
region 
Levels of phosphorylated ATF2 (pATF2) were assessed by en face staining of athero-
protected and athero-susceptible regions of the murine aorta of wild-type mice (red). ECs 
were identified by co-staining with anti-CD31 antibodies conjugated to FITC (green). Cell 
nuclei were identified using TOPRO-3 (purple). Fluorescence was assessed by confocal 
microscopy (40x magnification). Images shown are representative of 4 mice. Levels of 
phosphorylated ATF2 in EC nuclei were quantified using image analysis software and 
presented as mean fluorescent intensities (MFI ± SEM). Data were pooled from 
measurements in 4 mice [unpaired Student’s t-test; ** < 0.01] 
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3.3.6 NF-κB expression is regulated at the transcript level in aortic ECs 
in vivo 
It was reported that RelA expression was enhanced in ECs in athero-
susceptible regions compared to athero-protected regions by Hajra et al.131 
Given our observation that RelA is regulated at the mRNA level by ATF2 in 
cultured ECs, and that ATF2 is activated preferentially at athero-susceptible 
sites, we hypothesized that RelA transcripts would be expressed at higher 
levels at athero-susceptible regions compared to athero-protected regions. 
Therefore, we examined RelA mRNA expression in both regions by 
performing in situ hybridization using a fluorescently labelled oligonucleotide 
probe with sequence specificity for murine RelA mRNA. A non targeting 
control probe was utilised to optimise microscopic set up and avoid detection 
of autofluorescence or nonspecific binding. Using this approach, we 
observed that RelA mRNA expression was significantly enhanced in an 
athero-susceptible region compared to an athero-protected region in 
C57BL/6 animals (Figure 3.9). Taken together, these data suggest that the 
differential expression of RelA proteins observed in the athero-susceptible 
region and athero-protected region is caused by regulation of RelA at 
transcript level and that the anatomical location of RelA mRNA is similar to 
the distribution of activated JNK and ATF2. 
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Figure 3.9: In situ hybridization for RelA mRNA in athero-protected and 
athero-susceptible regions of the murine aorta 
RelA mRNA levels in ECs were assessed by en face in situ hybridization of athero-
susceptible or athero-protected regions of the aorta in wild-type mice (red). ECs were 
identified by co-staining with anti-CD31 antibodies conjugated to FITC (green). Fluorescence 
was assessed by confocal microscopy (40x magnification). Images shown are representative 
of 7 mice. RelA mRNA was quantified by using image analysis software and presented as 
mean fluorescent intensities (MFI ± SEM). Data were pooled from measurements in 7 mice. 
[unpaired Student’s t-test; *** < 0.001] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  103 
3.3.7 JNK1 positively regulates NF-κB expression in vivo 
We showed that the spatial distribution of activated JNK and ATF2 in the 
murine aorta correlates with the expression pattern of RelA. To determine 
whether JNK is a direct regulator of RelA we studied the expression and 
localisation of RelA proteins in the murine aorta of C57BL/6 and JNK1-
deficient mice (Figure 3.11). The expression of RelA in the athero-protected 
area was very low, which is consistent with previous findings,131 and it was 
not influenced by the genetic deletion of JNK1 (Figure 3.10 A). However, 
deletion of JNK1 influenced ECs at the athero-susceptible region by reducing 
the expression of RelA (Figure 3.10 B) and by reducing the proportion of 
RelA localised in the nucleus (Figure 3.10 C), which is a measure of activity. 
These data suggest that JNK is a positive regulator of RelA expression and 
activity at an athero-susceptible site in vivo.  
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Figure 3.10: JNK1 positively regulates NF-κB expression in ECs at an 
athero-susceptible site 
RelA expression levels in ECs were assessed by en face staining of athero-susceptible or 
athero-protected regions of the aorta in wild-type or JNK1 -/- mice (red). ECs were identified 
by co-staining with anti-CD31 antibodies conjugated to FITC (green). Cell nuclei were 
identified using TOPRO-3 (purple). Fluorescence was assessed by confocal microscopy 
(40x magnification). (A) Images shown are representative of 3 mice per group. (B) Total 
RelA expression was quantified by using image analysis software and presented as mean 
fluorescent intensities (MFI ± SEM). (C) The proportion of RelA localised to the nucleus was 
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calculated by dividing nuclear fluorescence by total fluorescence for multiple cells and mean 
values (± SEM) are shown. Data were pooled from measurements in 3 mice per group. 
[unpaired Student’s t-test; * < 0.05] 
 
 
3.3.8 JNK1 positively regulates VCAM-1 expression in ECs at athero-
susceptible sites 
Our observation that RelA expression and nuclear localisation are enhanced 
at the athero-susceptible region of wild-type compared to JNK1-deficient 
animals suggested that JNK1 may promote expression of RelA-dependent 
inflammatory molecules at this site. To test this, we examined the expression 
of one RelA target protein involved in endothelial activation, VCAM-1, which 
was significantly reduced in the athero-susceptible region of JNK1 -/- 
compared to wild-type animals (Figure 3.11). These data indicate that JNK1 
promotes VCAM-1 expression at the athero-susceptible region. 
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Figure 3.11: JNK1 positively regulates VCAM-1 expression at an athero-
susceptible site 
VCAM-1 expression levels in ECs were assessed by en face staining of athero-susceptible 
or athero-protected regions of the aorta in wild-type or JNK1 -/- mice (red). ECs were 
identified by co-staining with anti-CD31 antibodies conjugated to FITC (green). Cell nuclei 
were identified using TOPRO-3 (purple). Fluorescence was assessed by confocal 
microscopy (40x magnification). Images shown are representative of 3 mice per group. 
VCAM-1 expression was quantified by using image analysis software and presented as 
mean fluorescent intensities (MFI ± SEM). Data were pooled from measurements in 3 mice 
per group. [unpaired Student’s t-test; * < 0.05] 
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3.3.9 JNK1 positively regulates low-grade chronic inflammation at an 
athero-susceptible site 
We wanted to explore whether endothelial activation at the athero-
susceptible site is correlated with low-grade chronic inflammation in the 
murine aorta and determine the involvement of JNK1. Jongstra-Bilen et al. 
demonstrated low-grade chronic inflammation in the arterial sub-endothelium 
of an athero-susceptible region by staining for the macrophage/dendritic cell 
marker CD68.394 We observed by en face staining that accumulation of 
CD68-positive cells at the susceptible site was reduced in wild-type versus 
JNK1 -/- animals (Figure 3.12), indicating that JNK1 promotes inflammation 
at this region. We also noted that CD68-positive cells did not stain positive for 
CD31 (Figure 3.12 C, higher magnification) and were characterized by long 
processes, resembling dendritic cells which were shown to be resident at 
athero-susceptible sites by Myron Cybulsky’s group.394 
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Figure 3.12: JNK positively regulates low-grade chronic inflammation 
Accumulation of CD68-positive cells were assessed by en face staining of susceptible or 
protected regions of the aorta in wild-type or JNK1 -/- mice (red). EC were identified by co-
staining with anti-CD31 antibodies conjugated to FITC (green). Cell nuclei were identified 
using TOPRO-3 (purple). Fluorescence was assessed by confocal microscopy (40x 
magnification). (A) Images shown are representative of at least 3 mice per group (wild-type: 
n=6; JNK1 -/-: n=3). (B) Frequency of CD68-positive cells per field of view (0.0547 mm
2
) was 
quantified by using image analysis software and presented ± SEM. (C) high magnification of 
(A). Data were pooled from measurements in at least 3 mice per group (wild-type: n=6; JNK1 
-/-: n=3) [unpaired Student’s t-test; * < 0.05].  
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3.3.10 Shear stress regulates NF-κB expression and activity in murine 
ECs 
We and others have shown that RelA expression was enhanced in ECs at an 
athero-susceptible region of the murine aorta which is associated with a 
low/oscillatory shear stress, compared to the athero-protected region which is 
associated to high pulsatile shear stress. Our data suggest JNK1 as a 
positive regulator of RelA expression and activity in vivo. To investigate 
directly whether shear stress regulates RelA expression and the role of JNK 
in vivo we used a flow altering cuff 288 (Figure 3.13 A), which changes the 
geometry of the common carotid artery and introduces a low shear region 
proximal and a low/oscillatory shear region distal to the cuff. Due to its 
constrictive effect, a gradual increase of shear occurs in the cuffed area 
itself.289 We determined the effect of altering shear stress on JNK activation 
by measuring levels of phosphorylated JNK in carotid arteries that were 
modified with the shear altering device for 7 days (Figure 3.13 A). We could 
detect activation of JNK in the low shear and to a greater extent in the 
low/oscillatory shear stress region of cuffed arteries. However, JNK was not 
activated in the high shear stress region (Figure 3.13 A, upper panel; Figure 
3.13 B) 
 
Application of the device significantly enhanced total RelA levels in ECs 
exposed to low shear and low/oscillatory compared to high shear stress 
(Figure 3.13 A, middle panel; Figure 3.13 C). To determine whether shear-
induced expression of RelA is JNK1-dependent we placed the cuff around 
the carotid artery of JNK1-deficient animals. Strikingly, we found a significant 
reduction of RelA expression in the low shear region of JNK1 -/- compared to 
wild-type animals. Moreover, in the low oscillatory shear stress region we 
detected very little or no expression of RelA in JNK1 -/- mice (Figure 13 A, 
lower panel; Figure 3.13 C). These data show that low and low/oscillatory 
shear stress positively regulate RelA expression in vivo via JNK1.  
 
To assess the effects of altered blood flow on RelA activation, we analysed 
the amount of RelA in the nucleus of ECs in areas of flow alteration. We 
observed that the proportion of RelA in the nucleus of ECs was significantly 
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enhanced in low shear stress and low/oscillatory shear stress regions 
compared to the high shear region (Figure 3.13 D and E). Interestingly, we 
observed that RelA nuclear localisation was significantly enhanced in the 
low/oscillatory shear region compared to the low shear stress region, 
suggesting that RelA activation may be enhanced by oscillations in the shear 
stress field. Deletion of JNK1 significantly reduced the proportion of RelA 
localised in the nucleus in the low/oscillatory region while similar levels were 
obtained in the low shear region (Figure 3.13 E). 
 
To assess the functional relevance of elevated RelA expression in low and 
low/oscillatory shear regions we performed en face staining for one of the 
RelA target genes, VCAM-1. We observed that VCAM-1 levels were 
significantly enhanced in ECs in the low/oscillatory shear stress region 
compared to the high shear region (Figure 3.14). VCAM-1 levels also 
appeared elevated in the low shear stress region (compared to the high 
shear site), however this difference did not reach statistical significance. The 
elevated expression of VCAM-1 in the low oscillatory shear stress region 
aligns with our observation that RelA nuclear localisation was particularly 
high at this site. Therefore our data suggest that low shear and to a greater 
extend low/oscillatory shear activate ECs, as determined by VCAM-1 
expression. In conclusion, we were able to show that shear stress directly 
regulates JNK activation, RelA and VCAM-1 expression and that the 
induction of RelA by low or low/oscillatory shear is JNK1-dependent.  
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Figure 3.13: Effects of altering shear stress on JNK phosphorylation 
and NF-κB expression 
(A) Flow-altering, constrictive cuffs were placed on the right carotid arteries of wild-type or 
JNK1 -/- mice. Right carotid arteries were harvested after 7 days. Levels of phosphorylated 
JNK and RelA in ECs were assessed by en face staining of regions exposed to low (LSS), 
high (HSS) or low/oscillatory (OSS) shear stress (red). ECs were identified by co-staining 
with anti-CD31 antibodies conjugated to FITC (green). Cell nuclei were identified using 
TOPRO-3 (purple). Fluorescence was assessed by confocal microscopy (40x magnification). 
(A) Images shown are representative of at least 3 mice per group. (B) Levels of 
phosphorylated JNK were quantified by using image analysis software and presented as 
mean fluorescent intensities (MFI ± SEM) (wild-type: n=3). (C) Total expression levels of 
RelA (MFI ± SEM) were quantified as described above (wild-type: n=7; JNK1 -/-: n=3). (D, E) 
The proportion of RelA localised to the nucleus was calculated by dividing nuclear 
fluorescence by total fluorescence for multiple cells and mean values (± SEM) are shown. 
Data were pooled from measurements in at least 3 mice per group. Data generated from 
wild-type animals in D, E were derived from two independent experiments using at least 3 
animals per experiment (D: wild-type: n=4; E: wild-type n=3; JNK1 -/-: n=3). [one way 
ANOVA (Bonferroni's Multiple Comparison Test); * < 0.05; ** < 0.01; *** < 0.001, unpaired 
Student’s t-test; * < 0.05; ** < 0.01] 
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Figure 3.14: Shear stress regulates VCAM-1 expression 
Flow-altering constrictive cuffs were placed on the right carotid arteries of wild-type mice. 
Right carotid arteries were harvested after 7 days. VCAM-1 expression on ECs was 
assessed by en face staining of regions exposed to low (LSS), high (HSS) or low/oscillatory 
(OSS) shear stress (red). ECs were identified by co-staining with anti-CD31 antibodies 
conjugated to FITC (green). Cell nuclei were identified using TOPRO-3 (purple). 
Fluorescence was assessed by confocal microscopy (40x magnification). Images shown are 
representative of 4 mice. VCAM-1 expression was quantified by using image analysis 
software and presented as mean fluorescent intensities (MFI ± SEM). Data were pooled from 
measurements in 4 mice. [one way ANOVA (Bonferroni's Multiple Comparison Test); * < 0.05] 
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3.3.11 Low/oscillatory shear stress leads to an inflammatory response 
in the arterial sub-endothelium 
We wanted to investigate whether the shear stress induced EC activation 
also resulted in an inflammatory response in the sub-endothelium which 
would be consistent with low-grade chronic inflammation described in the 
murine aorta.394 Therefore we analysed the amount of CD68 positive cells in 
the high shear, low shear and low/oscillatory shear stress region after 14 
days of cuff placement (Figure 3.15). Strikingly, we were only able to detect 
CD68-positive cells in the region exposed to low/oscillatory shear stress 
(Figure 3.15, upper panel) where VCAM-1 expression was highest (Figure 
3.14). In addition, we investigated whether these signs of inflammation 
occurred through a JNK1-dependent mechanism by comparing wild-type and 
JNK1 -/- animals (Figure 3.12). In the JNK1 -/- mice, CD68 positive cells 
were detectable in the sub-endothelium of the low/oscillatory shear stress 
region but were significantly fewer compared to C57BL/6 animals (Figure 
3.15, lower panel). The detection of CD68 positive cells as characteristics of 
an inflammatory response would indicate that low/oscillatory shear stress 
promotes inflammation of the arterial intima. This occurs through a JNK1-
dependent mechanism. Since the cuff was placed only for 14 days we cannot 
conclude whether prolonged exposure of low/oscillatory shear stress leads to 
further inflammatory changes. 
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Figure 3.15: Role of JNK1 in shear-induced inflammatory responses 
Flow-altering, constrictive cuffs were placed on the right carotid arteries of wild-type or JNK1 
-/- mice. Right carotid arteries were harvested after 14 days. The accumulation of CD68-
positive cells was assessed by en face staining of regions exposed to low (LSS), high (HSS) 
or low/oscillatory (OSS) shear stress (red). ECs were identified by co-staining with anti-CD31 
antibodies conjugated to FITC (green). Cell nuclei were identified using TOPRO-3 (purple). 
Fluorescence was assessed by confocal microscopy (40x magnification). Images shown are 
representative of at least 3 animals per group. Frequency of CD68-positive cells per field of 
view (0.0547 mm
2
) was quantified using image analysis software and presented ± SEM. 
Data were pooled from measurements in at least 3 mice per group (wild-type: n=5; JNK1 -/-: 
n=3). [one way ANOVA (Bonferroni's Multiple Comparison Test); *** < 0.001; unpaired 
Student’s t-test; * < 0.05] 
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3.3.12 Conclusions 
 
A. Expression of RelA is positively regulated by JNK via the transcription 
factor ATF2 in cultured ECs. 
 
B. JNK1 positively regulates RelA expression and activity, VCAM-1 
expression in ECs and low-grade chronic inflammation at an athero-
susceptible site. 
 
C. Low/oscillatory shear stress promotes JNK activity and enhances RelA 
expression, endothelial activation and low-grade chronic inflammation 
via a JNK1-dependent mechanism. 
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3.4 Discussion 
The murine arterial tree contains regions that have markedly different 
susceptibilities to inflammation and atherogenesis. For example, regions of 
the aorta such as the inner curvature are susceptible to inflammatory 
activation and the development of atherosclerosis while regions such as the 
outer curvature are protected. Hajra et al. previously reported that RelA 
expression was increased in the athero-susceptible region compared to the 
athero-protected region but they did not identify the molecular mechanism 
that controls RelA expression.131 Indeed, although the signalling pathways 
that activate pro-inflammatory NF-κB transcription factors are relatively well 
defined, the regulation and physiological significance of differential NF-κB 
expression has received little attention. In this chapter, we report the first 
example of a signalling pathway that regulates NF-κB RelA expression and 
were able to demonstrate that this pathway is responsible for the enhanced 
expression of RelA at athero-susceptible regions.  
 
We could show in HUVEC that JNK positively regulates RelA expression 
through the transcription factor ATF2. The transcription factors c-jun and 
ATF2 are components of the AP-1 family and act as homodimers or 
heterodimers. Since c-Jun is a very important dimerization partner of ATF2 
and responsible for cellular processes 232 we tested the effects of ATF2 or c-
Jun silencing on RelA expression. Our data suggest that ATF2 but not c-Jun 
is a positive regulator of RelA expression. Therefore, we can assume that 
ATF2 is acting as a homodimer or it remains possible that ATF2 forms a 
complex with another member of the AP-1 family. Our in vitro data also 
suggest that the JNK-ATF2-RelA signalling pathway that we identified may 
play a role in inflammatory activation because JNK promoted expression of 
VCAM-1, partly, by priming cells for enhanced RelA activation in response to 
a pro-inflammatory stimulus. These data are consistent with previous studies 
which demonstrated that VCAM-1 expression is positively regulated by both 
RelA and JNK.328,333,393,395 ChIP experiments revealed that ATF2 can interact 
with the VCAM-1 promoter. Given our results and studies from others, it is 
plausible that JNK-ATF2 signalling regulates VCAM-1 expression through 
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two parallel pathways – a direct route involving ATF2 interactions with the 
VCAM-1 promoter 328 and an indirect route involving induction of RelA for 
VCAM-1 promoter interaction. 
 
Overall, our observations may have broad physiological importance since 
they indicate that RelA is regulated at the level of expression as well as at 
post-translational levels. Despite a variety of detailed reports on the 
regulation of NF-κB activity, few studies have focused on the potential 
physiological importance of differential NF-κB expression. Nevertheless, 
recent reports have suggested that NF-κB expression may be altered during 
cellular senescence which is a state of stable proliferative arrest.119-121 
However, the potential role of JNK in regulating RelA expression in 
senescent cells has not been assessed. In addition to its importance in 
regulating inflammatory activation, it is possible that the JNK-ATF2-RelA 
pathway also primes cells for enhanced induction of other NF-κB target 
genes that regulate diverse physiological processes including cytoprotection, 
proliferation and senescence. 
 
In this chapter, we could show that NF-κB expression is regulated by JNK 
and we revealed a novel mode of crosstalk between these pathways that 
controls vascular inflammation. Both NF-κB and MAP kinases are regulated 
through multiple mechanisms that involve crosstalk at several different levels. 
It has been shown that NF-κB induces several negative regulators of MAP 
kinases including MKP-1, A20 and GADD45β which regulate the kinetics of 
JNK and p38 activation.257-259 Thus, NF-κB plays a key role in maintaining 
cell viability by preventing prolonged activation of JNK which can lead to 
apoptosis.264 It would be very interesting to address the possibility that JNK-
ATF2 mediated induction of NF-κB may prime cells for enhanced expression 
of NF-κB-dependent negative regulators of JNK, thus forming a negative 
feedback loop in the JNK signaling pathway. 
 
 
 
  119 
To validate our in vitro data in vivo, we demonstrated that JNK1 positively 
regulates RelA expression and promotes inflammation in the mouse aorta 
and arteries. Previous studies from our group and others have revealed that 
the morphological and physiological properties of ECs differ greatly between 
athero-protected and athero-prone sites.50,131,246,325,333,339,395,396 ECs at 
athero-prone sites express relatively high levels of NF-κB proteins and are 
primed for inflammation, whereas ECs at protected sites express low 
amounts of NF-κB and are resistant to inflammation.50,131,339,394 Our data 
show that the mechanism underlying the distinct spatial distribution of RelA 
expression involves JNK1 signalling which enhances NF-κB expression and 
activity at athero-prone sites but is not active at protected sites. Furthermore, 
regulation of RelA takes place at the transcript level and the expression 
pattern of RelA mRNA is similar to that of activated ATF2. 
 
The spatial variation in EC morphology and physiology has been attributed to 
spatial differences in hemodynamics. Athero-protected regions are exposed 
to a high uni-directional undisturbed shear stress while athero-susceptible 
regions are exposed to low disturbed shear stress.279,397,398 The rate and 
directionality of blood flow can regulate EC physiology by driving an outside-
in flow-induced signalling response known as mechanotransduction.265 We 
hypothesized that JNK-mediated induction of RelA may be controlled directly 
by shear stress. Therefore, we investigated the influence of blood flow on EC 
physiology by applying a flow-altering constrictive cuff which generates two 
different forms of disturbed blood flow – a low shear environment and a 
low/oscillatory shear environment. Due to the constriction of the cuff, an 
undisturbed, high shear stress region occurs where the cuff was placed. We 
observed that both of these mechanical environments of low shear and 
low/oscillatory shear stress induced RelA expression via activation of JNK1. 
However, we noted differences in JNK and RelA activation (nuclear 
localisation), which were higher in ECs exposed to low/oscillatory shear 
compared to cells exposed to low shear stress. Strikingly, the activation of 
RelA and JNK in ECs exposed to low/oscillatory shear stress was associated 
with induction of VCAM-1 and the development of low-grade vascular 
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inflammation shown by staining for CD68-positive cells, whereas expression 
of inactive RelA and modest JNK activation in ECs exposed to low shear was 
not associated with inflammation. These data suggest that low and oscillatory 
forces have differential effects on EC activation and vascular inflammation 
that may be dictated by the degree of JNK1 activation. Thus, we propose that 
low shear may prime ECs for inflammatory activation by inducing NF-κB 
expression, whereas oscillatory shear triggers activation of NF-κB which 
subsequently promotes inflammation. At a broader level, our observation that 
different forms of disturbed flow have specific effects on EC physiology 
reinforces the concept that ECs at athero-susceptible sites may be highly 
heterogenous due to local differences in the magnitude or direction of shear 
forces that they are exposed to.339,395 
 
Our novel observation that low/oscillatory shear can promote vascular 
inflammation in normocholesterolemic conditions is consistent with previous 
reports of chronic low-grade inflammation at athero-susceptible regions in 
C57BL/6 wild-type mice.394 It suggests that low/oscillatory shear stress may 
promote early atherogenesis by enhancing the accumulation of macrophages 
at branches and bends. However, a previous study revealed that 
low/oscillatory shear stress promoted the formation of stable type lesions that 
contained few inflammatory cells in hypercholesterolemic ApoE -/- mice.75 
Collectively, these observations suggest that low/oscillatory shear stress may 
have differential effects on vascular inflammation during plaque initiation and 
progression.  
 
Given our finding that JNK1 promotes inflammation at athero-susceptible 
sites, it is plausible that this molecule may positively regulate early 
atherogenesis. A study which examined the role of JNK1 and JNK2 in 
atherosclerosis could not find a significant reduction of lesion development in 
ApoE -/- JNK1 -/- double knock out animals compared to ApoE -/- animals 
following 14 weeks on a high-cholesterol diet. They observed a minimal 
reduction in plaque area in these double knock outs, but this difference was 
not statistically significant and so this line of enquiry was not pursued further. 
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The authors also treated ApoE knock out mice with the pharmacological JNK 
inhibitor SP600125 and observed a significant reduction in plaque size. 
Interestingly, plaque size in age-matched ApoE -/- mice exposed to identical 
diets varied by more than 50% in this study, suggesting that the effect of 
JNK1 on atherogenesis may have been obscured by high levels of 
experimental variation. However, genetic deletion of JNK2 did reduce plaque 
size by reducing the uptake of oxidised lipoproteins by macrophages.251 Of 
note, this study did not assess the potential role of JNK1 in early 
atherogenesis and further work should now be conducted to address this.  
 
In summary, our findings illuminate a novel level of cross-talk between the 
NF-κB and JNK signalling pathways that influences the regulation of vascular 
inflammation at athero-susceptible sites. 
 
3.4.1 Future experiments 
To confirm that JNK positively regulates RelA expression through a 
transcriptional mechanism, further experiments are required: 
 
A. Determine the AP-1 binding site(s) in the RelA promoter that are 
responsible for RelA expression. This can be achieved by introducing 
point mutations into the putative ATF2 binding sites in the RelA 
promoter and monitoring their effects on RelA promoter activity using 
a luciferase reporter gene in vitro system. 
 
B. Further ChIP experiments to assess whether RNA polymerase II or 
active histone components bind to the RelA promoter through a JNK-
dependent mechanism would also determine whether active 
transcription occurs. 
 
Finally, it would be of great interest to extend our understanding of the 
regulation and role of NF-κB in ECs to other NF-κB subunits such as p50 and 
c-Rel which are known to be expressed in ECs. 
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Chapter Four: Vascular inflammation 
imaging using PET 
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4.1 Introduction 
Molecular imaging involves the in vivo characterisation and assessment of 
biological processes in cells, tissues or whole organisms through imaging of 
specific, labelled molecules. These approaches require a molecular probe 
and a method to monitor it. This chapter will focus on a non-invasive imaging 
technique, FDG-PET, which allows to identify regions of high metabolism in 
whole organisms and has been used to study inflammation in atherosclerotic 
lesions.362 Furthermore, it has been suggested that vascular uptake of FDG 
occurs at early stages of atherogenesis.358,399 
 
Using the flow-altering cuff, we showed in Chapter 3 that a causal 
relationship between shear stress, JNK activity, RelA expression, endothelial 
activation and low-grade chronic inflammation exists. Strikingly, RelA 
expression was highest in the low/oscillatory shear stress area, which was 
the only area where CD68-positive inflammatory cells were detected in the 
intima. The aim of this project was to assess whether PET can be used as an 
experimental tool to detect physiological changes in regions of the murine 
carotid artery exposed to low and low/oscillatory shear stress. Moreover, as 
far as we are aware, this is the first application of PET to assess directly the 
effects of flow disturbances/ perturbations on vascular physiology in a living 
animal. 
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4.2 Hypothesis and Aims 
We hypothesise that FDG imaging can be used to detect low-grade chronic 
inflammation caused by the alteration of shear stress in the murine common 
carotid artery. 
 
To assess and verify this hypothesis, the following aims were explored: 
 
A. Determine whether computed tomography angiography (CTA) can be 
used to visualise the flow altering cuff. 
 
B. Determine by PET imaging whether 18F-FDG uptake is enhanced by 
disturbed flow in cuffed murine carotid arteries. 
 
C. If so, assess whether JNK1 is a positive regulator of inflammation-
related FDG uptake in cuffed arteries. 
 
D. Use the macrophage-specific radio tracer 18F-FEDAA to confirm that 
disturbed flow promotes the accumulation of macrophages in cuffed 
murine carotid arteries. 
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4.3 Results 
4.3.1 Computed tomography angiography to visualize the flow-altering 
cuff 
Initially, we attempted to visualize the flow-altering device by CTA. We 
therefore placed a cuff around the common carotid artery and performed 
CTA 14 days later using Ultravist370 as a contrast agent. Figure 4.1 clearly 
shows the feasibility of using CTA to visualise the flow altering device 
(highlighted with red arrow). Furthermore, this approach was able to detect 
tapering of the lumen of the carotid artery (highlighted with yellow arrow). In 
addition, the visualisation of the left carotid artery was useful because it 
enabled comparisons between the cuffed and unmanipulated artery to be 
made. 
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Figure 4.1: Visualisation of the flow altering cuff by CTA 
Flow-altering, constrictive cuffs were placed on the right carotid arteries of wild-type mice. 
After 14 days, the anatomical location of the cuff was visualized by CTA (red arrows) using 
iodine based contrast agent. The lumen of the cuffed artery can be visualised (yellow arrow). 
Representative images (sagittal; coronal; transverse view) are shown. The described 
experiments were carried out with the help of Dr. Willy Gsell. 
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4.3.2 In vivo detection of cuff-induced low-grade inflammation using 
18F-FDG in C57BL/6 and JNK1-deficient animals 
This project assessed whether PET can be used as a technique to detect 
low-grade inflammation in regions of the carotid artery exposed to low or 
low/oscillatory shear stress. We altered shear stress in the carotid artery 
using a constrictive cuff (described in Chapter 2). Alternatively, we placed a 
non-constrictive control cuff around the carotid artery to control for the 
possible effects of surgical manipulation per se. The radio tracer we used, 
18F-FDG, is taken up by cells with a high metabolic rate. In all experimental 
groups (wild-type/constrictive cuff, wild-type/non-constrictive cuff, JNK1 -/- 
/constrictive cuff), we detected FDG uptake in the brain and the heart which 
was expected due to the high metabolic rate of these organs. FDG uptake 
from the contralateral carotid artery (control side opposite to the cuff) was 
similar in all groups (0.79 ± 0.02; 1.07 ± 0.21 and 0.99 ± 0.01 g/ml for wild-
type with constrictive cuff, JNK1 -/- with constrictive cuff and wild-type with 
non-constrictive cuff respectively). Because of this, we decided to express 
the data as the ratio between ipsi (cuffed) and contralateral artery uptake. We 
observed that FDG uptake was significantly higher in both the low shear 
stress region and the low/oscillatory shear stress compared to the 
contralateral (Figure 4.2). Moreover, FDG uptake in the low/oscillatory region 
was significantly higher than the uptake in the low shear region (Figure 4.2.B 
upper panel; Figure 4.2.C). Interestingly, in the JNK1-deficient animals, we 
did not observe increased uptake of FDG in the shear-altered regions (Figure 
4.2 B, middle panel; Figure 4.2 C) and FDG accumulation in the region 
exposed to low/oscillatory shear stress was significantly less in JNK1-
deficient animals compared to wild-type animals (Figure 4.2 C).  
 
To confirm that elevated FDG uptake at distal and proximal sites (of cuffed 
arteries of wild-type mice) was due to altered shear stress and not due to the 
cuff placement itself, we assessed FDG uptake in arteries modified with a 
non-constrictive cuff that does not alter shear stress (Figure 4.2 A). Hereby, 
we tested whether the surgical procedure or the material of the cuff 
influences FDG uptake at proximal or distal sites. Compared to the 
unmanipulated, contralateral artery, minimal FDG uptake was detected in the 
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distal region and less in the proximal region in arteries modified with non-
constrictive cuff (Figure 4.2 B, lower panel; Figure 4.2 C). The analysis of the 
high shear stress region was complicated due to a variety of reasons. We 
detected a PET signal in the cuffed region in mice that received either 
constrictive or non-constrictive cuffs, but this may be due to fibrous tissue 
which developed around the flow altering device itself and not due to flow 
alteration. In addition, as the PET resolution is only 1.4 mm and the cuff itself 
is 1 mm in length, it is possible that positrons emitted at the proximal or distal 
regions may have been detected in the cuffed area in mice that received a 
constrictive cuff. Because of these considerations, we can not make any firm 
conclusions about the extent of FDG uptake in the arterial segment that is 
within the cuff. 
 
In summary, our data suggest that shear stress induced low-grade 
inflammation that can be detected non-invasively by molecular imaging using 
18F-FDG, and they indicate that shear-induced FDG uptake occurs through a 
JNK1-dependent mechanism. 
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Figure 4.2: Low/oscillatory shear stress enhances FDG uptake in 
murine arteries via JNK1 
(A) Flow-altering, constrictive cuffs or control, non-constrictive cuffs were placed on the right 
carotid arteries of wild-type (WT) or JNK1 -/- mice. (B) After 14 days, the spatial distribution 
of 
18
F-FDG uptake was studied in ipsi (experimental) and contralateral (unmanipulated) 
arteries by PET/CT. Positron emission data and CT angiography images were overlaid and 
representative images of 5 mice per group are shown. Each PET image was scaled from 0.5 
to 3 SUV (g/ml). (C) Positron emission was quantified at regions located proximal (P) or 
distal (D) or on the cuff (C) and normalized to the uptake values obtained from the 
contralateral carotid artery. Mean ratios of FDG uptake (± SEM) are shown. [unpaired 
Student’s t-test; * < 0.05]. The described experiments were carried out with the help of Dr. 
Willy Gsell. 
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4.3.3 Low/oscillatory shear stress enhances FEDAA uptake in murine 
arteries 
We suggest that low or low/oscillatory shear stress elevates FDG uptake by 
promoting inflammation. However, as FDG is taken up by all cells that display 
a high metabolic rate, we can not rule out other possible mechanisms. 
Therefore, we wished to confirm our observations by using a radio tracer that 
is more specific for inflammatory cells. The translocator protein/peripheral 
benzodiazepine receptor (TSPO/PBR) is highly expressed in macrophages 
350 and the radio tracer 18F-FEDAA has a highly selective and specific binding 
to it.356,357 Therefore, we assessed the distribution of FEDAA binding in 
arteries of wild-type mice that were modified with a constrictive cuff for 14 
days. In preliminary experiments using 2 animals, we observed an increased 
FEDAA signal in the low/oscillatory shear region (Figure 4.3). In summary 
these data show a positive correlation between the uptake of FDG, FEDAA 
and the accumulation of macrophages in the low/oscillatory shear stress 
region. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  132 
0.5
1
cuff
cuff
 
Figure 4.3: Low/oscillatory shear stress enhances FEDAA uptake in 
murine arteries 
Flow-altering, constrictive cuffs were placed on the right carotid arteries of wild-type mice. 
After 14 days, the spatial distribution of 
18
F-FEDAA uptake was studied in ipsi (experimental) 
and contralateral (unmanipulated) arteries by PET/CT. Positron emission data and CT 
angiography images were overlaid and representative images of 2 independent experiments 
that gave closely similar results are shown. Displayed is a Vd (Volume distribution) map of 
the data and scaled from 0.5 to 1 ml/g. The described experiments were carried out with the 
help of Dr. Willy Gsell. 
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4.3.4 Conclusions 
 
A. Computed tomography angiography can be used to visualize the flow-
altering cuff. 
 
B. Shear alteration leads to an increased uptake of FDG in regions 
exposed to low and, to a much greater extent, low/oscillatory shear 
stress. 
 
C. Uptake of FDG in regions of low/oscillatory shear stress is mediated 
by a JNK1-dependent mechanism. 
 
D. Low/oscillatory shear stress may also cause an increased binding of 
FEDAA, a ligand for TSPO/PBR which are highly enriched in 
macrophages. 
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4.4 Discussion 
Imaging techniques such as PET have been used previously to assess 
inflammation in atherosclerotic lesions.345 Moreover, hybrid imaging systems 
such as PET/CT allow imaging of atherosclerotic plaques at relatively early 
stages of development.344 Given our observation that low/oscillatory shear 
stress promoted endothelial activation and low-grade chronic inflammation, 
we wanted to assess whether FDG PET can be used to detect focal, low-
grade inflammation in murine arteries. In preliminary studies, we attempted to 
assess FDG-PET uptake in regions of the murine aorta exposed to disturbed 
(inner curvature of arch) or unidirectional flow (outer curvature), however this 
approach was unsuccessful because PET did not have sufficient spatial 
resolution to distinguish between these two sites (data not shown). By 
contrast, modification of carotid arteries with a constrictive cuff (1 mm length) 
generated distinct flow fields with sufficient spatial separation for PET. Using 
this approach, we demonstrated a significant uptake of FDG in regions 
exposed to low/oscillatory shear. To our knowledge, this is the first PET 
imaging study of vascular responses to altered flow in living animals. It is 
therefore potentially significant because it provides a technical/ 
methodological platform that can be used to assess the influence of 
biomechanical forces on other aspects of vascular physiology including 
remodelling 400 and apoptosis.401 
 
Collectively, en face staining and PET imaging demonstrated that the 
application of low/oscillatory shear stress enhanced FDG uptake as well as 
FEDAA binding, and this correlated with the accumulation of CD68-positive 
inflammatory cells. Thus it is plausible that FDG uptake reflects vascular 
inflammation in this setting. Consistent with this idea, a previous study 
suggested that early inflammation in human carotid arteries with low to 
moderate stenosis can be detected using FDG-PET.399 The authors of this 
manuscript correlated FDG accumulation with active inflammation by staining 
for CD68 positive cells.399 In addition, Rudd et al. demonstrated that human 
vessels containing atherosclerotic plaques showed an increased uptake of 
FDG, and also displayed dense macrophage infiltration.402 
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In addition, several animal studies have suggested that inflammatory cells 
are responsible for FDG uptake in plaques. Vallabhajosula et al. observed a 
significant accumulation of FDG in aortas of cholesterol–fed rabbits and 
histological data indicated that FDG accumulation correlated with 
macrophage density in the aorta.367 Similarly, Ogawa et al. studied 
hypercholesterolemic and control rabbits using FDG–PET and demonstrated 
that vascular FDG uptake correlates with the number of macrophages in the 
vessel wall.368 A study by Davies et al. also supports the correlation between 
the infiltration of macrophages and FDG accumulation in 
hypercholesterolemic rabbits but only when aortas were imaged ex vivo. 
Their in vivo measurements did not support this correlation to the same 
extent, possibly due to interfering signals from blood or surrounding 
tissues.369 Taken together, the before mentioned human and animal studies 
of atherosclerotic plaques have shown a positive correlation between uptake 
of FDG or 3H–2HDG and the accumulation of macrophages by using 
histochemical staining and the evaluation of gene expression.362,368-
374,377,378,403,404 
 
In addition to the in vivo data, in vitro data have been performed to further 
analyse the role of macrophages in the uptake of FDG. It has been shown 
that cultured monocytes and macrophages showed an increased uptake of 
FDG subsequent to the exposure to pro–inflammatory stimuli such as LPS 
and interferon-γ 379-381 These data would therefore support the hypothesis 
that activated macrophages are characterised by increased glucose 
metabolism and thus are responsible for the elevated uptake of FDG in the 
low/oscillatory shear stress region and atherosclerotic lesions in general. 
 
Despite these studies, FDG imaging of atherosclerotic lesions is an area of 
study not without controversy because, although atherosclerotic plaques 
have been associated with an increased FDG signal compared to unaffected 
vessels, 362-366 these findings do not explain the source and mechanisms of 
FDG accumulation in atherosclerosis. Several studies have shown that, in 
addition to macrophages, other factors such as neovascularisation and 
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calcification have also been associated with FDG uptake.385,405 In addition, 
studies on ApoE deficient mice showed a poor correlation between 14C–2DG 
uptake and en face macrophage staining in the aorta.383 Further work on 
ApoE deficient mice demonstrated that removal of the interscapular brown fat 
led to reduced FDG uptake in atherosclerotic lesions.382 These and other 
work 369,384-386 underline the requirement of further investigation of the 
mechanism of FDG uptake in the vasculature.358 Thus, it is not possible to 
determine conclusively whether the uptake of FDG that we observed in the 
murine carotid artery is macrophage-dependent or whether it is due to other 
shear-regulated processes. In addition, there are other potential mediators of 
enhanced FDG uptake in the low/oscillatory regions such as increased EC 
proliferation or SMC remodelling. Thus, it will be important in future 
experiments to define the cells responsible for FDG uptake by combining 
autoradiography with immunohistochemistry. 
 
More recently, the radiotracer PK11195 has been used to study vascular 
inflammation in humans and animal models 351-353 due to its specific binding 
to TSPO/PBR which are greatly enriched on macrophages.350 However, 
PK11195 displays a low signal-to-noise ratio and high levels of non-specific 
binding were detected in vivo.355,406 Because of these considerations, we 
assessed the effects of disturbed flow on binding of FEDAA, which is also an 
agonist of TSPO/PBR but has a higher selectivity and specificity compared to 
PK11195.356,357 Although our findings are very preliminary, we found 
enhanced FEDAA binding in the low/oscillatory shear stress region which 
correlated with the accumulation of CD68-positive inflammatory cells. It 
would be useful to extend our FEDAA experiments and study more animals 
in the future and also use additional probes to assess inflammatory 
activation. In this regard, several groups are now developing new molecular 
imaging tools that may be able to detect inflammation more specifically. For 
example, molecular imaging approaches to detect adhesion molecules such 
as VCAM-1 and macrophages using different radiotracers are currently under 
development.344 For example, using peptide-based ligands with binding 
specificity to VCAM-1, PET/CT was used to study inflammatory activation of 
ECs in the aorta of ApoE -/- mice.346 Nahrendorf et al. developed a 
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trimodality nanoparticle 64Cu-TNP which could directly detect macrophages 
in atherosclerotic lesions. They observed a similar but not 100% identical 
distribution for FDG uptake in ApoE -/- mice.349 It would be of great interest to 
see whether molecular imaging using an adhesion molecule marker can be 
used to confirm our observation that shear alteration leads to increased 
endothelial activation and low-grade inflammation.  
 
Interestingly, Cheng et al. demonstrated by using the flow-altering cuff in 
hypercholesterolemic ApoE-/- mice, that low/oscillatory shear stress led to 
the formation of stable type lesions that contained few inflammatory cells. In 
contrast, plaques that developed at the low shear region had characteristics 
of vulnerability, including the accumulation of inflammatory cells.75 We 
observed increased inflammation in the low/oscillatory shear region under 
normocholesterolemic conditions which would suggest that the inflammatory 
state of the low shear and low/oscillatory shear regions change during 
atherogenesis. Therefore, it would be interesting to monitor inflammation 
during the development of different plaque phenotypes in living 
hypercholesterolemic ApoE -/- or LDLR -/- knock out animals using molecular 
imaging approaches. 
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Chapter Five: NF-κB dynamics 
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5.1 Introduction 
The dynamics of nuclear : cytoplasmic shuttling of the RelA NF-κB sub-unit in 
response to a stimulus are tightly regulated, since the duration of RelA 
nuclear localisation is an important regulator of the magnitude and specificity 
of target gene expression.158,159 
 
Numerous reports have shown that sustained activation of cells with TNFα 
results in NF-κB oscillations, a process that depends on the continuous 
degradation and re-synthesis of IκB proteins.147,159-162 In contrast, LPS 
treatment does not induce oscillations in NF-κB activation.167,168 However, it 
has been shown that cellular responses to LPS are very heterogenous. This 
is due to the secretion of TNFα and the subsequent overlap of the TNF and 
LPS signalling cascades. Therefore, in a single population of fibroblasts, LPS 
triggered rapid nuclear localisation of RelA followed by rapid export in some 
cells, but prolonged nuclear localisation in others. The latter response was 
linked to a secondary paracrine TNFα signal leading to a late phase of LPS-
dependent NF-κB activation.169 
 
As shown in Chapter 3, we could demonstrate that RelA expression differs in 
the athero-susceptible compared to the athero-protected region of the mouse 
aorta. In addition to the differential expression of RelA, we assessed whether 
the dynamics of RelA nuclear : cytoplasmic shuttling in response to LPS 
stimulation differed in the two regions, and examined the mechanisms that 
regulate RelA dynamics in ECs of the murine aorta.  
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5.2 Hypothesis and Aims 
We hypothesise that the kinetics of RelA nuclear localisation in response to 
LPS differs in the athero-susceptible region compared to the athero-protected 
region. 
 
To assess this hypothesis, the following aims were addressed: 
 
A. Assess the dynamics of RelA nuclear localisation at the athero-
susceptible compared to the athero-protected region in arterial ECs. 
 
B. Assess the role of IκBα re-synthesis in the regulation of RelA kinetics 
in ECs of the murine aorta. 
 
C. Examine the molecular mechanisms that may influence the kinetics of 
RelA nuclear localisation in arterial ECs at athero-susceptible and 
athero-protected regions. 
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5.3 Results 
5.3.1 Prolonged nuclear localisation of RelA in response to LPS 
stimulation at athero-susceptible regions 
The kinetics of RelA nuclear localisation in response to LPS were studied 
using the en face staining technique (Figure 5.1). To assess the dynamics of 
RelA nuclear : cytoplasmic shuttling after LPS treatment, the proportion of 
RelA in the nucleus (i.e. nuclear/ total RelA ratio) was calculated. We 
observed the proportion of RelA that localised to the nucleus was significantly 
enhanced in the athero-susceptible region compared to the athero-protected 
region in untreated animals (Figure 5.1 B, panels 1 and 2), possibly reflecting 
a state of enhanced basal EC activation. At the athero-protected site, LPS 
treatment transiently enhanced the proportion of RelA in the nucleus which 
peaked at 30 min stimulation but subsequently returned to the basal state at 
240 min (Figure 5.1 B, panels 1,3,5,7). In contrast, LPS treatment led to a 
more prolonged nuclear localisation of RelA in the athero-susceptible site 
(Figure 5.1 B, panels 2,4,6,8). These data suggest that export of RelA from 
the nucleus to the cytoplasm in response to prolonged LPS stimulation 
occurs rapidly in ECs in the athero-protected region but not in the susceptible 
region. This leads to prolonged nuclear localisation of RelA in the susceptible 
region. Overall, these data suggest that ECs in the athero-susceptible region 
are primed for enhanced NF-κB transcriptional activity in response to pro-
inflammatory stimuli because (compared to ECs in the athero-protected 
region), they express elevated total levels of RelA (shown in Chapter 3), and 
also display a prolonged nuclear localisation of RelA in response to a pro-
inflammatory stimulus. 
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Figure 5.1: Prolonged nuclear localisation in LPS stimulated ECs at 
athero-susceptible sites 
RelA intracellular localisation in ECs was assessed by en face staining of athero-susceptible 
(S) or athero-protected (P) regions of the aorta in wild-type mice (red). Animals remained 
untreated to assess the basal state or were treated with LPS (4 mg/kg; i.p.) and studied 
following 30, 120 or 240 min. ECs were identified by co-staining with anti-CD31 antibodies 
conjugated to FITC (green). Cell nuclei were identified using TOPRO-3 (purple). 
Fluorescence was assessed by confocal microscopy (40x magnification). (A) Images shown 
are representative of 3 mice per group. (B) The proportion of RelA localised to the nucleus 
was calculated using image analysis software by dividing nuclear fluorescence by total 
fluorescence for multiple cells and mean values (± SEM) are shown. Data were pooled from 
measurements in 3 mice per group. [unpaired Student’s t-test; *** < 0.001] 
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5.3.2 Enhanced re-synthesis of IκBα in LPS-stimulated ECs at athero-
susceptible sites 
Previous studies have demonstrated that RelA nuclear localisation is 
suppressed following prolonged pro-inflammatory stimulation due to the 
export of RelA from the nucleus to the cytoplasm, a process that depends on 
the re-synthesis of IκBα. 147,148,407,408 In addition, it was shown that the 
absence of IκBα leads to prolonged RelA activation upon TNFα 
stimulation.409,410 We observed that RelA nuclear localisation in response to 
LPS was prolonged in the athero-susceptible site compared to the athero-
protected site (Figure 5.1). Therefore, we assessed whether the differential 
dynamics of RelA may be due to differences in IκBα degradation and 
subsequent re-synthesis at these sites. To address this hypothesis, the 
expression of IκBα was studied by en face staining in untreated and LPS-
treated mice (Figure 5.2). Total IκBα expression was significantly enhanced 
in ECs in the athero-susceptible site compared to the athero-protected site in 
untreated animals (Figure 5.2 B, panels 1 and 2). IκBα expression at both 
sites was reduced in animals treated with LPS for 30 min compared to 
untreated animals (Figure 5.2 B, panels 3 and 4). In contrast, IκBα 
expression in animals treated with LPS for 120 or 240 mins either exceeded 
or was similar to the levels of IκBα that were detected in untreated animals 
(Figure 5.2 B, panels 5,6,7,8). Thus, we suggest that LPS treatment leads to 
rapid degradation of IκBα followed by re-synthesis of IκBα at both 
susceptible and protected sites. However, although IκBα was expressed at 
the susceptible region in mice treated with LPS for 240 min (Figure 5.2), this 
was not sufficient to export RelA from the nucleus to the cytoplasm (Figure 
5.1). 
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Figure 5.2: IκBα expression in ECs is enhanced at athero-susceptible 
sites in untreated and LPS-treated mice 
IκBα expression levels in ECs were assessed by en face staining of athero-susceptible (S) 
or athero-protected (P) regions of the aorta in wild-type mice (red). Animals remained 
untreated to assess basal expression or were treated with LPS (4 mg/kg; i.p.) and studied 
following 30, 120 or 240 min. ECs were identified by co-staining with anti-CD31 antibodies 
conjugated to FITC (green). Cell nuclei were identified using TOPRO-3 (purple). 
Fluorescence was assessed by confocal microscopy (40x magnification). (A) Images shown 
are representative of 3 mice per group. (B) Total IκBα expression was quantified by using 
image analysis software and presented as mean fluorescent intensities (MFI ± SEM). Data 
were pooled from measurements in 3 mice per group. [unpaired Student’s t-test; * < 0.05] 
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5.3.3 HDACs influence RelA dynamics in aortic ECs in LPS-treated mice 
Acetylation of RelA at certain lysine residues (e.g. Lys-221) decreases its 
ability to bind IκBα and simultaneously increases its binding affinity for 
DNA.133 Acetyl groups are removed by HDACs. It has been demonstrated 
that HDAC3 deacetylates Lys-221 of RelA in the nucleus leading to the 
binding of RelA to IκBα and subsequent nuclear export and termination of 
RelA activity.133 
 
Given that RelA is retained in the nucleus for shorter periods in the protected 
compared to the susceptible region (despite expression of IκBα at both 
sites), we hypothesized that HDAC3 may be more active at the protected 
site. We assessed the expression of HDAC3 by en face staining and 
observed that it was expressed at significantly higher levels in the susceptible 
compared to the protected region (Figure 5.3 B), an observation that is 
consistent with a previous report.411 However, the nuclear proportion of 
HDAC3, which is an indicator of its activity, was significantly higher in the 
protected compared to the susceptible region (Figure 5.3 C). We therefore 
suggest that increased activity of HDAC3 in the protected region may 
enhance deacetylation of RelA which may in turn promote export of RelA 
from the nucleus. 
 
To define the mechanism that reduces the duration of RelA nuclear 
localisation in the protected region, we assessed the role of HDAC3 by 
inhibiting its activity. Therefore, we treated mice with the HDAC inhibitor MS-
275, which has a high affinity for HDAC1 and HDAC3.145,146 Subsequently, 
we assessed RelA kinetics in response to LPS (30 and 240 min) using the en 
face staining technique (Figure 5.4). In mice treated with LPS for 30 min, 
RelA localised predominantly to the nucleus in both the susceptible and 
protected sites and RelA localisation was not influenced by pre-treatment 
with MS-275 (Figure 5.4 B, panels 3,4,5,6). At a later time point of LPS 
treatment (240 min), RelA localisation was predominantly cytoplasmic at the 
protected site but remained nuclear at the susceptible site (Figure 5.4 B, 
panels 7 and 8). Pre-treatment with MS-275 significantly enhanced nuclear 
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localisation of RelA at the protected region (but not at the susceptible region) 
in mice treated with LPS for 240 min (Figure 5.4 B, panels 9 and 10). These 
data suggest that HDAC is partially responsible for the export of RelA from 
the nucleus to the cytoplasm in the protected region. Similar to the previous 
experiment (Figure 5.1 B), RelA nuclear localisation was prolonged at the 
susceptible region compared to the protected region and inhibition of HDAC 
had no effect on RelA dynamics in this region (Figure 5.4 B). We suggest 
therefore that HDAC3 promotes export of RelA from the nucleus to the 
cytoplasm at the protected site but not at the susceptible site. 
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Figure 5.3: Expression and intracellular localisation of HDAC3 in aortic 
ECs 
HDAC3 expression and localisation in ECs were assessed by en face staining of athero-
susceptible (S) or athero-protected (P) regions of the aorta in wild-type mice (red). ECs were 
identified by co-staining with anti-CD31 antibodies conjugated to FITC (green). Cell nuclei 
were identified using TOPRO-3 (purple). Fluorescence was assessed by confocal 
microscopy (40x magnification). (A) Images shown are representative of 6 mice per group. 
(B) Total HDAC3 expression was quantified by using image analysis software and presented 
as mean fluorescent intensities (MFI ± SEM). (C) The proportion of HDAC3 localised to the 
nucleus was calculated by dividing nuclear fluorescence by total fluorescence for multiple 
cells and mean values (± SEM) are shown. Data were pooled from measurements in 6 mice 
per group. [unpaired Student’s t-test; * < 0.05;  ** < 0.01] 
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Figure 5.4: Nuclear localisation of RelA at the athero-protected site was 
enhanced by a HDAC inhibitor in LPS-treated mice 
RelA intracellular localisation in ECs was assessed by en face staining of athero-susceptible 
(S) or athero-protected (P) regions of the aorta in wild-type mice (red). Animals remained 
were injected with the HDAC inhibitor MS-275 (10 mg/kg; i.p) and studied following 120 min 
or remained untreated as a control. Subsequently animals were treated with LPS (4 mg/kg; 
i.p) and studied following 30 or 240 min. ECs were identified by co-staining with anti-CD31 
antibodies conjugated to FITC (green). Cell nuclei were identified using TOPRO-3 (purple). 
Fluorescence was assessed by confocal microscopy (40x magnification). (A) Images shown 
are representative of 3 mice per group. (C) The proportion of RelA localised to the nucleus 
was calculated by dividing nuclear fluorescence by total fluorescence for multiple cells and 
mean values (± SEM) are shown. Data were pooled from measurements in 3 mice per 
group. [unpaired Student’s t-test; * < 0.05] 
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5.3.4 Conclusions 
 
A. Nuclear localisation of RelA is prolonged in response to LPS at athero-
susceptible sites compared to athero-protected sites. 
 
B. This observation can not be explained by differences in IκBα re-
synthesis which occurred at both the susceptible and the protected 
site. 
 
C. Export of RelA from the nucleus to the cytoplasm in response to 
prolonged LPS treatment is partially regulated by HDACs. 
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Figure 5.5: Conclusion: Effects of LPS on RelA kinetics and IκBα 
synthesis in the murine aorta 
Graphical presentation of the results described in Chapter 5. (Black) Intracellular localisation 
of RelA (Proportion of nuclear RelA (%)) in untreated or LPS treated ECs (30, 120 or 240 
min) in (A) athero-protected or (B) athero-susceptible regions of the murine aorta. Nuclear 
localisation of RelA is prolonged at athero-susceptible regions in response to LPS (Figure 
5.1). (Red) Effects of LPS treatment on IκBα expression (determined by fluorescent 
intensity). LPS treatment leads to IκBα degradation and subsequent re-synthesis at both (A) 
the athero-protected and (B) athero-susceptible site (Figure 5.2). (Green) The export of Rel 
of RelA from the nucleus to the cytoplasm at the (A) athero-protected site is partially 
regulated by HDACs, since pharmacological inhibition with MS-275 led to an enhanced 
nuclear localisation of RelA compared to (Purple) vehicle treated control ECs. This effect 
was not observed in the (B) athero-susceptible region (Figure 5.4). 
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5.4 Discussion 
A previous study in our laboratory assessed the effect of LPS on the 
transcriptional activity of NF-κB in the susceptible and protected regions of 
the aorta using transgenic NF-κB-luciferase reporter mice (Sandvik G, 
unpublished). It demonstrated that NF-κB transcriptional activity in response 
to LPS was significantly enhanced in ECs at the athero-susceptible region. In 
this chapter, we attempted to define the underlying mechanism by examining 
the kinetics of RelA nuclear localisation in response to LPS at both athero-
protected and athero- susceptible sites.  
 
We demonstrated that nuclear localisation of RelA was prolonged in the 
susceptible region compared to the protected region in arterial ECs in mice 
exposed to LPS. RelA contains an N-terminal RHD, which is required for the 
association with inhibitory proteins such as IκB.110 In unstimulated cells, RelA 
is maintained in the cytoplasm due to the binding to IκBs, which thereby 
mask the nuclear localisation sequence of RelA.115 Activation of the NF-κB 
signalling cascade results in the release of RelA from IκB, which is usually 
because of the ubiquination and subsequent degradation of IκB, allowing 
RelA to translocate to the nucleus. NF-κB activation is tightly regulated by 
several negative feedback mechanisms including NF-κB dependent induction 
of IκBα, A20 147-149 and Cezanne.150,151 It has been described previously that 
the nuclear localisation of RelA was suppressed following prolonged pro-
inflammatory stimulation due to the export of RelA from the nucleus to the 
cytoplasm. This process was dependent on the re-synthesis of 
IκBα.147,148,407,408 Thus, the absence of IκBα can lead to prolonged RelA 
activation in stimulated cells.409,410 Therefore, we assessed the involvement 
of IκBα degradation and subsequent re-synthesis in the differential dynamics 
of RelA at the protected and susceptible site. However, our observations 
indicate that prolonged nuclear localisation of RelA at the susceptible site 
was not due to an absence of IκBα expression. Indeed, our data suggest that 
re-synthesis of IκBα occurred to a similar extent in protected and susceptible 
regions. Thus, although IκBα was expressed at the susceptible site in LPS-
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treated animals, this was not sufficient to prevent RelA nuclear localisation. 
We therefore sought an alternative mechanism to explain the prolonged 
nuclear localisation of RelA at the athero-susceptible site. 
 
It has been demonstrated, that post-translational modification of NF-κB can 
regulate its binding to DNA or IκBs. RelA can be acetylated by HATs at five 
different lysine residues (Lys-122, Lys-123, Lys-218, Lys-221, Lys-310).132 
These modifications have different effects on the binding properties of RelA. 
Interestingly, acetylation at Lys-221 attenuates the binding of RelA to IκBα 
and furthermore increases the binding affinity of RelA to DNA.133 Acetylation 
of RelA is a reversible process. Removal of the acetyl group is catalysed by 
HDACs and studies have shown that HDAC3 deacetylates Lys-221 of RelA 
in the nucleus leading to enhanced binding of RelA to IκBα and subsequent 
export of RelA to the cytoplasm and termination of RelA activity.133 
Furthermore, work in cardiomyocytes revealed that HDAC3 can be activated 
by LPS treatment which enhances its nuclear localisation and activity.137 
 
Because of these considerations, we hypothesised that differential HDAC3 
activity in the athero-susceptible compared to the athero-protected site may 
result in different kinetics of RelA nuclear localisation and transcriptional 
activity. Studies by Zampetaki et al. described an increased expression of 
HDAC3 in the susceptible region of ApoE -/- mice.411 Here, we also 
demonstrated that HDAC3 is expressed predominantly at the susceptible site 
in wild-type animals. In addition, we observed that the nuclear proportion of 
HDAC3 (an indicator of its activity) was higher in the protected region 
compared to the susceptible region. This difference may reflect the 
hemodynamic conditions at these sites as laminar shear stress 
(characteristic of the protected site) can elevate HDAC3 activity.412 These 
data led us to suggest that increased activity of HDAC3 in the protected 
region may lead to enhanced deacetylation of RelA, which may result in 
increased nuclear export and termination of RelA activity. To directly assess 
this hypothesis, we inhibited HDAC activity prior to LPS treatment using MS-
275, a specific inhibitor for class I HDACS. Using this approach, we 
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demonstrated that HDACs promote export of RelA to the cytoplasm at the 
protected site but not the susceptible site in LPS-treated mice. These 
observations lead us to suggest that in regions exposed to high laminar 
shear stress, such as the protected region of the murine aorta, the 
deacetylase activity of HDAC3 is higher compared to the susceptible site 
which is exposed to low and oscillatory shear stress. This may subsequently 
promote export of RelA to the cytoplasm and therefore result in faster 
termination of RelA activity in the protected region subsequent to LPS 
activation (Figure 5.5). It is important to mention that despite its specificity for 
class I HDACS, MS-275 inhibits HDAC1, HDAC3, HDAC8 and 
HDAC2.145,146,413 Therefore, we cannot conclude that its effect on RelA 
localisation is via inhibition of HDAC3. Therefore, further experiments are 
necessary to determine the HDAC that is responsible for regulation of 
nuclear retention of RelA in the protected region. 
 
Our studies are consistent with previous suggestions that chronic 
inflammation is linked to reduced HDAC activity which can result in 
hyperacetylation of histones and transcription factors leading to increased 
expression of pro-inflammatory genes.414 For example HDAC2 was 
expressed at reduced levels in atherosclerotic lesions of human coronary 
arteries compared to healthy vessels.414 Interestingly, in the context of 
atherosclerosis, inhibition of HDAC using trichostatin A (TSA) increased 
atherogenesis in LDL -/- animals.415 This study demonstrated the HDAC 
inhibition led to increased expression of the macrophage scavenger receptor 
CD36, which was linked to increased uptake of oxLDL. Interestingly, CD36 
expression has been shown to be increased by NF-κB activation and it is 
therefore plausible that HDAC inhibitors elevate CD36 by enhancing NF-κB 
activity.416 Moreover, HDAC expression has also been shown to be reduced 
in other chronic inflammatory conditions including chronic obstructive 
pulmonary disease.417,418 
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In summary, we propose the following working model (Figure 5.5): ECs at 
athero-susceptible regions which are exposed to low/oscillatory shear stress 
display decreased HDAC3 activity. In contrast, ECs in athero-protected 
regions are exposed to high laminar shear stress and show increased 
HDAC3 activity. Increased HDAC3 activity results in deacetylation of RelA in 
the nucleus leading to the binding of RelA to IκBα and subsequent export to 
the cytoplasm and termination of RelA activity. 
 
5.4.1 Future experiments 
A. Assess the acetylation status of RelA at the athero-susceptible and 
athero-protected region by immunohistochemical analysis. 
 
B. Determine the potential role of specific HDACs in RelA regulation by 
studying their expression in the susceptible and protected regions, and 
by monitoring RelA dynamics in mouse strains that lack specific HDAC 
genes. 
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Figure 5.6: Model: The effects of shear stress on HDAC activity and its 
role in RelA regulation 
High laminar shear stress increases HDAC3 deacetylase activity leading to reduced 
acetylation (AC) of RelA. Deacetylation of RelA leads to the binding of IκBα to RelA resulting 
in the subsequent export of RelA from the nucleus to the cytoplasm. 
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Chapter Six: General Discussion 
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6.1 Conclusions 
 
A. ECs at athero-susceptible sites are primed for inflammatory activation 
because they express high levels of RelA and exhibit prolonged RelA 
activation in response to an inflammatory stimulus. By contrast, ECs at 
protected regions express relatively low levels of RelA and activation 
is relatively transient. 
 
B. These observations suggest that enhanced RelA activity may be 
responsible for the elevated inflammation that is observed at athero-
susceptible sites. 
 
C. Disturbed flow (low/oscillatory shear stress) enhances RelA 
expression at athero-susceptible sites via a JNK1-dependent 
mechanism. 
 
D. The relatively prolonged duration of RelA activation at susceptible 
sites in mice challenged with LPS may be related to reduced activity of 
HDAC3, a molecule that promotes export of RelA from the nucleus to 
the cytoplasm. 
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6.2 Discussion 
6.2.1 A model of the effects of shear stress on inflammatory signalling 
pathways 
This project assessed the effects of shear stress on NF-κB transcription 
factors in the context of endothelial activation and the initiation of 
atherosclerosis. The role of shear stress in the focal distribution of 
atherosclerosis has been validated by numerous studies.270-278 Observations 
from our group and others suggest that shear stress influences EC activation 
and vascular inflammation by regulating both NF-κB and MAP kinase 
signalling pathways.192,221,246,326,327,329,333 High shear stress (characteristic of 
protected sites) suppresses inflammatory activation, whereas low/oscillatory 
shear stress (characteristic of susceptible sites) has the opposite effect. 
 
It is now evident that shear stress influences both the expression and activity 
of NF-κB transcription factors in ECs. The in vitro and in vivo studies 
presented in this thesis reveal a novel mode of crosstalk between the MAP 
kinase and NF-κB pathways. Specifically, we demonstrated that 
low/oscillatory shear stress elevated JNK1 MAP kinase activity at athero-
susceptible sites, which in turn led to enhanced expression of RelA (Figure 
6.1, pathway 1). Our work provides the first example of a signalling pathway 
that positively regulates RelA expression to promote endothelial activation 
and low-grade chronic inflammation at athero-susceptible regions (Figure 
6.1, pathway 1).  
 
Previous studies demonstrated that shear stress also regulates NF-κB 
activity. The transcription factor KLF2 has been shown to be activated by 
high shear stress and can reduce NF-κB activity in cultured cells by 
sequestering the NF-κB co-activator CBP/p300 (Figure 6.1, pathway 2).321,322 
In addition, high shear stress also induces Cezanne which negatively 
regulates signalling to NF-κB.150 
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In addition to its influence on NF-κB expression and activity, shear stress 
also regulates vascular inflammation by modulating p38 and JNK signalling 
pathways. The activation of JNK occurs via upstream MAP3Ks such as 
apoptosis signal-regulating kinase 1 (ASK1).206-212 It has been shown that 
high shear stress inhibits TNFα-induced ASK1 activation by promoting the 
reduced form of thioredoxin, a redox-sensitive enzyme that promotes ASK1 
ubiquination and subsequent degradation (Figure 6.1, pathway 3).323,324 In 
addition, high shear stress reduces p38 and JNK activity in cultured ECs by 
the induction of MKP-1 and Nrf2. Furthermore, enhanced expression and 
activity of MKP-1 and Nrf2 were observed in the high shear, athero-protected 
region of the murine aorta, where they suppressed inflammatory activation 
(Figure 6.1, pathways 4 and 5).246,325 Recent studies also revealed that MKP-
1 expression in ECs reduces JNK-dependent apoptosis at athero-protected 
sites.333 Collectively, these observations reveal that shear stress influences 
endothelial activation and vascular inflammation through multiple 
mechanisms that simultaneously target both NF-κB and MAP kinase 
signalling. 
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Figure 6.1: Model of the influence of shear stress on NF-κB and MAP 
kinase signalling 
Shear stress influences the NF-κB and MAP kinase signalling pathways through multiple 
mechanisms: (1) Shear stress regulates RelA expression levels via JNK1 (findings 
presented in this thesis). (2): KLF2, Cezanne and HDACs are activated by shear stress and 
reduce NF-κB activity.
133,150,321,322,412
 (3) High shear stress inhibits TNFα-induced ASK1 and 
JNK activation.
323,324
 High shear stress also reduces inflammatory activation by inhibiting 
JNK and p38 via induction of MKP-1 (4) 
246
 and Nrf2 (5) 
325
, and also suppresses pro-
apoptotic JNK signalling (6).
333
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6.2.2 Future perspectives 
Our observations have opened up several new lines of enquiry that should 
now be addressed experimentally in future studies. 
 
6.2.2.1 Does JNK1 promote the initiation of atherosclerosis? 
Given our observation that JNK1 promotes inflammation at athero-
susceptible sites, we predict that this molecule positively regulates early 
atherogenesis. Thus, it would be interesting to assess the role of JNK in the 
initiation, and progression of atherogenesis using hypercholesterolemic JNK1 
-/- ApoE -/- or JNK1 -/- LDLR -/- double knock out animals. Indeed, JNK1 -/- 
have already been crossed with LDLR -/- by our group to carry out this study. 
Of note, a previous study of ApoE -/- JNK1 -/- animals did not observe any 
influence of JNK1 deletion on lesion size in mice ages 24 weeks.251 However, 
this study does not preclude a role for JNK1 in early atherogenesis as this 
stage of the disease was not studied. In addition, the observation by Ricci et 
al. may have been confounded by high levels of experimental variation.251 
 
By using the flow altering cuff, Cheng et al. revealed that low/oscillatory 
shear stress led to the formation of stable type lesions that contained few 
inflammatory cells in hypercholesterolemic ApoE -/- mice. In contrast, 
plaques that developed at the low shear region had characteristics of 
vulnerability such as a large lipid core, a thin fibrous cap, a paucity of smooth 
muscle cells in the cap and an accumulation of inflammatory cells in the 
fibrous cap and spontaneous intra-plaque hemorrages.75 Consequently, the 
flow altering cuff provides the possibility to assess the role of JNK1 in the 
development of the different plaque phenotypes. Thus, it would be interesting 
to assess the effects of JNK1 deletion on stable and vulnerable plaque 
development in cuffed ApoE -/- or LDLR -/- mice. Furthermore, the JNK 
inhibitor CT536706 has not been studied in vivo and it should be examined 
whether this compound can influence atherogenesis using animal models. 
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6.2.2.2 Shear stress and NF-κB dynamics 
We demonstrated a prolonged nuclear localisation of RelA in arterial ECs in 
the athero-susceptible region compared to the athero-protected region. By 
using transgenic NF-κB-luciferase reporter mice, we observed that NF-κB 
transcriptional activity was also enhanced at susceptible sites (Sandvik G, 
unpublished). Our data also suggest that differential HDAC activity may 
partially regulate the differential RelA dynamics at anatomically-distinct sites 
because inhibition of HDAC led to a significantly prolonged nuclear 
localisation of RelA in the protected site. However, the inhibition of HDAC 
had no effect on RelA dynamics in the athero-susceptible region. It would be 
interesting in future studies to assess the effects of HDAC inhibition on EC 
activation e.g. expression of VCAM-1 and NF-κB transcriptional activity 
(using transgenic NF-κB luciferase reporter mice). 
 
Given the fact that MS-275 inhibits HDAC1, HDAC3, HDAC8 and HDAC2 
145,146,413 it will be important to examine the expression of individual HDACs in 
the athero-protected and athero-susceptible region and their role in NF-κB 
regulation. This could be achieved using specific knock out strains of mice. 
 
It would also be very interesting to assess the effects of low shear and 
low/oscillatory shear stress on RelA dynamics directly. This could be 
achieved using knock-in mice expressing a GFP-RelA fusion protein which 
can be used to study RelA dynamics in vivo.419 ECs cultured from these mice 
could be studied by live cell imaging under different hemodynamic conditions 
and used to assess the effect of HDAC inhibition on RelA dynamics. 
Furthermore, it would be interesting to examine the feasibility of using in vivo 
imaging approaches such as two-photon fluorescence microscopy to study 
RelA dynamics in cuffed carotid arteries in GFP-RelA mice. This approach 
could be used to show the direct effect of low shear, high shear and 
low/oscillatory shear stress on the dynamics of RelA in response to a pro-
inflammatory stimulus and the involvement of HDACs in the regulation of NF-
κB dynamics. 
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6.2.2.3 Does JNK1-ATF2 signalling enhance NF-κB expression in 
senescent cells? 
NF-κB expression has been suggested to be altered during cellular 
senescence which is a state of stable proliferative arrest.119-121 It would be 
therefore interesting to assess whether JNK regulates RelA expression 
during senescence or in other physiological contexts. 
 
6.2.2.4 Molecular imaging of cuffed arteries 
We detected low-grade inflammation in the regions of cuffed arteries that 
were exposed to low/oscillatory shear stress and demonstrated that 
PET/CTA can be used to study flow-induced vascular inflammation. Our data 
showed that FDG uptake in the low/oscillatory region was significantly higher 
than the uptake in the low shear region and that disturbed flow promoted 
inflammation via a JNK1-dependent mechanism. Preliminary results using 
18F-FEDAA which is highly selective and specific probe for TSPO/PBR, 356,357 
demonstrated elevated binding at low/oscillatory shear regions. Thus, 
FEDAA binding correlated with uptake of FDG as well as the accumulation of 
macrophages in the low/oscillatory shear stress region. However, further 
work including autoradiography should be carried out to define whether FDG 
and FEDAA signals are mediated by inflammatory cells.  
 
Molecular imaging such as PET provides the opportunity to assess molecular 
changes over time in individual animals. Our work revealed for the first time 
that PET imaging of cuffed arteries can be used to study vascular responses 
to altered shear stress in living mice. The flow-altering cuff was a key 
element in this approach because it generated distinct flow fields with spatial 
separation that was suitable for PET. In addition, the cuff model may allow 
molecular imaging studies of different forms of atherogenesis, as the cuff 
generates spatially-distinct stable- and vulnerable-type lesions in 
hypercholesterolemic mice.75 Future studies should employ molecular 
imaging with FDG, FEDAA or other probes to assess the kinetics of 
inflammation in vulnerable and stable plaque genesis using cuffed ApoE -/- 
or LDLR -/- mice. In addition, the approach could be used to study other 
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aspects of physiology in atherogenesis. For instance, plaque rupture has 
been associated with high MMP activity in macrophages which can lead to 
the destruction of the extracellular matrix and weakening of the fibrous cap, 
thus rendering lesions liable to rupture and thrombosis.345 Due to their 
importance, a variety of active site binders and imaging prodrugs have been 
described for molecular imaging of MMPs and future studies should use 
these probes to assess MMP activation in atherogenesis in living animals.420-
425 
 
6.2.3 Translation to the clinic 
We observed that JNK inhibition can suppress inflammatory activation of 
ECs, partly by reducing RelA expression, and that HDACs may suppress 
ECs activation by reducing the duration of RelA nuclear localisation. These 
findings may inform the development of new pharmacological strategies to 
decrease RelA expression and activity resulting in decreased vascular 
inflammation.  
 
HDAC inhibitors can lead to growth arrest, cellular differentiation, and 
apoptosis and they have been used previously as anti-cancer drugs.139,426 In 
addition, anti-inflammatory properties have been described for HDAC 
inhibitors.141,427 For example, the HDAC inhibitor TSA has been shown to 
reduce disease severity in murine models of multiple sclerosis, arthritis and 
asthma.428-430 However, TSA exacerbates atherogenesis in 
hypercholesteremic LDLR -/- mice.415 The latter study is in accordance to our 
findings that HDAC inhibition leads to prolonged RelA nuclear localisation in 
the athero-protected region, which may subsequently promote vascular 
inflammation. Our studies suggest that increasing HDAC activity in the 
susceptible region may terminate RelA activity and decrease vascular 
inflammation. Interestingly, recent studies suggest that statins (simvastatin) 
may enhance HDAC activity and suppress NF-κB activity in ECs exposed to 
oxLDL.414 Therefore, it would be interesting to assess the effect of 
simvastatin on vascular inflammation, especially at the athero-susceptible 
region. Interestingly, a recent study demonstrated that atorvastatin treatment 
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can induce the cytoprotective enzyme heme oxygenase-1 in the athero-
protected region but less efficiently at the athero-susceptible site. Therefore, 
the authors suggest that protection from statins may be suboptimal at regions 
with the highest susceptibility to atherosclerosis.431 However, the effects of 
statins on NF-κB activity at athero-susceptible sites has not been studied. In 
addition, statins may have different potencies for NF-κB regulation e.g. 
simvastatin, but not atorvastatin, inhibited TNFα-induced NF-κB activation in 
myeloid cells.432 Thus, we propose that simvastatin may have a beneficial 
effect on vascular inflammation and the development of atherosclerotic lesion 
by activating HDACs at athero-susceptible sites.  
 
In addition to the role of HDAC in the regulation of RelA activity, we could 
demonstrate that JNK1 positively regulates RelA expression. These data 
reveal JNK as a potential target to reduce RelA activity and inflammation in 
cardiovascular disease. Consistent with this idea, a pharmacological JNK 
inhibitor (SP600125) significantly reduced plaque size in ApoE knock out 
animals. Moreover, ApoE -/- JNK2 -/- double knock outs displayed reduced 
plaque size, possibly by limiting the uptake of oxidised lipoproteins by 
macrophages.251 Thus, we suggest that pharmacological inhibitors of JNK 
may have clinical utility for the prevention or treatment of vascular 
inflammation and atherosclerosis. 
 
Studies from our group suggest that the beneficial effects of green vegetable 
on cardiovascular health may involve the induction of a protective gene at 
athero-susceptible sites. Specifically, we could show that sulforaphane (SFN) 
which can be found in Brassicaceae vegetables such as broccoli can reduce 
inflammatory activation of ECs at athero-susceptible regions by activating 
Nrf2.325 This work was performed in wild-type C57BL/6 animals and it would 
be interesting to assess whether SFN can limit the development of 
atherosclerotic lesions in LDL -/- or ApoE -/- animals on a high-fat, high- 
cholesterol diet. The usage of different dietary doses of SFN will be important 
to determine the optimal amount of SFN or green vegatables that need to be 
consumed in order to generate vascular protection. Interestingly, recent 
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reports have demonstrated that SFN or similar synthetic compounds can 
reduce inflammatory activation by inhibiting NF-κB.433,434 Thus, SFN is a 
potential therapeutic approach against cardiovascular disease in clinic. It may 
be delivered either through the consumption of vegetables or via SFN 
supplements, and it may reduce vascular inflammation, in part, by inhibiting 
NF-κB. 
 
High shear stress protects arteries from inflammatory activation and the 
development of atherosclerotic lesions. A variety of studies describe exercise 
training as a potential stimulus to reduce primary and secondary 
cardiovascular events.435-438 Exercise training has been shown to increase 
endothelial nitric oxide-dependent vasodilatation in both large and small 
vessels.439 The underlying mechanism may be related directly to shear stress 
because exercise has been associated with acute changes in endothelial 
shear stress 440,441 and described as an important stimulus for acute 
enhancement of endothelial function in vivo.442 Therefore, it would be 
interesting to assess the effect of exercise-mediated elevation of shear stress 
(e.g. by providing mice with an exercise wheel and compare them to control 
groups which do not exercise) on the expression of RelA and vascular 
inflammation to better understand the benefits of training on cardiovascular 
health. 
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Table 7.1: Media for primary cell culture 
 
Medium 
 
Ingredients 
 
Growth medium 
 
M199, 200 mM L-glutamine, 20% FCS, 100 U/ml penicillin G, 100 
µg/ml streptomycin, 30 µg/ml ECGF and 100 U/ml heparin 
 
Basal medium 
 
M199, 200 mM L-glutamine, 20% FCS, 100 U/ml penicillin G, 100 
µg/ml streptomycin 
 
Transfection medium 
 
M199, 20% FCS, 200 mM L-glutamine, 30 µg/ml ECGF and 100 
U/ml heparin. 
 
Table 7.2: Buffers used for ChIP 
 
Buffer 
 
Components 
 
Cell lysis buffer 
 
50 mM Hepes-KOH, pH 7.5 
  
140 mM NaCl 
  
1 mM EDTA 
  
10% glycerol 
  
0.5% NP-40 
  
0.25%TritonX-100 
  
ddH2O 
 
Lysis buffer 
 
10 mM Tris-HCL, pH8 
  
200 mM NaCl, 
  
1 mM EDTA 
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0.5 mM EGTA 
  
ddH2O 
 
Nuclear lysis buffer 
 
10 mM Tris-HCL, pH8 
  
100 mM NaCl 
  
1 mM EDTA 
  
0.5 mM EGTA 
  
0.1% Na-Deoxycholate 
  
0.5% N-lauroylsarcosine 
  
ddH2O 
 
RIPA 
 
50 mM Hepes-KOH, pH 7.6 
  
500 mM LiCl 
  
1 mM EDTA 
  
1% NP-40 
  
0.7% Na-Deoxycholate 
  
ddH2O  
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Table 7.3: Composition of buffers used for Western blotting 
 
Buffer 
 
Content 
 
Transfer Buffer 
 
5.5% NuPAGE
TM 
transfer buffer (20x), 50 ml 
  
0.1% NuPAGE
TM 
 
  
MiliQ Water 
 
Running Buffer 
 
5% NuPAGE
TM 
MOPS SDS running buffer (20x) 
  
MiliQ Water 
 
Loading dye 
 
10% DTT (1 M) 
  
NuPAGE
TM  
LDS sample buffer 
 
PBST 
 
10% PBS (10x) 
  
1% Tween20 
  
MiliQ Water 
 
Blocking solution 
 
2% Milk powder 
  
PBST 
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ANG II  Angiotensin II 
ANOVA  Analysis of variance 
AP-1   Activator protein-1 
ApoE   Apolipoprotein E 
ASK1   Apoptosis signal-regulating kinase 1 
ATF   Activating transcription factor 
ATP   Adenosine tris-phosphate 
BAFF   B-cellactivation factor 
BCL-2   B-cell lymphoma 2 
BSA   Bovine serum albumin 
bZIP   Basic region leucine zipper 
CD14   Cluster of Differentiation 14 
CD36   Cluster of Differentiation 36 
CD68   Cluster of Differentiation 68 
CDK4   Cyclin-dependent kinase 4 
cDNA   Complementary DNA 
cIAP   Cellular inhibitor of apoptosis protein 
c-FLIP  Cellular FLICE inhibitory protein 
ChIP   Chromatin immunoprecipitation 
CRE   cyclic AMP responsive element 
CRE-BPa  cyclic AMP-responsive element-binding protein 5 
CT   Cycle threshold 
CTA   Computed tomography angiography 
CYLD   Cylindromatosis (turban tumor syndrome) 
DEPC   Diethylpyrocarbonate 
DMSO  Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
DTT   Dithiotreitol 
EC   Endothelial cell 
ECGF   Endothelial cell growth factor 
EDTA   Ethylenediaminetetraacetic acid 
EEA1   Early endosome antigen 1 
ECL   Enhanced chemiluminescence 
ELISA   Enzyme-linked immunosorbent assay 
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Elk-1   ETS domain-containing protein Elk-1 
eNOS   Endothelial NO synthase 
Erg v-ets erythroblastosis virus E26 oncogene homolog 
(avian) 
ERK   Extracellular signal-regulated kinase 
FADD   Fas-associated death domain 
FBP Filtered backprojection reconstruction 
FCM Flow cytometry 
FCS Fetal calf serum 
FDG Fluorodeoxyglucose 
FEDAA (N-(5-Fluoro-2-phenoxyphenyl)-N-(2-18F-fluoroethyl-5-
methoxybenzyl) acetamide) 
FITC   Fluorescein isothiocyanate 
FOS   FBJ murine osteosarcoma viral oncogene homolog 
FRA   Fos-related antigen 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
GADD45β  Growth arrest and DNA-damage-inducible β 
GBq   Giga Becquerel 
GFP   Green fluorescent protein 
GLUT   Glucose transporter 
GPCR   G-protein-coupled receptor 
GRR   Glycine-rich region 
H2O2   Hydrogen peroxide 
HAT   Histone acetyltransferase 
HBSS   Hanks balanced salt solution 
HDAC   Histone deactylase 
HDI   HDAC inhibitor 
HK   Hexokinase 
HP   High probability 
HRP   Horseradish peroxidase 
HSS   High shear stress 
HUVEC  Human umbilical vein endothelial cells 
ICAM-1  Intracellular adhesion molecule-1 
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IFN   Type 1 interferon 
IgG   Immunoglobulin G 
IKK   IκB kinase complex 
IL-1   Interleukin-1 
IRAK   IL-1 receptor-associated-kinase 
IκB   Inhibitory κB 
JIP   JNK-interacting protein 
JNK   c-Jun NH2-terminal kinase 
JUN   jun proto-oncogene 
KLF2   Krueppel-like factor 2 
LBP   LPS binding protein 
LDL   Low-density lipoproteins 
LDLR   Low-density lipoprotein receptor 
LP   Low probability region 
LPS   Lipopolysaccharide 
LSS   Low shear stress 
LT-β   Lymphotoxin-β 
LZ   Leucine zipper 
Maf v-maf musculoaponeurotic fibrosarcoma oncogene 
homolog (avian) 
Mal   MyD88-adapter-like; also known as TIRAP 
MAPK   Mitogen activated protein kinase 
MAPKKK  MAPK kinase kinase 
MCP-1  Monocyte chemoattractant protein-1 
M-CSF  Macrophage colony stimulation factor 
MD-2   Lymphocyte antigen 96 
MFI   Mean fluorescence intensity 
MKP-1  Mitogen-activated protein kinase phosphatase 1 
MLK3   Mixed lineage kinase 3 
MMP   Matrix metalloproteinase 
MyD88  Myeloid differentiation primary response gene 88 
NaCL   Sodium chloride 
N-CoR  Nuclear receptor corepressors 
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NEMO  NF-κB essential modulator 
NF-κB   Nuclear factor kappa B 
NIK   NF-κB-inducing kinase 
NF1   Neurofibromatosis 1 
NO   Nitric oxide 
NRF2   NF-E2 related factor 2 
OD   Optical density 
OSS   Oscillatory shear stress 
ox-LDL  Oxidised Low-density lipoproteins 
PA   Pascal 
PAMP   Pathogen-associated molecular patterns 
PBR   Peripheral benzodiazepine receptor 
PBS   Phosphate buffered saline 
PBST   Phosphate buffered saline tween 
PCR   Polymerase chain reaction 
PDGF   Platelet-derived growth factor 
PECAM-1  Platelet endothelial cell adhesion molecule-1 (CD31) 
PET   Positron emission tomography 
PFA   Paraformaldehyde 
PGI2   Prostacyclin 
PMSF   Phenylmethanesulfonylfluoride 
PRR   Pattern-recognition receptor 
PTM   Post-translational modification 
PVDF   Polyvinylidene fluoride 
RANKL  Receptor activator of activation of NF-κB ligand 
RANTES Regulated upon activation, normal T cell expressed and 
secreted 
REL v-rel reticuloendotheliosis viral oncogene homolog 
(avian) 
RE Reynolds number 
RHD   Rel-homology domain 
RIPA   Radioimmunoprecipitation assay 
RIP1   Receptor interacting protein kinase 1 
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RNA   Ribonucleic acid 
ROI   Region of interest 
ROS   Reactive oxygen species 
RPM   Rounds per minute 
SAPK   Stress-activated protein kinase 
SARM   Sterile α and HEAT-Armadillo motifs-containing protein 
SD   Standard deviation 
SDS   Sodium dodecyl sulfate 
SEM   Standard error of the mean 
SFN   Sulforaphane 
siRNA   small interfering RNA 
SGLT   Sodium glucose co-transporter 
SMCs   Smooth muscle cells 
SMRT Silencing mediator for retinoid and thyroid hormone 
receptors 
SPECT  Single photon emission CT 
SR-A   Scavenger receptor-A 
SSC   Saline-sodium citrate 
SUV   Standardised uptake values 
TAB2   TAK1-binding protein 2 
TACE   TNFα converting enzyme 
TAD   Transcription activation domain 
TAK1   Transforming growth factor-β-activated kinase 1 
TE-buffer  Tris and EDTA buffer 
TF   Tissue factor 
TGFβ   Transforming growth factor β  
TIR   Toll-IL-1 
TLR   Toll-like receptor 
TNFα   Tumor necrosis factor-α  
TNP   Trimodality nanoparticle 
TNFR   Tumor necrosis factor receptor 
TOLLIP  Toll interacting protein 
tPA   Tissue plasminogen activator 
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TRADD  TNFR1-associated death domain 
TRAF   TNF receptor-associated factor 
TRAM   TRIF related adaptor molecule 
TRIF   TIR domain-containing adaptor inducing IFN-β 
Tris-buffer  Tris(hydroxymethyl)aminomethane 
TSA   Trichostatin A 
TSPO   Translocator protein 
UB   Ubiquitin 
VCAM-1  Vascular cell adhesion molecule-1 
VD   Volume distribution 
VE-cadherin  Vascular endothelial cadherin 
VEGFR2  Vascular endothelial growth factor receptor 2 
XIAP   X-linked Inhibitor of Apoptosis Protein 
2DG   2–deoxy–D–glucose 
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